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Chapter I 
GENERAL INTRODUCTION 
One of the major causes of human mortality is cancer (Parkin et al, 1988). Cancer is a 
disease in which regulatory systems of normal cell-growth and -differentiation are 
disturbed thereby causing cells to multiply in a disorganized fashion. Depending on the 
type of cells which proliferate, various tumors can be found in man. Solid tumors 
represent 93% of all human neoplasms while the remaining 7% is accounted for by 
leukemias and lymphomas which arise from blood cells and lymph nodes respectively. 
The way in which normal cell-growth and -differentiation are controlled has been an 
enigma for ages. Even more so, the events taking place during neoplastic transformation 
have been largly unknown. Yet, around the turn of the century Van Hansemann and 
Boveri already postulated that the chromosomes in the cell-nucleus might play a role in 
tumorigenesis (Van Hansemann, 1890, Boveri, 1914). However, it would take more than 
half a century before a specific association between chromosomes and cancer was 
discovered. 
1. Abnormal chromosomes are found in human tumors. 
The foundation of human cancer genetics was laid in 1960 when Nowell and Hungerford 
detected an abnormal small chromosome 21 or 22 in bone marrow cells from patients 
with chronic myeloid leukemia (CML) (Nowell and Hungerford, 1960). They called this 
abnormal chromosome the Philadelphia (Ph) chromosome after the city of Philadelphia. 
At that time, the identification of each individual chromosome out of the 46 human 
chromosomes was still impossible and chromosomes were categorized according to size in 
7 different groups. However, karyotyping took a flight in the following decades due to 
the development of "banding" techniques and this enabled cytogeneticists to recognize 
each chromosome separately by size and structure (Caspersson et al, 1970, Yunis, 1981). 
In fact, using these refined methods Rowley discovered in 1973 that the Ph chromosome 
was an abnormal chromosome 22, which had lost part of the long arm in a translocation 
to the long arm of chromosome 9 (Rowley, 1973). Since that discovery an increasing 
number of human neoplasms has been associated with non-random chromosomal abnor-
malities. These abnormalities can be subdivided into two main groups (Mitelman and 
Levan, 1981, Trent et al, 1989): 
I. Structural ahlWrmalities. 
Four categories of structural abnonnalities in chromosomes occur in malignancies: 
a. Deletions: part of a chromosome is missing. This phenomenon is mainly seen in solid 
tumors, like small-cell lung cancer where deletion of the short arm of chromosome 3 may 
occur, or in neuroblastoma in which deletion of part of the short arm of chromosome 1 is 
found (Whang-Peng et al, 1982, Brodeur et al, 1977). 
b. Amplifications: part of the genetic material is present in more than its normal copy 
number. The karyotypic abnormalities representing this phenomenon are Double Minutes 
(DM's) or chromosomes with Homogeneously Staining Regions (HSR's). These aberrati-
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ons are found in a wide variety of human solid tumors (Barker, 1982, Kovacs, 1979). 
c. Translocations: part of a chromosome moves to another chromosome. Usually, 
exchange of material occurs between two chromosomes which is called a "reciprocal" 
translocation. This type of aberration is mostly found in leukemias and lymphomas. Well-
known examples are the t(8;14) in Burkitt's lymphoma (BL) and the t(9;22) in CML 
(Manolova et al, 1979, Rowley, 1973). 
d. Inversions: part of a chromosome is dislodged and reinserts at the same position in 
reverse orientation. For example, in a specific morphologic subtype of acute myeloid 
leukemia (AML) an inversion of the centromeric part of chromosome 16 is often found 
(LeBeau et al, 1983). 
Il. Numerical abnormalities. 
Chromosomes are either missing ("monosomies") such as -22 in meningioma or present in 
more than two copies, e.g. trisomy 12 in chronic lymphocytic leukemia (CLL) (Mark et 
al, 1972, Knuutila et al, 1986). 
While cytogenetic investigation of leukemias and lymphomas proved to be quite success-
ful from the beginning, karyotyping of solid tumors was difficult (for review, see 
Sandberg and Turc-Carel, 1987). Research on solid tumors lagged behind for some years 
but due to adjusted culture- and banding techniques a growing number of specific 
chromosomal aberrations was found in a variety of these tumors (for review, see 
Teyssier, 1989). 
In Table 1 a representation is given of the cytogenetic abnormalities which are found in 
human solid tumors, leukemias and lymphomas. 
2. Cytogenetic abnonnalities are tbe symptoms of gene-deregulation. 
The involvement of specific chromosomes, or more precisely of specific chromosomal 
regions, in cytogenetic abnormalities led to the concept that in these areas genetic 
information was located which played a crucial role in tumorigenesis (Rowley, 1983, 
Yunis, !983, Heim and Mitelman, 1987). An example of such a region is band qll of 
chromosome 22. This area is involved in translocations which characterize various 
leukemias and lymphomas (t(9;22)(q34;qll) in CML, acute lymphoblastic leukemia 
(ALL), AML; t(8;22)(q24;qll) in Burkitt's lymphoma) and in deletions in tumors like 
meningioma (del(22)(qll)). Moreover, the existence of hereditary forms of cancer and the 
tumorigenic potency of certain agents which damage deoxyribonucleic acid (DNA) 
convinced scientists that genes must play a major role in the origin of cancer (Heath and 
Moloney, 1965, Papadrianos et al, 1967, Fraumeni and Thomas, 1967, Lynch et al, 
1967, Li and Fraumeni, 1969, McCann et al, 1975, McCann and Ames, 1976). 
While cytogenetic investigations expanded fast, several lines of research in the developing 
scientific field of molecular biology provided strang evidence in favor of this theory (for 
review, see Bishop, 1988). Molecular techniques allowed analysis of genes at the DNA-
level which meant a totally new approach of the cancer-problem. Using these techniques 
two types of genes were discovered to be involved in tumorigenesis. 
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Table 1. 
Cytogenetic Abnormalities in Human Solid Tumors, Leukemias and Lymphomas 
Carcinomas 
bladder 
breast 
colon 
kidney 
lung (small cell) 
ovary 
prostate 
uterus 
Germ cell tumors 
Glioblastoma 
Melanoma 
Meningioma 
Neuroblastoma (progressive) 
Retinoblastoma 
Sarcomas 
liposarcoma (myxoid) 
synovial 
rhabdomyosarcoma 
Leukemias 
chronic myelocytic (CML) 
acute myeloblastic (AML) 
Secondary AML•l 
Chronic lymphocytic (CLL) 
Acute lymphoblastic (ALL) 
Myelodysplastic syndrome (MDS) 
Myeloproliferative disorder (MPD) 
Polycythemia Vera 
Multiple myeloma 
Lymphomas 
Burkitt's, non-Burkitt's 
follicular 
small cell lymphocytic 
i(Sp), +7,-9/9q-,llp-, + 13 
-8,-13 
-17,17(qll),-18,12q-, +7, +8, + 12 
del(3)(p21) 
del(3)(pl4p23) 
6q-,1(6;14)(q2l;q24),del(3)(p14p21),-X 
del(10)(q24) 
1q-
i(12p) 
9p24- pter (reammgements),+7,-10 
del(6)(q11q27),i(6p),del(1)(p11p23),1(1;19)(ql2;q13) 
-22,22q-
del(l)(p32p36) 
del(13)(q14) 
t(12;16)(q13;p11) 
t(X;18)(pll;qll) 
t(2;13)(q37;q14) 
t(9;22)(q34;qll) 
inv(3)(q21q25-27),1(3;S)(q26;q22),1(8;21)(q22;q22) 
t(!S; 17)( q22;q 11 ),inv(16)(p 13;q22), 16q-( q22) 
t(9; 11 )(p22;q23),t(9 ;22)( q34;q 11 ),t(6;9)(p23 ;q34) 
trisomy 4, trisomy 8 
del Sq/-5, del 7q/-7 
trisomy 12, t(ll;14)(q13;q32) 
t(9 ;22)( q34;q 11 ),t( 4; 11 )( q21 ;q23), 1(8; 14)( q24;q32) 
t(l ;19)(q21-23;p13),1(11; 14)(p13;q13) 
t(2;8)(p 11-13 ;q24), 1(8;22)( q24;q 11 ),del( 6)( q21q25) ,9p-, 12p-, 
14q-,14q+,+21 
t(1;3)(p36;q21 ),t(1 ;7)(pll ;pi!) ,t(2;ll)(p11;q23) 
del(9)( q 13q22) ,del(20)( q 12q 13),Sq-, 7 q-,-7 ,12p-, + 8, t(3; 17) 
( q26;q22) 't(ll ;21 )( q22;q21) ,2lq-, 9q-,20q-
del(20)(q!lql3) 
t(!l;l4)(ql3;q32) 
t(8;!4)(q24;q32) 
t(l4;18)(q32;q21) 
trisomy 12 
•lSecondary to mutagen/carcinogen exposure 
References Yunis, 1983 
Sandberg, !986 
Sandberg and Turc-c&rel, 1987 
Teyssier, 1989 
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I. Twnor-suppressor genes. 
The normal function of these genes is probably to hold cellular growth in check in 
specific types of tissue. The history of the gene involved in the development of retinoblas-
toma (an eye tumor) can stand model as the classic example of the discovery of a tumor-
suppressor gene (for review, see Weinberg, 1988). 
Until the first half of the 19th century children with a malignant tumor of the retina or 
retinoblastoma died. However, since the invention of the ophthalmoscope the diagnosis of 
this disease was possible and treatment existed of enucleation of the affected eye. 
Children of these ex-patients suffered from retinoblastomas in a high number of cases and 
often both their eyes were affected. Besides this form of hereditary retinoblastoma, cases 
were known without a family history: the so-called "sporadic" cases. Here, only one eye 
was affected and the disease was not transmitted to the off-spring of the patient. A 
hypothesis for the genetic mechanism underlying this disease was postulated by Knudson 
in 1970 (Knudson, 1971). He proposed that according to its Mendelian behaviour a 
recessive gene must be involved which had a protective function against tumor-formation. 
In the hereditary form of retinoblastoma, the child inherits a non-functioning allele from 
the affected parent and is heterozygous for this gene in all the cells of the body. Only one 
mutation in the other allele in one of the retinal cells is necessary to abolish its protective 
function thereby allowing growth of the tumor. In sporadic cases of retinoblastoma both 
loci in one retinal cell must be knocked out by mutations to allow formation of this tumor 
in that particular celL However, in this case the disease is non~inheritable, since the germ 
cells of the patient are not affected. 
Meanwhile, cytogenetic analysis of retinoblastoma cells had shown a deletion of band 14 
of the long arm of chromosome 13 which was thought to contain the protective gene or 
retinoblastoma (RB) gene (Yunis and Ramsay, 1978). Probes derived from the deleted 
region became available. Southern blot analysis showed frequent homozygous deletions of 
some of these probes in retinoblastoma tumors (Dryja eta!, 1984). In 1987 the whole RB 
gene was isolated and identified (Lee et a!, 1987). Abnormalities in the structure of the 
RB-gene are not only found in retinoblastomas but also in osteosarcomas, breastcarcino-
mas and small-cell lung cancer (Friend et a!, 1986, Lee et a!, 1988, Harbour et a!, 1988). 
These findings are in concordance with the clinical observation that many patients with 
retinoblastoma suffer from osteosarcoma in later life and that a higher incidence of breast 
cancer is found in female relatives of patients with osteosarcomas. It seems that the 
inheritance of an affected RB-allel increases the probability of tumor formation in various 
types of tissue. 
The search for other tumor suppressor genes intensified and was partly guided by the 
work done on the RB-gene. In fast succession several tumor suppressor genes were 
isolated such as the WT-1 gene (Wilms' tumor), the NF-1 gene (neurofibromatosis), the 
gene encoding the p53 protein (osteosarcomas, brain tumors, leukemias, carcinomas of 
breast and lung, Li-Fraumeni syndrome) and the DCC-gene (colorectal cancer) (Cali et 
a!, 1990, Haber et a!, 1990, Gessler et a!, 1990, Viskochil et a!, 1990, Cawthon et a!, 
1990, Malkin et a!, 1990, Srivastava et a!, 1990, Chen et a!, 1990, Fearon et a!, 1990). 
All these genes are similar in that abolishment of their normal function allows tumor 
growth (Table 2). Due to the 'recessive' behaviour at the cellular level of the tumor-
suppressor genes, their detection is more complicated than that of the second type of gene 
which will be discussed, the oncogene. 
10 
Table 2. 
Genes incriminated in human twnors 
Tumor suppressor genes 
RBI 
p53 
WTI 
DCC (deleted in colorectal 
carcinoma) 
NFI 
FAP (familial adenomatous polyposis) 
Oncogenes 
abl 
erbb-2 (neu) 
myc 
L-myc 
N~myc 
H-ras 
K·ras 
N-ras 
References Verma, 1986 
Bishop, 1991 
Cbromosomal 
localization 
13ql4 
17ql2-13 
llpl3 
18q21 
17q!l 
5q21- 22 
9q34 
17qll • ql2 
8q24 
lp32 
2p24 
llpl5 
6pll - pl2 
lp22 or pl3 
Tumor 
Retinoblastoma, osteosarcoma 
cancer of breast/bladder/lung 
Astrocyto~ osteosarcoma 
cancer of breast:llung 
Wilms' tumor 
Colon cancer 
Neurofibromatosis type 1 
Colon carcinoma 
CML, ALL, AML 
Adenocarcinoma of breast/ 
ovary/stomach 
Burkitt's lymphoma, cancer of 
lung/breast/cervix 
Carcinoma of lung 
Neuroblastoma, small cell 
lung carcinoma 
Cancer of colon/lung/ 
pancreas, melanoma 
AML, ALL,. thyroid cancer 
melanoma 
Cancer of genitourinary tract 
and thyroid, melanoma 
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II. Oncogenes. 
The study of oncogenes is mainly based on two lines of research. 
a. Onco-viruses 
The discovery in 1910 by Peyton Rous that the Rous Sarcoma Virus is responsible for 
tumor formation in chicken is one of the pillars of oncogene research (Rous, 1911). The 
validity of Rous' s discovery was confirmed by the growing number of animal tumors 
which were found to be the result of viral infection (Jarret et al, 1964, Snyder and 
Theilen, 1969, Rickard et al, 1969). However, it would take more than 50 years before 
viruses could even be visualized via the electron microscope and before their genomic 
organization was unraveled (Coffin and Billeter, 1976). 
In 1969, Huebner and Todaro proposed a model for the mode in which viruses can cause 
tumors (Huebner and Todaro, 1969). Sera-epidemiological studies and cell culture studies 
had given evidence for the presence of viral genes in the genome of many vertebrates. 
The viral genetic sequences contained genes which supposedly transformed normal cells 
into tumor cells, hence these genes were called "oncogenes". Huebner and Todaro 
postulated that the viral genes, which were integrated into the host cell genome, were 
transmitted in a vertical fashion (i.e. from animal to progeny animal and from cell to 
progeny cell). Due to modifying factors in the host cell environment, the viral genes 
stayed in a functionally "repressed" form. Factors such as carcinogens, irradiation or the 
aging process might overcome the control exerted by the host cell. Under the influence of 
mutagens viral genes, especially oncogenes, were expressed and tumorigenesis was 
initiated. However, one problem still had to be solved in this hypothetical model. At that 
time, it was generally assumed that the only way in which genetic information could be 
transmitted was from DNA in the cell-nucleus to RNA in the cytoplasm. However, the 
genome of most of the acutely transforming viruses found in animal tumors consisted of 
RNA. The discovery of the enzyme reverse transcriptase by Baltimore and Temin in !970 
made clear that genetic information could also flow from RNA to DNA (Baltimore, 1970, 
Temin and Mizutani, 1970). So, if an RNA-virus infects a cell, reverse transcriptase 
transcribes viral genes into DNA that integrates into the host cell genome. Via the host 
cell systems the viral genes are expressed (Varmus, 1983). Ever since the discovery of 
reverse transcriptase, onco-viruses were accepted as model systems to study tumor 
formation (Coffin eta!, 1981, Besmer et al, 1983). 
One of the most surprising findings was that viral oncogenes were shown to have normal 
homologues in non-tumorigenic cells, not only in animals but also in humans (Varmus et 
a!, 1972, Stehelin et al, 1976, Oskarsson et a!, 1980). These were called "proto-oncoge-
nes". The hypothesis for the origin of oncogenes is that during evolution viruses integra-
ted into a host cell genome and copied normal cellular genes of the host cell during their 
life cycle. In this process the normal cellular genes or proto-oncogenes were mutated and 
became oncogenes (Bishop, 1983). 
Proto-oncogenes encode proteins which have a function during normal cell-growth and 
differentiation. So far, three types of proteins encoded for by proto-oncogenes were 
found: !) Proteins with phosphorylating capacities 
2) Proteins that use GTP-GDP for signal transduction 
3) Proteins that control transcription of DNA (Bishop,l99l). 
For the discussion of the role of these proteins in normal cell-growth and differentiation 
and the role of tumor proteins in carcinogenesis, I refer to Chapter IV. 
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b. Transjection assays. 
Another line of research generated additional evidence for the existence of tumorigenic 
genes. This work was based on experiments by Hill and Hillova (1972). Tumors were 
induced in mice by chemical substances or oncogenic viruses. DNA was isolated from 
these tumors. When the isolated DNA was introduced into a non-tumorigenic cell line, 
the cells acquired a malignant phenotype (Shih et al, 1979, Cooper et al, 1980). The 
conclusion was that the introduced DNA contained tumorigenic properties. Later 
experiments using DNA that was directly isolated from human tumors showed the same 
results (Krontiris and Cooper, 1981). 
Both the study of onco-viruses and transfection assays largly contributed to the basic 
understanding of tumor formation by oncogenes. One of the first human oncogenes which 
was cloned was derived from a human bladder carcinoma cell line (Pulciani et al, 1982, 
Shih and Weinberg, 1982). Structural analysis revealed that the gene was homologous to 
the retroviral ras oncogene and that it was a slightly altered version of a normal cellular 
gene (Parada et al, 1982, Santos et a!, 1982). The fmal proof that prot(H)ncogenes can 
turn into oncogenes was given by a functional assay: a normal human proto-oncogene was 
linked to viral sequences which caused overexpression of the human gene. Introduction of 
the construct gene into non-tumorigenic cells caused transformation (Chang et al, 1982). 
The link between oncogenes and chromosomal aberrations in man was made when 
translocation breakpoints were found to be located close to or in proto-oncogenes (Taub et 
a!, 1982, Dalla-Favera et al, 1982 and 1983, De Klein et al, !982, Heisterkarnp et al, 
1983). The first two genes which were discovered to be deregulated by chromosomal 
translocation were the mvc gene, involved in the t(8;14), and the abl gene, disrupted by 
the t(9;22). Since mutation of one allel in a somatic cell is sufficient for activation of 
oncogenes, they are regarded as dominant in their behaviour as opposed to the tumor 
suppressor genes (Table 2). 
3. Gene dantage is found in many human tumors. 
Many proteins encoded for by the normal homologues of tumor suppressor genes and 
oncogenes are probably components of a transducing system which conducts signals for 
growth and differentiation from outside the cell to the nucleus. Inactivation of tumor-
suppressor genes or activation of oncogenes generates quantitatively or qualitatively 
abnormal gene products. These abnormal proteins deregulate processes involved in 
normal cell-growth and -differentiation (for review, see Nishimura and Sekiya, 1987). 
The study of human tumors at the genetic level indicates that abnormalities of both tumor-
suppressor genes and oncogenes show a restricted number of structural changes. The 
main groups are: deletions, amplifications, point mutations and rearrangements. 
a. Deletion: the complete gene or part of it is removed from the genome. This type of 
damage is often found in tumor-suppressor genes. In fact, the isolation of the RB-gene 
and other similar genes was possible by studying patients having large deletions in these 
genes (Friend et al, 1986, Gessler eta!, 1990). 
b. Amplification: the gene is present in more than its usual copy number. A well-known 
example is the amplified mvc gene, resulting in its increased expression. This aberration 
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is found in neuroblastomas and small-cell lung cancer for example (Schwab et al, 1983, 
Nau et a!, 1986). Amplification of J:Jm< in neuroblastomas indicates an increased malig-
nant state of the tumor (Seeger eta!, 1985). 
c. Point mutation: one of the four bases in the DNA-molecule is replaced by any of the 
other three bases. Point mutations can either inactivate tumor-suppressor genes or activate 
oncogenes. The most extensively studied oncogene which is altered by point mutation is 
the na> oncogene (for review, see U>wy and Willumsen, 1986). Point mutations in m 
have been found in many human tumors and leukemias (Lyons et al, 1988, Vogelstein et 
a!, 1988, Bos, 1989, Radich et a!, 1990, Hirsch-Ginsberg et a!, 1990, Liibbert et a!, 
1990). 
d. Rearra:ngement: part of the gene is juxtaposed to a different area in the genome. This 
type of gene disturbance is mostly found in leukemias and lymphomas. An example is 
Burkitt's lymphoma which is a B cell neoplasm. In 85% of such tumors a t(8;14) 
(q24;q32) is found. The translocation moves the c-J:Jm; gene on chromosome 8 to the 
immunoglobulin heavy chain locus on chromosome 14. Either intact c-J:Jm; or a 5' 
truncated C·J:Jm< is joined to one of the heavy chain constant region genes, usually Cp.. 
Since translation of myc starts in the second exon of the gene, no difference exists 
between MYC proteins from an intact or 5' truncated c·J:Jm< gene. However, the 
translocation causes loss of control at the transcriptional level resulting in increased 
expression of the c-mvc gene (for review, see Croce and Nowell, 1985). 
Part of this thesis deals with the t(9;22) which is found in the leukemic cells of patients 
with CML and ALL This translocation moves the ll!ll-gene from chromosome 9 to 
chromosome 22 where it fuses with the Qg:-gene (De Klein et a!, 1982, Heisterkamp et 
a!, 1983, Groffen et al, 1984, for review, see Kurzrock et al, 1988). The structure of the 
chimeric ll&r-ll!ll gene will be discussed in Chapters IL2 and ll.3. Furthermore, implicati-
ons of the translocation for the function of the ABL protein are exposed in Chapter IV. 
Abnormalities at the genetic level in neoplasms are non-random. Specific changes are 
associated with specific tumors or subtypes of leukemia in humans. Besides a diagnostic 
value, several of these gene abnormalities have a prognostic significance in predicting the 
outcome of certain diseases. Amplification of C·J:Jm< is found in advanced tumors or 
aggressive subtypes of colorectal cancer (Yokota et a!, 1986, Heerdt et a!, 1991). 
Deletions of H-ras or c-myb are a sign of progression in carcinomas and sarcomas 
(Yokota et al, 1986). Amplification of the HER-2/neu oncogene indicates proneness to 
relapse and shorter survival in patients with breast cancer (Slamon et al, 1987, 1989). K-
!la> point mutation is found in a subgroup of patients with adenocarcinomas of the lung 
associated with a poor prognosis and short survival (Slebos et al, 1990). 
The exact role of the abnormal proteins in the origin or progression of human tumors is 
not completely clear. Study of the structure and function of altered genes and their protein 
products is essential to understand the origin and development of cancer (See further 
Chapter IV). 
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4. Scope of the thesis. 
In this thesis the genetic analysis of two types of acute leukemia characterized by 
translocations will be described. Both translocations generate chimeric genes which are 
specific for these subtypes of leukemia. The non-random changes that occur at the 
molecular level can be used in addition to karyotyping to diagnose the presence of tumor 
cells. 
The linkage of specific subtypes of acute myeloid leukemia with t(6;9) to a consistent 
rearrangement involving the ~-gene on chromosome 6 and the g.n-gene on chromosome 
9 will be shown (Chapters III.2 and ill.3). This is of clinical importance since a correct 
diagnosis and subclassification indicates the prognosis of the diaease and helps to choose 
the right therapy, thereby improving the prognosis for a patient. 
The second type of acute leukemia that will be discussed is the acute lymphoblastic 
leukemia associated with the t(9;22). Here, rearrangement of genes results in a chimeric 
bcr-abl gene on the Philadelphia chromosome. A variant of this chimeric gene was found 
and analyzed (Chapter II.3). The study of altered genes in leukemia provides us with a 
multitude of questions conceroing their function and role in the origin of the tumor. 
However, unusual variants of tumor-specific products may help to solve parts of the 
mystery of tumor formation. 
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Chapter II.l 
AN INTRODUCTION TO THE DISEASE ACUTE LYMPHOBLASTIC LEUKEMIA 
(ALL). 
Acute lymphoblastic leukemia (ALL) is characterized by the uninhibited proliferation of 
cells derived from the lymphoid compartment of the blood. Normally, these cells defend 
the body against attacks by foreign microorganisms or entrance by non-self material. B-
cells produce immunoglobulines which are mediators of the humoral defense response 
while T -cells are the effectors of the cell-mediated immunity (Roitt, 1980). 
ALL is a disease of childhood and among malignancies in children of the Western world 
it is the main cause of death (Breslow and Langholz, 1983). In adults this type of 
leukemia accounts for 20% of the acute leukemias. Forty years ago the diagnosis of acute 
leukemias was mainly based on clinical characteristics and morphology of the blood. The 
sudden onset of the disease which was often accompanied by fever was one of the striking 
features hence the name "acute" leukemia. The clinical features of ALL result from the 
effects of bone marrow failure (bleeding, infection, fatigue) and from the accumulation of 
leukemic cells (enlarged lymph nodes, hepatosplenomegaly, central nervous system 
involvement) (Macleod, 1981). 
ln the past the prognosis for a patient with this disease was gloomy and survival was 
short. However, examination of groups of patients with acute leukemia showed that 
parameters such as age and white blood cell count (WBC) were important indicators of 
prognosis. Development and use of a wide array of diagnostic methods revealed that 
diagnosis 'acute leukemia' covers a large number of subgroups, each showing its own 
response to therapy. Nowadays, patients with acute lymphoblastic leukemia are subclassi-
fied according to a combination of parameters. Current efforts are directed toward more 
individual therapy, which depends partly on the subgroup in which the patient is classi-
fied. 
Classification of ALL. 
ln 1986 a group of physicians devised a mode for classifying ALL using morphologic, 
immunologic and cytogenetic findings (First MIC Cooperative Study Group, 1986). 
Nowadays, their stratification scheme is widely used and is based on the following 
phenotypes of the leukemic cells: 
Hematomorplwlogic pheMrype. 
The joint efforts of hematologists from several countries resulted in the so-called F AB 
(French-American-British)-classification of leukemias which is based on hematomorpholo-
gic criteria (Bennett et a!, 1976). This classification separated the acute leukemias of 
lymphoid origin from those of myeloid origin. Acute lymphoblastic leukemia is subdivi-
ded into three groups (Ll, L2 and L3) according to the F AB-classification. ln table I the 
main characteristics of each subgroup are given. 
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Table l. Hematomorphologic phenotype of ALL according to the F AS-classification 
FAll Blasts Age-distribution 
Ll Small uniform lymphoblasts Most common subtype in children 
!2 Large pleomorphic lymphoblasts More common in adults 
L3 Large uniform lymphoblasts Children or young adults 
one or more cytoplasmic vacuoles 
(resembles Burkitt's lymphoma) 
Ref. Bennett et al •• 1976. 
Ll and L3 mainly occur in children while L2 is mostly found in adults. The F AB-
classification per se is a minor contributor to the prediction of the prognosis of ALL but 
is essential for diagnosis in combination with other parameters (see below). 
JmmUIU)phenotype. 
A second system of subclassification of ALL is based on immunologic criteria. Here, the 
blasts are characterized via various antigens which are mainly expressed on the cell surfa-
ce (Foon and Todd, 1986). Specific patterns of antigen expression indicate the B- or T-
cell lineage as the origin of the blast. Moreover, analysis of immunoglobulin-genes and 
T -cell receptor genes at the DNA-level defines specific stages of B- or T -cell development 
in which leukemic derangement has occurred (Arnold eta!, 1983, Waldmann eta!, 1985). 
In table 2 a simplified scheme is given for the subclassification of ALL, based on 
immunologic criteria. 80% of cases of ALL are derived from the B-cell lineage and are 
mostly seen in children, while T -cell ALL is mainly found in adults. Some ALLs neither 
have B- nor T -cell features and are called nu!l-ALLs. 
Due to increasingly refined techniques quite a number of ALLs are found to express both 
myeloid and lymphoid markers on their cell surface (Smith et al, 1983, Mirra eta!, 1985, 
Sobol et a!, 1987). These are called the hybrid or biphenotypic leukemias. This specific 
subgroup is associated with a poorer prognosis than the exclusively lymphoid ALL (Pui et 
a!, 1987a). Moreover, prognostic adverse translocations such as t(9;22) or those involving 
llq23 are found in this subgroup (Stong et a!, 1985, Mirro et a!, 1986, Berger et a!, 
1990). 
Karyotype. 
Since ALL is a disease mainly occurring in children, large scale cytogenetic research was 
focused on this age group. Clonal abnormalities, both numerical and structural, are found 
in 75 to 90% of childhood-ALL cases (Stewart et a!, 1986, Heinonen et a!, 1988). 
However, similar studies on adult patients are reported with increased frequency (Bloom-
field et a!, 1989, Seeker-Walker, 1990). These indicate that the same numerical and 
structural chromosomal abnormalities may be found in this age group albeit in different 
frequencies from those found in children. 
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Table 2. Subclassification of ALL based on lmmunofoglc criteria 
lineage 
ALL 80% B cell 
10-20% T cell 
blast cells 
majority CALLA(= CD to) + (mosUy children) 
B cell differenllatlon antigens + 
lg genes rearranged 
L 80 % cytoplasmic !g - = 
20 % cytoplasmic lg + = 
(= clg + 
surface lg · 
< 5 % : express surface antigens of mature B cells 
~nclud!ng surface !g) 
often found with : high WBC 
E-rosette receptor + 
CNS Involvement 
translocatlons (± 100 %) 
FAB- L, 
= CD19 +) 
lmmunophenotvno 
early pre B 
pre B 
B cell 
earty 
more In adults T cell d!fferentlaUon antigens + Intermediate thymocyte 
44 % + translocallons CALLA . 
CALLA: common All antigen 
tg: Immunoglobulin 
WBC: white blood cell count 
CNS: central nervous system 
T cell receptor genes rearranged 
ref.: Champlin and Gale, 1989; Crist eta!, 1989 
types 
mature 
ll!QillJQlli 
favoumble 
worse than early pro B 
poor 
chlld: poor 
adult: better with Intensified 
chemotherapy 
N 
In fact, the difference in frequency of the Ph chromosome in both groups is one of the 
important reasons for the adverse prognosis of ALL in adults in contrast to the rather 
good prognosis of ALL in children. 
Cytogenetic findings are an independent prognostic factor in children with ALL while in 
adults it largly contributes to prognosis in combination with other parameters (Bloomfield 
et al, 1989). Karyotypic abnormalities can be divided into abnormal chromosome number 
or structural abnormalities. 
1. Numerical ahlWnnalities: 
According to chromosome number three main groups are discerned: hyperdiploid (more 
than 46 chromosomes), pseudodiploid (46 chromosomes but structural abnormalities 
present), and hypodiploid (less than 46 chromosomes). A representation of these groups is 
given in tabel 3. 
Especially in the hyperdiploid group, the subgroup with more than 50 chromosomes per 
leukemic cell but no structural abnormalities carries a favourable prognosis (Seeker-
Walker et al, 1978, Bloomfield et al, 1989, Pui et al, !989). The majority of patients in 
this specific group show other favorable features such as low WBC and a cALL immun-
ophenotype (Kaneko et al, 1982). Although the over-all long term event free survival in 
this group is 75% a problem may be late relapse (Bloomfield et al, !989, Seeker-Walker 
et al, 1989). 
Table3. Chromosomal ploidy in childhood ALL 
Ploidy 
Near haploid 
Hypodiploid ( < 46 chromosomes) 
Peudodiplold (46 chromosomes, + abnormalities) 
Normal diploid (46 chromosomes, -abnormalities) 
Hyperdiploid (> 46 chromosomes) 47-50 chr. 
> 50 cbr. 
Near triploid/tetraploid 
Ref. Pui eta! .• 199<1'. 
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Frequency 
< 1% 
± 7% 
41.5% 
8% 
15.5% 
27% 
< 2% 
Prognosis 
Poor 
Poor 
Poor 
Intermediate 
Intermediate 
Good 
Unknown 
Table 4. Non-random chromosomal abnormalities In ALL 
Pre·B/Early pre·B 
t(9;22)(q34;qll) 
t(1;19)(q23;p13) 
t(ll:V)(q23;V) 
t(12;V)(p12-p13;V) 
dic(9;12)(pll · p12; p12) 
dic(7;9)(p13;pll) 
Mature B-cells 
!(8;14)( q24;q32.3) 
t(8;22)(q24;qll) 
t(2;8)(pll . p12; q24) 
t(14;18)(q21;q32) 
T-cells 
t(11;14)(p13;qll) 
t(11;14)(p15;qll) 
t(10;14)(q24;qll) 
inv(14)( qll;q32.3) 
t(1;14)(p32 - p34; qll) 
t(8;14)(q24;qll) 
t(7;V)(q34. q36; V) 
t(7;19)(q35;p13) 
6q·, 9p· 
Involved ~nes 
ABL 
PRL 
MYC 
MYC 
lgK 
BCL2 
TCL2 
TCL! 
TCL3 
TCRa/6 
TALl 
MYC 
TCR8 
TCR8 
BCR 
E2A 
lgH 
lgL 
MYC 
lgH 
TCRa/6 
TCRa/6 
TCRa/6 
TCRa/6 
TCRa/6 
LYL! 
V = variable chromosome, variable region 
&f. Champlin and Gale, 1989 
Seeker-Walker, 1990 
Pui et al., 199ff' 
tll 
Child 
3·5% 
5·6% 
6% 
5% 
1·2% 
< 1% 
2% 
0.3% 
Rare 
1% 
Rare 
< 1% 
< 1% 
Rare 
Rare 
2% 
Rare 
Frequency 
Adult 
17-25% 
Prognosis 
Poor 
Modest - Poor 
Poor (especially t(4;11)) 
Poor 
Poor 
Poor 
Variable 
Poor 
2. Structural ablUJrmalities: 
Structural aberrations are mainly seen in the pseudodiploid and hypodiploid groups and 
are mostly translocations. They usually herald a deteriorated prognosis for an individual 
patient since they are associated with an increased risk for early treatment failure (Third 
International Workshop on Chromosomes in Leukemia, 1981, Williams eta!, 1986, Pui et 
a!, 1990b). Some translocations are particularly associated with a poor prognosis such as 
t(9;22), t(8;14) or t(4;ll). So far, several oncogenes involved in translocations have been 
isolated. Their exact role in the origin of the leukemia is still unknown. However, the 
general assumption is that most play a crucial role in this proces. In table 4 the subdivisi-
on of ALL according to cytogenetic characteristics is given. 
Subdivision of ALL into risk-groups. 
Prognosis for each individual patient depends on various interrelated factors. These are: 
age, sex, race, WBC, karyotype, immunophenotype, involvement of the central nervous 
system (CNS) in the disease, extent of lymphadenopathy and response to therapy (Bennett 
eta!, 1976, Sather et a!, 1981, Kalwinsky et a!, 1985, Pui eta!, 1987a, Hoelzer eta!, 
1988). The stratification of ALL into different risk-groups is essential for predicting the 
chance of cure for a patient and for choosing the appropriate therapy regimen in each 
individual case (reviewed by Champlin and Gale, 1989). Coincidentally, this subdivision 
follows the parameter age. 
1nfrmts 0-1 year: this group in general is annotated as a high-risk group and carries a poor 
prognosis (Crist et al, 1986). ALL in infants shows aggressive behaviour (high WBC, 
CNS-involvement, hepatosplenomegaly) and poor response to modem chemotherapeutic 
regimen. The unfavourable prognosis in this specific age group is mainly due to increased 
incidence of hybrid leukemias and overrepresentation of translocations involving ilq23 
(Reaman eta!, 1985, Pui eta!, 1987b, Ludwig eta!, 1989, Raimondi eta!, 1989). 
Children 2-10 years: this is the low to average risk-group. Most patients with ALL are 
found here. The majority carries a good prognosis and responds very well to the 
chemotherapy courses (Champlin and Gale, 1989, Pui eta!, 1990b). This is mainly due to 
the presence of most cases of hyperdiploidy with more than 50 chromosomes, the subtype 
of ALL which is curable, in this age group. However, as soon as a translocation is found 
the prognosis declines and is defined by the structural aberration (Williams et al, 1990). 
Adolescents 11-21 years: this group was recently separated from the children since their 
sole age showed to have an adverse effect on prognosis (Crist et a!, 1988, Santana et al, 
1990). Research so far indicates that adolescents of 11 to 16 years tend to show some 
favorable prognostic features as found in children while adolescents 16 to 21 years resem-
ble adult ALL-patients. However, more research on a larger number of adolescent 
patients is needed before any defined conclusions can be given concerning prognosis and 
treatment outcome in this particular age group. 
Adults over 21 years: this age group forms a minority in ALLs and prognosis is clearly 
inferior to that in children. Most adults with ALL are less than 30 years of age. Increa-
sing age predicts lower remission rates and shorter remissions after chemotherapy, both 
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indicators of a poor outcome (Hoelzer et al, 1988). T-cell and null-cell ALLs are 
relatively common in this age group. 
Modern chemotherapy, using vincristine and prednisone as induction treatment followed 
by maintenance therapy, can cure 60% of children and 30% of adults suffering from ALL 
(Jacobs and Gale, 1984, Pinkel, 1987, Champli11 and Gale, 1989, Rivera et al, 1990). 
Indispensable for this success rate was the recognition of the various risk-groups in ALL, 
each with its own clinical and biologic characteristics. The practical consequence of this 
subdivision was that groups with poorer prognoses were treated with intensified chemo-
therapeutic regimen. As a result, several prognostic factors lost their predictive value 
especially for a dire outcome of the disease (Gaynon et al, 1988, Fletcher et al, 1989, 
Seeker-Walker et al, 1989, Pui et al, 1990a). However, many high-risk groups remain, 
e.g. with hypodiploidy or the Ph translocation, in which even the contemporary chemo-
therapeutic courses seem to have little or no effect (Bloomfield et al, 1990). Probably, in 
these specific patients alternative ways of therapy should be tried such as bone marrow 
transplantation (Forman et al, 1987, Crist et al, 1990). 
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Swnmary 
As a consequence of the Ph translocation, a 2£!:-abl fusion gene is formed that encodes 
chimeric BCR·ABL proteins. The latter are probably causally involved in 
leukemogenesis, although the mechanism is not yet koown. Meanwhile, the heterogeneous 
aspects of the Ph translocation have been explored in an effort to disclose their eventual 
clinical significance. Innovative and useful methods have been devised for the detection of 
the Ph translocation products e.g. the PCR technique or the produc-tion of specific 
antibodies that undoubtedly will prove to be of great help to patients and clinicians in 
future. 
Introduction 
The Philadelphia (Ph) chromosome is the hallmark of chronic myeloid leukemia (CML), 
where it is found in more than 95% of the cases. Cytogenetica]lv, the stttndard Ph results 
from a reciprocal translocation t(9;22)(q34;qll). Variant translocations involving at least 
one additional chromosome are seen in about 5% of the cases (1). Molecularly, a 
truncated c-abl oncogene is transferred from 9q34 to the 2£!: gene on chromosome 22qll. 
A recombinant gene consisting of 5' 2£!: sequences and 3' c·ill2! sequences is formed. This 
gene encodes a hybrid mRNA, which is translated into chimeric BCR-ABL proteins 
exhibiting enhanced tyrosine khtase activity (2). The fusion proteins presumably play a 
key role in the oncogenesis of Ph+ leukemia. But, so far, the crucial question regarding 
the mechanism by which the activated l!!ll oncogene participates in leukentic 
transformation is not yet answered. 
The heterogeneity of the Ph chromosome can be analyzed using molecular techniques, that 
demonstrate variation in chromosomal breakpoints or in 2£!:-abl gene products. In recent 
years, clinically distinct groups of patients with Ph+ leukemias, have been investigated 
(for review see 3). 
Ph+ Leukemias: Clinical association. 
The Ph chromosome is found most consistently in CML at diagnosis and throughout the 
chronic phase. When acceleration or blast crisis occurs, a second Ph is often observed, 
together with other non-random additional chromosomal changes. The Ph is also found in 
other leukemias, particularly in 15 to 20% of adult ALL cases and in 1 to 2% of AML. It 
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is occasionally present in childhood leukemia (AML, ALL or adult type CML), in 
myelodysplastic syndrome, essential thrombocythemia or other myeloproliferative 
disorders. 
In CML, the Ph indicates a more favorable outcome of the disease than in Philadel-
phia negative cases (Ph-), in contrast with acute leukemia where the Ph is associated with 
pocr response to treatment and shorter survival. 
Breakpoint in c-1!!21 in CML aJUi AIL. 
The c-llll! gene has two first exons (lA and lB) that can be spliced to a set of c-llll! 
common exons of which the first is termed a2 (2). The breakpoints in the Ph translocation 
are localized 5' of a2 and can be scattered over more than 200 kb of DNA. Whatever the 
localization of the breakpoint in c-llll!, the exon a2 serves as splice acceptor for the l1£I 
exon that is juxtaposed to it by the Ph translocation. In three exceptional cases, two Ph+ 
ALLs and one Ph+ CML, the llhl exon a3 has been found to be spliced to l1£I exons. 
(4,5). 
Breakpoint in /zQ: gene in CML aJUi AIL. 
In CML, the breaks on chromosome 22 are clustered within a 5.8 kb Bgill restriction 
fragment, termed M-BCR-1 for major Breakpoint Cluster Region (6). The M-BCR-1 is 
situated in the central part of the l1£I gene and contains 4 small exons designated bl to b4 
(Fig. I). Breakpoints cluster precisely in the 2 introns between b2 and b3 
and between b3 and b4. After translocation of c-Jlhl sequences, splicing of either b2 or b3 
to the abl a2 exon takes place during pre-mRNA processing, resulting in 8.5 kb chimeric 
mRNA with specific b2a2 or b3a2 l!£r-l!Q! joining regions. As a result of this 
heterogeneity, two different p210""~" fusion proteins are encoded that differ by only 25 
amino-acids (encoded by exon b3). In Ph+ ALL, the breakpoint in l1£I may take place 
much further upstream of M-BCR-1 in the first intron of the ll£r gene, designated m-BCR 
(Minor Breakpoint Cluster Region). 
0 60 80 100 120 140 Kbp 
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Fig.! Schematic representation of the bcr gene according to Heisterkamp et al. (8). Exons are indicated by 
vertical barre. The M-BCR-1 region is enlarged, showing the exons bl to b4, the restriction sites and the 
arbitrary division in S' and 3. segments. Bg: Bglii, H: HiD.diii, Ba: BamHI. 
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Translocation of c-abl to this position of lll;r results in transcription of a 7 kb lll;r-l!lll 
fusion mRNA in which the first exon of lll;r (el) is spliced to l!lll exon a2, producing an 
in frame el-a2 junction (7). This mRNA encodes a chimeric protein of 190 kD (Pl90'"· 
""') with enhanced phosphotyrosine kinase activity. The first intron of lll;r measures 68 kb 
(8) and detection of chromosomal breakpoints by Southern blotting is not very practical 
(9). Alternative methods have been used to demonstrate the occurrence of breakpoints in 
first lll;r intron i.e. 1) long range mapping by pulsed-field gel electrophoresis (10); 2) 
amplification by PCR of eDNA fragments containing the el-a2 junction; 3) demonstration 
of the Pl90""""'' protein by immunoprecipitation technique. Approximately half of the 
cases of Ph+ ALL are M-BCR-1+ (with CML specific breakpoint); the other half is 
Ph+, M-BCR-1- and in the majority of these cases a breakpoint is found in the first 
intron of the !2£!: gene (m-BCR). Actually, in a small number of ALL patients with 
(variant) Ph translocation, neither type of breakpoint could be demonstrated. However, 
few, if any of these cases have been analyzed carefully enough to jump to the conclusion 
that an alternative oncogenic c~ahl activation may exist, not involving Qg. 
Mapping of BCR breakpoint in CML. 
Southern blot analysis of !2£!: has been performed in a large number of CML patients. 
Because of polymorphism in restriction sites and comigration of restriction fragments, 
several probes and enzymes should be used to allow a solid mapping of the breakpoint 
within M-BCR-1 (Fig. 1). In 1987, Schaeffer-Rego eta!., reported a positive correlation 
between a 3' localization of M-BCR-1 breakpoint and early occurrence of blast crisis 
(11). These results were not confirmed by a number of other investigators (12-14). A 
methodological difficulty in these studies is that the restriction analysis used does not 
defme the position of the breakpoints accurately enough. Therefore, the area designated as 
5' may have a breakpoint at either 5' or 3' sides of exon b3. Also, recruitment and 
treatment of patients in different series is too heterogeneous for valid comparison. 
In blast crisis of CML, the lll;r rearrangements remain the same as in chronic phase, 
although secondary changes are observed in approximatively 10% of the cases. But, so 
far, the number of patients sequentially studied is still very limited. 
Ph negll!ive CML. 
A small percentage (,;; 5%) of patients with a presumptive diagnosis of CML do not have 
the Ph chromosome (3, 15). The karyotype is normal in 2/3 of the cases. A variety of 
chromosomal abnormalities are found in the remaining cases, among which translocation 
of 9q34 with another chromosome than 22 was observed. Currently patients of earlier 
reports have been reclassified as MDS (mostly CMML and Juvenile CML) on 
morphological ground (16). A number of patients with rypical CML clinical features and 
evolution shows molecular changes identical to the normal Ph translocation, and in situ 
hybridization studies have mapped bcr and c-l!lll sequences at unusual chromosomal 
positions (15). These cases are clinically indistinguishable from the patients with Ph+ 
CML. A small group of patients remains that appears to have rather rypical CML disease 
at presentation, but fails to show a Ph chromosome both cytogenetically and molecularly. 
Follow-up information on these cases is too scarce for clinical evaluation. Larger 
prospective studies are needed to assess the clinical significance of these negative findings 
and to explore the possibility of completely novel molecular events participating in 
leukemogenesis in these patients. 
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PCR studies of the Ph translocation. 
The polymerase chain reaction (PCR) method allows enzymatic amplification of short 
genomic DNA segments in vitro. However, the technique is not immediately applicable to 
the detection of the t(9;22) on genomic DNA in CML because of the wide variation of 
chromosomal breakpoints. The PCR technique has been modified in order to amplify the 
eDNA copied from the hybrid portion of the specific ~-lll11 mRNA transcripts, i.e. the 
el-a2, b2-a2 or b3-a2 junctions. Adequate choice of primers will allow amplification of 
the junction specific cDNAs and of normal c-lll11 eDNA as internal controL This is 
particularly useful to demonstrate a breakpoint in the first intron of ~ (m-BCR) (7) 
although it is also used to discriminate between b2-a2 and b3-a2 mRNA junctions in 
Ph+, M-BCR -1 + leukemia. Dilution experiments have shown that one Ph positive 
cell/10' to 106 normal cells can be detected. Thus, the PCR method is used to diagnose 
residual disease in autografts and for follow-up of patients that became Ph- by cytogenetic 
analysis (and Southern blotting) after bone marrow transplantation or interferon treatment 
(17). But, because of the extreme sensitivity of the PCR method, the danger of finding 
false positive signals due to DNA contamination is quite high. Extreme care should be 
taken carrying out these experiments, and negative controls should always be included. 
lmmwwdiagnosis of CML. 
P210""~bl and P190,.,_.,1 are expressed exclusively in Ph+ leukemias and are thus by 
definition tumor specific proteins. However, they are hybrid proteins composed in part of 
BCR and ABL sequences which themselves are normal cellular proteins, expressed in 
most cells. The tumor specific determinant of the fusion proteins is found in the unique 
amino-acid composition found at the joining of BCR and ABL sequences. Three types of 
junction are currently found at the mRNA level i.e. el-a2, b2-a2 and b3-a2 (7). 
Oligopeptides corresponding to the predicted amino-acid sequences of the different BCR-
ABL junctions have been synthesized and used as immunogens. Van Denderen et al. have 
isolated a polyclonal antiserum "BP-ALL" that specifically and uniquely recognizes el-a2 
P190'"""1 and not P210"'""1 (18). Another antiserum "BP-1" recognizing the b2-a2 
junction sequences of P210"'~ had been isolated previously (19). Attempts to isolate an 
antiserum specific for the b3-a2 joining in P210""""'1 have not yet been successfuL BP-1 
and BP-ALL are used to determine the specific BCR-ABL protein expressed by the cells 
using immune-precipitation experiments combined with autophosphorylation. Therefore 
this approach is applicable to the study of acute leukemia, blast crisis of CML or otherwi-
se purified blast cell populations. Methodological difficulties still have to be overcome to 
make this antisera directly applicable and perform immunocytochemical detection of BCR-
ABL fusion proteins. 
So far, the demonstration of antigenic specificity of the fusion protein opens perspectives 
for future immunodiagnosis of CML and ALL, a development of great interest to 
clinicians. 
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Summary 
Two patients with Philadelphia chromosome-positive acute lymphoblastic leukemia 
showed novel variants of the chimeric ~-g]ll mRNA. The ~-g]ll breakpoint region on 
eDNA derived from the chimeric mRNA was amplified, using the polymerase chain 
reaction (PCR). Sequence analysis of the breakpoint-containing fragment showed that in 
both patients exon a2 of the gQ]_ gene was deleted, giving rise to an in-frame joining at the 
mRNA level of 5' ~-sequences to the lll!! exon a3. These findings were confirmed by 
Southern blot analysis and cloning of chromosomal DNA. Protein studies showed a BCR-
ABL protein with heightened tyrosine kinase activity in blast cells of both patients: one of 
the Pl90 type, the other of the P210 type. The significance of these findings and the role 
of this new type of translocation in the deregulation of the gQ]_ gene are discussed. 
Introduction 
In 95% of the patients with chronic myeloid leukemia (CML) the Philadelphia (Ph) 
chromosome is found, which is the result of a reciprocal translocation between 
chromosomes 9(q34) and 22(qll) (1). Due to this event the gQ]_ oncogene is translocated 
to the major breakpoint cluster region (M-BCR-1) of the ~ gene on chromosome 22 
(2,3). So far, the breakpoint in the gQ]_ gene on chromosome 9 seems to occur in a 200-
kilobase (kb) intron, always 5' of gQ]_ exon a2 (4). Most breakpoints in the M-BCR-1 
region on chromosome 22 are located between exons b2 and b3 or b3 and b4. The ~-g]ll 
fusion gene on the Ph chromosome is transcribed into an 8.5-kb chimeric ~-g]ll mRNA 
that shows either a b2a2 or a b3a2 joining at the mRNA level (5-8). The 8.5-kb ~-g]ll 
mRNA is translated into a 210-kilodalton (kD) BCR-ABL fusion protein showing 
enhanced in vitro tyrosine kinase activity when compared to the normal 145-kD ABL 
protein (9). 
The Ph chromosome does not solely occur in CML but can also be found in 
approximately 20% of adult patients with acute lymphoblastic leukemia (ALL) (10). 
Roughly 50% of these cases show a ~-lll!! joining at the mRNA level similar to CML 
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(11). The remaining 50% have a breakpoint 5' upstream from the M-BCR-1 region, i.e. 
in the first intron of the bcr gene (minor breakpoint cluster region, m-BCR-1) (12). In the 
latter case the ll!;r-abl fusion gene on chromosome 22 gives rise to a 7 .0-kb mRNA. Here 
the first exon of the ll!;r gene (el) is spliced to the second exon of the c-l!lll gene (a2), 
resulting in an ela2 joining (13). The corresponding hybrid protein has a molecular 
weight of 190 kD and also shows enhanced tyrosine kinase activity (14-17, for review see 
Ref. 18). 
The elucidation of the molecular structure of the ll!;r-WJ. chimeric product and the 
development of the highly specific and sensitive polymerase chain reaction (PCR) allows 
us to diagnose Ph positivity in patients with leukemia. Therefore, patients with a Ph 
chromosome are routinely screened in our laboratory by PCR analysis to determine 
breakpoint joinings at the mRNA-Ievel, i.e. ela2, b2a2 and b3a2 (19). Surprisingly two 
patients with ALL were found who showed an amplified ll!;r-Wl fragment that did not 
hybridize to any of the available breakpoint probes. Sequence analysis revealed a deletion 
of abl exon a2 in the bcr-abl mRNA, which was confirmed by DNA-studies. Both patients 
expressed a BCR-ABL protein, one of the Pl90 type, the other of the P210 type. To our 
knowledge, these two patients are the first reported to have such a deletion in association 
with a Ph-positive leukemia. 
Materials and methods. 
Patients. 
Both patients were diagnosed and treated in Rotterdam, the Netherlands: patient 1 at the 
University Hospital Dijkzigt, patient 2 at the Dr. Daniel den Hoed Cancer Center. The 
diagnosis ALL was based on the clinical and hematologic data, bone marrow morphology 
and immunophenotyping of the blast cells (Table 1). 
At the time of diagnosis patient 1, a 39-year-old female, presented with a history of 
bleeding and infections. On clinical examination there were no signs of lymphadenopathy 
or hepatosplenomegaly. The white blood cell count (WBC) was 8.4xl09/liter showing 
60% lymphoblasts. A bone marrow aspirate showed hyperce!lularity with 75% 
lymphoblasts. Cytochemically, 70% of the blasts were characterized by positivity for 
ANA esterase with resistance to NaF; 30% of the blasts were PAS-positive. Peroxidase 
and acid phosphatase staining were negative. Immunophenotypical analysis of the 
lymphoblasts showed reactivity with antibodies for CDlO, CD19, CD24, HLA-DR and 
TdT. 
Table 1. 
Patient 
2 
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HEMATOLOGIC AND CYTOGENETIC DATA OF CELLS USED FOR THE 
MOLECULAR INVESTIGATION OF PATIENT I AND 2. 
Age/Sex Clinical WBC %Blasts Immuno- Karyotype 
(Yrs) Phase xl09/l BM PB phenotype 
39,F relapse 40.0 89 82 pre-pre-B 46,XX(70%)/46,XX,t(9;22) 
+ other aberrations (30%) 
6l,F diagn. 209.0 79 53 pre-B 46,XX(44%)/46,XX, 
1(9;11;22)(56%). 
Partial positivity for CD20 and CD34 existed. From this pattern it was concluded that the 
patient had pre-pre-B acute lymphoblastic leukemia. Remission-induction treatment 
consisted of daunorubicin, vincristin, L-asparaginase, and prednisone. In addition, CNS 
prophylaxis was given (methotrexate and dexamethasone). Complete remission was 
attained 2.5 months after diagnosis. Despite consolidation-maintenance therapy, 3 months 
later a florid relapse occurred with more than 80% blast cells in bone marrow and 
peripheral blood. The patient died 9 months after diagnosis. 
Data of patient 2 have been published previously (ref.ll: patient R6, 20). Briefly, at the 
time of diagnosis this 61-year-old female presented with a 3-month history of fatigue and 
fever. Clinical examination showed a hepatosplenomegaly and a leucocytosis (WBC 
209xl09/liter). The differential count showed 53% blast cells, 1% myelocytes, 5% 
metamyelocytes, 20% neutrophils, 9% bands, 4% monocytes, 1% eosinophils, 6% 
lymphocytes. The bone marrow was hypercellular with 79% blast cells, which were 
Sudan Black negative and PAS positive. The blasts were of the immunologic pre-B 
phenotype (TdT+, CDIO+, Cig+). The diagnosis ALL was made although a CML in 
blast crisis at presentation could not be ruled out. Remission-induction treatment 
(daunorubicin, vincristin and prednisolone) and CNS prophylaxis were given, and 
subsequently a complete remission was achieved. Notably, although cytogenetic study of 
the bone marrow showed persistence of the Ph chromosome in 70% of the metaphases, 
there were no hematologic features during remission to suggest a chronic phase of CML; 
10.5 months later this patient suffered from a relapse of the ALL and died after a total 
survival time of 14 months. 
Samples. 
Bone marrow aspirates and blood samples were part of diagnostic and clinical follow-up 
studies. Data of specimen used for the molecular investigations are presented in Table I. 
Sterile samples were collected in heparinized tubes. After isolation of blast cells by 
Dextran or a Ficoli-Hypaque gradient, cells were frozen and stored in liquid Nitrogen 
until used. 
Karyotyping. 
Cytogenetic studies were performed using standard procedures. Chromosomes were 
identified by G, Q and R banding techniques and classified according to the !SCN (1985) 
(21). In both patients PHA-stimulated blood cultures were used to determine the 
constitutional karyotype. 
Polymerase Chain Reaction (PCR). 
The RNA·cDNA preparation was performed as described by Hermans et a!. (19) with the 
following modifications for the PCR: Half of the eDNA preparation was used for 
amplification of a control abl fragment; the other half was used for amplification of the 
Qg:-abl fragment. The PCR was performed in a volume of 55 JLI. Changes in the 
composition of the Taq polymerase buffer were as follows: the molarity of MgCI2 was 
raised from 6 mM to 9 mM, and 40 mM KCI was added. The molarity of the dNTPs was 
raised from 2.5 mM to 5 mM each. Amplification of the 11£1:-ill fragment was performed 
by adding 0.25 JLg of primer 2 and 3 per PCR-reaction (Fig.!). As a positive control for 
the PCR experiment, a 450-bp ill fragment was amplified, which was present both in 
healthy individuals and in patients with leukemia. This was done by combining primer 1 
with a 25-mer sense oligonucleotide located in exon IB of the human ill gene 
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7 kb bcr-abl mRNA 
190 kD protein 
8.5 kb bcr-abl mRNA 
21 0 kD protein 
7 kb c-abl mRNA 
145 kD protein 
l~ila2laal 
"1 
319 b9/394 bp 
1 1s I a21 aal 
460bp 
Figure 1. The various mRNA-molecules studied by eDNA preparation and the PCR are represented by bars. 
Exons derived from the her gene are hatched, and exons from the !hi gene are open. Primers for the PCR 
are depicted as arrows and numbered according to the text. Our primers 1, 2 and 3 are the same as c-~ 
a3, mer b2, and bcr gene 1st exon el, respectively, in Hermans et al (19). The size of the fragments 
generated by the PCR is given underneath the corresponding fragments. The triangle indicates that exon b3 
may be present or absent in the 8.5 kb bcr-abl mRNA. 
(ATGCAGCGAATGTGAAATCCCACGT, primer 4 in Fig.!). To exclude contamination 
during the PCR by )lg:-abl-containing fragments, RNA from a healthy individual was 
reverse transcribed and amplified as a control in all the experiments. One unit of Taq 
polymerase (Cetus Corp., Emeryville, CA.) was added per PCR-reaction, and the 
reaction mixture was covered by a layer of paraffin oil. Denaturation of the sample was 
allowed for 3 min. at 93°C, and annealing of the primers was allowed for 2 min. at 550C. 
This was followed by 24 cycles of extension (5 min., 70"C), denaturation (1 min., 93°C), 
and annealing (! min., 55°C). Ten percent of the reaction was used for another 24 cycles 
after adding new reagents. Ethanol precipitation was followed by electrophoresis of 30% 
of the reaction mixture after 48 cycles of amplification through a 2% agarose gel. Four 
identical Southern blots on nylon filter (Zeta probe, Biorad Lab., Richmond, CA.) were 
prepared from this gel. Each filter was hybridized separately to 32P end-labeled breakpoint 
oligonucleotides specific for the b2/b3-a2 and ela2 junctions at 65°C (probes described in 
Ref. 19). A 25-mer oligonucleotide (TTGAACCCTCTTCTGGAAAGGGGTA), situated 
43 nucleotides 3' of primer 4 in the IB exon of the human abl gene, was hybridized at 
42°C to detect the normalllhl fragment. 
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Construction and Screening of A EMBL-3 Library of Patient 2. 
High molecular weight DNA of patient 2 was pattially digested with Mbol and cloned 
into the BamHI site of A EMBL-3 as described by Frischauf et a! (22); 10' independent 
plaques were screened according to the method of Benton and Davis (23), using a 
genomic 2-kb 5' M-BCR Bglii-Hindiii fragment. Four hybridizing plaques were 
rescreened with the 0.9-kb Saui-Kpni genomic w fragment. One of the four plaques 
appeared to hybridize to thew probe and contained a 13.5-kb insert. The 3.5-kb ]2g:-abl 
chimeric Bglii fragment was subcloned into the BamHI site of PUC 19. 
Sequence Analysis. 
After amplification of the l1£!-l!!ll fragment of patient 1 by the PCR, the reaction-mixture 
was loaded on a 2% low-melting point agarose gel (BRL, Gaithersburg, MD.), and the 
band of interest was cut out from the gel. DNA was isolated using phenol/chloroform 
extraction, and the amplified fragment was cloned into a Bluescript vector (Stratagene, La 
Jolla, CA.). Nucleotide sequences were obtained by the dideoxy chain termination method 
(24) on double stranded DNA (25). In the case of patient 2, separation of the amplified 
bcr-abl fragment from the PCR amplification primers was obtained by filtration over a 
Centricon S-100 device (Amicon, Danvers, MA.) (26). Direct sequencing of the purified 
fragment was performed according to Winship (27). 
For sequence analysis of chromosomal DNA fragments of patient 2, a 0.5-kb M-BCR 
Psti-Smai genomic fragment that contains the M-BCR 5' BamHI site was subcloned into 
PUC 19. The DNA sequence of both strands was determined according to the method of 
Maxam and Gilbert (28) using Pstl, BamHI and Smal as labeling sites. The sequence 
strategy for the genomic Saul-Kpnl l!!ll fragment containing parts of l!!ll exons a2 and a3 
has been published by Grosveld et a! (6). The sequence of the chimeric portion of the 
3.5-kb Bglii l1£!-l!.!ll fragment of patient 2 was determined by the method of Maxam and 
Gilbert (28) using the BamHI site in M-BCR and the Sail site in w as labeling sites. 
Southern Blot Analysis of Patient 1. 
High molecular weight DNA was extracted by the usual techniques and blotted, after 
digestion with the restriction enzymes Bglll, BamHI or Kpni (29). As a probe for the 
detection of a breakpoint between abl exon a2 and a3, a 0.9-kb Saui-Kpni genomic 
fragment was used that covers the intron between both exons (6). 
Protein Studies. 
Chimeric proteins from blast cells of both patients were analyzed by immunoprecipitation 
and followed by autophosphorylation as described previously (30). BCR-ABL proteins 
were precipitated with anti-ABL and anti-BCR polycloual antisera. The anti-ABL 
antiserum was raised against a synthetic peptide with proven antigenecity comprising the 
amino acids: CSISDEVEKELGK (31). 
The polyclonal anti-BCR antiserum was raised in rabbits against the NH2-terminus of 
the BCR protein as described previously (30). Blast cells of an ALL patient with ela2 
Pl9QBCR-ABL were precipitated as a control for patient I. In the case of patient 2, blast 
cells of a CML patient and BV173 cells, both containing b2a2BCR·ABL (32), were 
precipitated as controls. 
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Results 
At the time of diagnosis only five metaphases from peripheral blood of patient I could be 
analysed. They showed a 46, XX normal karyotype. At the time of relapse, cytogenetic 
analyses were performed twice on bone marrow and blood, mounting to a total of 110 
cells karyotyped. These showed a mosaicism of normal and Ph positive cells with 
additional changes of the following type: 46, XX(70%)/ 46, XX, t(9;22)(q34;qll)(2%)/ 
46, XX, 1(9;22), inv(l)(p36;q42), del(15)(q22)(10%)/ 46, XX, 1(9;22), inv(l), del(l5), 
1(4;6;17)(q26;q16;q24)(18%) (Fig. 2A). 
Figure 2A. Karyogram of patient 1 showing t(9;22), inv(l), del(lS), t(4;6;!7). R-banding with acridine 
orange. 
9 
t 
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Figure 2B. Partial karyotype of patient 2 showing t(9; 11 ;22). G-banding with Trypsin-Giemsa staining. 
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Patient 2 was previously reported (11) and showed a variant of the Ph translocation at 
diagnosis, i.e t(9;ll;22) in 56% of the metaphases (Fig.2B). Seventy percent of the 
karyotypes remained Ph-positive during clinical and hematologic remission, and additional 
chromosome abnormalities heralded progression and relapse of the disease. 
Since patient 1 showed a Ph chromosome in metaphases of blood and bone marrow cells, 
PCR analysis was performed on eDNA preparations of RNA of this patient in order to 
determine the type of ll£!:-<.!11 joining at the mRNA leveL None of the available 
oligonucleotide probes complementary to the already known breakpoint joining regions 
that occur in Ph-positive leukemia (i.e., ela2, b2a2, or b3a2) hybridized to any llg:-abl 
fragment in the PCR mixture of this patient (Fig. 3, sensitivity of the PCR 1:10'-10', D. 
Soekarman, unpublished results). However, the PCR generated a fragment of 
approximately 120 bp, which was clearly visible on the agarose gel stained with ethidium 
bromide (Fig. 3, patient 1). We hypothesized that a fragment of such size could be 
produced if <.!11 exon a2, spanning 174 bp, miased from the 298-bp fragment normally 
detected after amplification of the e1a2ll£!:-ill joining in ALL patients (19). 
We described one other patient with Ph-positive leukemia previously, analyzed by 
Northern blotting in our laboratory, whose ll£!:-ill mRNA apparently lacked ill exon a2 
(20). We proposed that in this chimeric RNA, joining had occurred of llg: exon b2 to ill 
exon a3. To prove this hypothesis, PCR was performed on eDNA derived from this 
patient using primers I , 2 and 3. 
145bpP.. 
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Figure 3. On the left side of the figure the results of the PCR experiment are shown on gel; on the right 
side the corresponding autoradiogram is depicted. Lanes 1 and 3 contain the PCR-mixture of patient 1 and 2 
after amplification of the 450-bp abl fragment. Lanes 2 and 4 contain the PCR-mixture of patient 1 and 2 
after amplification of the bcr-abl fragment. l.snes 5 to 7 contain the result of amplification of the ~-abl 
fragment of 3 patients with Ph' positive leukemia who show, respectively, an ela2, b2a2 and b3a2joining. 
Sizes of the PCR-fragments usually found in our experiments are given in the middle of the figure. 
Arrowheads indicate the aberrant 2£!-abl fragments of patient 1 and 2 on gel. 
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A fragment of approximately 150-bp length was generated (Fig. 3, patient 2) that matched 
the size of a fragment covering the b2a2 junction missing the 174 bp of l!lll exon a2 (319-
174=145 bp). 
Sequence analysis of the amplified l!&J:-l!lll fragments of both patients confirmed our 
suppositions: the joining in patient 1 consisted of the first exon of the l!&J: gene to l!lll 
exon a3, giving rise to an ela3 l!&r-l!lll mRNA, while in patient 2 a b2a3 joining was 
found (data not shown). 
These data were confirmed by Southern blot analysis. DNA of patient 1, digested with 
restriction enzymes BamHI, Bglii and Kpni, shows two extra bands in all digests after 
hybridization with a Saui-Kpni fragment that covers the intron between l!lll exon a2 and 
a3 (Fig. 4). Since no aberrant bands are detected in corresponding digests of normal 
human thymus DNA, we conclude that the breakpoint of patient 1 in the l!lll gene is 
located between l!lll exon a2 and a3. 
Southern blot analysis of patient 2 (R6 in Ref. 11) showed that 5' M-BCR probes 
hybridized to a 3.5-kb rearranged Bglii M-BCR fragment on the Ph chromosome. To 
investigate the molecular structure, this fragment was cloned in E. Coli in order to 
sequence the l!&r-illll junction. From the DNA of the leukemic cells of this patient, an 
Mbol-partiallibrary was constructed in A. EMBL-3. Screening of the library with a 5' M-
BCR probe (2-kb Bglii-Hindlii fragment) yielded four independent hybridizing phage-
plaques. Since Northern blot analysis indicated that the breakpoint in the l!lll gene would 
map between l!lll exons a2 and a3 (20), the phage-plaques were rescreened with a probe 
covering the intron between a2 and a3 (0.9-kb Saui-Kpni, Fig.4 and 5A). One of the four 
plaques appeared to hybridize to the l!lll-probe. This phage clone contained an insert of 
13.5 kb, which was mapped with the enzymes Bglii, Hindiii, BamHI, Sail and EcoRI 
(not shown). Comparison of the map with the known Q£! and l!lll maps indicated that this 
phage insert consisted of ll.5 kb of 5' l!&r sequeoces linked to 2 kb of l!lll sequences. 
Furthermore, the clone contained the 3.5-kb aberrant Bg!IT M-BCR fragment that was 
also detected on the Southern blots of patient 2. This fragment was subcloned and 
analyzed in more detail. Its 5' side was identical to 5' M-BCR sequences, but the 
similarity stopped just 3' of the BamHI side. The 3' part of the 3.5-kb Bglii fragment was 
identical to the c-sQl-map, starting in or just 3' of exon a2 of l!lll (Fig. 5A). To exactly 
localize the breakpoint, the area of the breakpoint of the 3.5-kb Bg!IT fragment was 
sequenced on both strands. Comparison with the corresponding l!&J: and l!lll sequences 
showed that chromosome 22 sequences stop 11-14 bp 3' of the M-BCR BamHI site (i.e., 
!75 bp 5' of exon b3) and the 9 sequences start 21-24 bp 3' of l!lll exon a2. At the site of 
the breakpoint, the redundant dinucleotide AG is present that could be derived from either 
chromosome (Fig.5B). No nucleotides are inserted or deleted during the translocation 
event. 
Finally, blast cells of patient 1 and 2 were analyzed in an immunoprecipitation assay 
followed by autophosphorylation. Using antisera directed against l!lll-sequences and Q£!-
sequences, a protein of approximately 190 kD was precipitated from blast cells of patient 
I. This "Pl90-like" protein exhibits similar tyrosine kinase activity as ela2 Pl90oc1<-A8L in 
blast cells of a Ph-positive ALL patient, as equivalent amounts of cells were takeo (Fig. 
6A). From blast cells isolated from patient 2, a protein was precipitated both by anti-ABL 
and anti-BCR antisera with a molecular weight of 210 kD. The tyrosine kinase activity of 
this "P210-like" protein is comparable with the activity of the b2a2 P21QBCR·ABL molecule, 
derived from a comparable number of blast cells from a Ph-positive CML patient and 
BV173 cells (Fig.6B). 
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Figure 4. Southern blot analysis of patient 1. DNA of patient 1 was digested with restriction enzymes 
BamHI, Bglii and Kpnl. Normal human thymus DNA (N) was used as a controL A 0.9-kb Saul-Kpni 
fragment was used as a probe. Germline bands are indicated by arrowheads, and the size of the fragments is 
given on the left for the BamHI digest, and on the right for the Bglll and Kpnl digests. Below the Southern 
blot a simplified restriction map of the region of interest is given. B=BamHI. BG=Bglli, K=Kpnl, 
S=Saul. .tJ2.! exons a2 and a3 are depicted as boxes and numbered 2 and 3, accordingly. The loca.IWltion of 
the Saui-Kpni fragment used as a probe is given. 
49 
A 
I 
I 
BG S I H Hll 8 BG 
I L:Sa lr lr I I ! I 9 
a2 I a3 
I 
I 
I 
8G H 81 H HII 8 8G 
I l I:Sa lr lr I I 0 :I 22q-I 
b1 b2 I I 
a3 
I 
I 
8G H 
I 
81 H 
I 0 l II 0 I 22 
b1 b2 i b$ 
I 
1K8 
B 
- ~ TTJ:C1' CGCCA G'ICCA CATM CActC TMGC ATMC 'I:ANI.C rn.AA ACCCT 'ICTCC C:CAGC TACTC 
ATTAC AC'ITC GACTC ACTCC TTrCC CTG'l:A TTCCT MACC MCTC CATCC TCAGA TCGCC MCTC 22q· 
ATTAC AC'ITC CACTC ACTCC TTICC CTCTA 'ITCTC AAACC ACCTG CA'l'CC TGAGA TCCCC AACAC 22 
CTCCT TCCAC CAGAT AGAJIA TCTCC CAA.TT CCCCT T'!GAC CJ:ACC ACCCT TTCCT CCTTA MCGA 
C!(:CT TCCAC CAGAT ACAM TCTCC GAATT CCCCT TTCAC CTACC ACCCT TTCCT Cr:IT'!A MCCA 22q· 
ACIIAA TCATC ATGAC TATCT TIT!C CCCCA TCACA CTCCC TTACC TTCTC CCACC CAGAT CCCAC 22 
Figure 5 
A. Restriction map of part of the abl gene on chromosome 9 (upper line), the 3.5-kb Bgl fragment 
containing the bcr-abl joining of patient 2 (middle line) and part of the bcr gene on chromosome 22 (lower 
line). Chromosome 9 sequences are depicted as black lines, chromosome 22 as open lines. Exons of the abl 
gene are depicted as black boxes and of the !:?£! gene as open boxes. Exons are numbered according to the 
text. The arrowhead and the dashed line indicate the breakpoint localization of patient 2. The 0.9-kb Saui-
Kpnl probe is depicted as a black bar underneath the restriction map of part of the rull gene. BG=Bgl n, 
S=Saul, llll=Hincl!, K=Kpnl, H=Hindlll, B=BamHI, Sa=Sall, E=EcoRl. 
B. Corresponding sequence analysis of part of the fragments depicted in Figure SA. The arrow indicates the 
end of exon a2 of abl. The arrowhead points at the AG dinucleotide at the transition of the Qg to the ahl 
sequences. The BamBI site in the .P.£r sequence is underlined. 
50 
A 
2 3 4 
, 2 3 B 
.!. 5 6 
I 
- • -~~-
-P1SO 
• 
-PHlO 
antl·ABL 
Figure 6 
A. Immunoprecipitation analysis followed by autophosphorylation of blast cells isolated from patient 1; 
lxl07 blast cells were isolated from peripher:al blood and precipitated with 50 JL1 N~~zSO,. precipitated anti-
ABL antiserum (lane 1) and anti-BCR antiserum (lane 3). As a positive control, 1x107 blast cells from an 
ALL patient with an ela28CR·A.BI .. junction were precipitated with anti-ABL antiserum (lane 2) and anti-BCR 
antiserum (lane 4). 
B. Immunoprecipitation analysis followed by autophosphorylation of blast cells isolated from patient 2; 
lx107 blast cells were isolated from peripheral blood and precipitated with 50 J.d. Naz$04 precipitated anti-
BCR antiserum (lane 1) and anti-ABL antiserum (lane 4). As positive controls, lxl07 blast cells from a 
CML patient with a b2a2BCR-ABL junction (lane 2 and 5) and lxl07 BV173 cells (lane 3 and 6) were 
precipitated, respectively. 
Discussion. 
In this article we present the clinical, cytogenetic, and molecular data of two patients with 
Ph-positive ALL. We investigated the ll£!:-W rearrangements in both patients using the 
polymerase chain reaction (PCR) on eDNA. Sequence analysis of the amplified bcr-abl 
fragments showed that in both patients a deletion of exon a2 of the illJ! gene had occurred 
in the chimeric ll£!:-abl mRNA. Consequently, the joining-configuration in patient I was 
ela3 and in patient 2 b2a3. This is a remarkable finding since all patients with Ph-positive 
leukemia molecularly investigated so far always seem to include illJ! exon a2 in their 
chimeric bcr-abl mRNA. In addition, Southern blotting data from patient 1 (Fig.4) and 
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chromosomal cloning and sequencing data from patient 2 (Fig.5, A and B) showed that 
the deletion of illll exon a2 from the chimeric ll£!-illll mRNA was due to the position of 
the breakpoint in the illll gene on chromosome 9. In both cases the breakpoint maps in the 
0.6-kb intron, separating illll exons a2 and a3. Since breakpoints in illll can be scattered 
over an area of more than 200 kb (4,6,33), and assuming that the position of the 
breakpoint would be random, the small target size of the intron between illll exons a2 and 
a3 predicts that in theory < 0.3% of the Ph translocations will take place here 
(0.6kb:200kb=0.003). Unfortunately there are no large-scale data available on the 
position of illll breakpoints to check this prediction. 
From both eDNA sequencing and the protein studies, we conclude that deletion of the 
illll exon a2 results in the generation of in-frame 2£!:-illll chimeric mRNAs, which in both 
patients give rise to the expression of a chimeric ll£!-illll protein with enhanced tyrosine 
kinase activity. Although the tyrosine kinase assay is not quantitative, the signals on the 
autoradiogram suggest that the tyrosine kinase activity of the proteins missing a2-
sequences is not significantly different from the ones containing a2 sequences. Therefore, 
we expect that the tumorigenicity of the BCR-ABL proteins without illll exon a2 
sequences will not be different from their counterparts containing exon a2 sequences. 
The finding of the novel BCR-ABL variant with deletion of illll exon a2 and increased 
tyrosine kinase activity is of interest since it may help to clarify the mechanism by which 
the c-ABL tyrosine kinase is activated. The kinase activity of ABL seems to be crucial in 
tumorigenesis, as the transforming activity of the v-illll gene in the Abelson Murine 
Leukemia Virus (AMuL V) is directly dependent on this activity (34). Evidence is 
accumulating that disruption of the illll gene (either by viral transduction as occurring in 
AMuLV, or by translocation as in Ph-positive leukemia) and concomittant deregulation of 
its kinase domain could play a pivotal role in the origin of the leukemia (35-38). As has 
been published, the kinase domain of the illll gene shows strong homology with the kinase 
domain of the e-m: oncogene and is called the _m:-homology 1 region (SH!) (39). Amino-
terminal from this region, two additional homology regions have been described in the illll 
gene: the SH2 and the SH3 region (Fig. 7). 
NH2 SH3 SH2 SH1 COOH 
P145""" 
Figure 7. The orientation of the various SH-regions in the c-ABL protein is given. Src-homology 1 region 
(SHl) contains the kinase domain of c-abl. SH2 is a positive regulator and SH3 is a negative regulator of 
SH!. 
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The SH2-region is suggested to be a positive regulatory region immediately N-terminal of 
the kinase domain (39), and this region· is needed by the v-ABL kinase for its 
transforming activity (37). The SH3-region is located directly N-terminal of SH2 and 
comprises 50 amino acids (40). Deletions in this particular region of the c-SRC (41,42) as 
well as deletions in the homologous domains encoding for mouse ABL type IV proteins 
activate the tyrosine kinase (43,44). 
The mutant proteins show transforming abilities in N1H3T3 cells. Therefore, a negative 
regulatory influence on the kinase domain of the aJ21 gene has been proposed for the SH3-
region (43,44). Jackson and Baltimore (43) suggested that the SH3 inhibiting function on 
the catalytic domain may be modulated by interaCtion of the SH3 region with an as yet 
unidentified cellular factor. Deletions in SH3 would prevent the interaction with this 
factor, resulting in the loss of the blocking function and concomittant unleashing of the 
tyrosine kinase activity. Supporting evidence for this mechanism already exists in vivo 
since in the v-ABL protein, which has heightened tyrosine kinase activity, the SH3-region 
has been deleted. 
The two patients described in this article also show a deletion in the SH3-region, since 
the SH3-region is partly encoded by aJ2l exon a2 which is missing in both patients. Due to 
this deletion, 17 N-terminal antino acids of the SH3-region are removed from the BCR-
ABL fusion proteins in both patients. This includes amino acids, which upon deletion 
potentiate the c-SRC transforming activity and in this way may give rise to a BCR-ABL 
transforming protein with enhanced tyrosine kinase activity. However, in published data 
of patients with Ph-positive leukemia, so far an ela2, b2a2 or b3a2 joining has been 
found at the mRNA level. This implicates that ill!! exon a2 is present and that the SH3-
region is still intact in the BCR-ABL fusion proteins of these patients. Since these 
proteins show enhanced tyrosine kinase activity, we assume that the inhibiting function of 
the SH3-region is impaired by the BCR-moiety of the proteins by an unknown 
mechanism. Probably the 5' BCR-sequences downregulate SH3-function either by steric 
hindrance or by binding to the cellular factor, which regulates SH3. Thus, negative 
regulation of the kinase domain of ABL can be disturbed either by deletion of the SH3-
region (as in v-ABL or in both patients described in this article) or by interfering 5' 
sequences that impair the function of SH3 (as in most patients with Ph-positive leukemia). 
In this respect no difference exists between the two patients described in this article and 
the majority of patients with Ph-positive leukemia. 
Understanding of the regulation of the kinase domain of ABL and identification of 
substrate proteins for the tyrosine kinase activity will elucidate its significance for the 
origin and development of Ph-positive leukemias. Patients as described in this paper may 
help to unravel this issue. 
This paper is dedicated to the memory of Andr6 Hermans, M.D. 
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CHAPTER ill 
ACUTE MYELOID LEUKEMIA 
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Chapter m.l 
AN INTRODUCTION TO THE DISEASE ACUTE MYELOID LEUKEMIA (AML). 
While ALL is a childhood disease, acute myeloid leukemia (AML) occurs mainly in 
adults with a preference for the age group older than 50 years (Copplestone and Prentice, 
1988). Its incidence increases with age. Symptoms and signs of this disease may have 
been present from a few days to several months and are often directly related to bone 
marrow failure (Macleod, 1981). Acute onset of fever, malaise and anemia can be found 
accompanied by an increased bleeding tendency, mouth ulcers, leukemic infiltrations (e.g. 
of the skin) and hepatosplenomegaly. While normal hematopoiesis results via maturation 
of bone marrow stem cells in the population of the periferal blood by normal leucocytes, 
erythrocytes and thrombocytes, this proces is disturbed in AML. Here, failure of 
maturation in a developmental stage of a myeloid stem cell occurs and stage specific blast 
cells are generated (Figure 1). Therefore, examination of the blood and bone marrow is 
essential for a correct diagnosis of AML. 
Myeloid 
stem cell 
Macrophage 
Granulocyte 
...................................... @'0 
~ 
Erythrocyte 
"" 
..... ~~ 
Thrombocyte 
Figure 1. Schematic representation of the differentiation-pathways of a myeloid stem cell into mature blood 
cells. The various subtypes of AML according to the F AB-classification are indicated at the developmental 
stage they belong to. 
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~ Table 1 Cytogenetlc-Morpbologtc Subclassification of AML1) 
FAB definition Frequency of Cytogenetic Abo. Frequency of the Prognosis 
FAB subtypes often found karyotypic change 
in AM:L1l in de novo AML 
AUL acute undifferentiated < 1% 
leukemia 
M1 acute myelogenous leukemia 15% 
without maturation 
M2 acute myelogenous leukemia 34% 1(8;21) 7-12% intermediate · 
with maturation good 
M3 acute promyelocytic leukemia 9% 1(15;17) 6-10% intermediate 
M4 acute myelomonocytic lcuk. 23% inv(16) 2-5% good 
+ /· eosinophilia 
M5 acute monocytic leukemia 14% abn.llq23 4-6% intermediate -
a poorly differentiated poor 
(monoblastic) 
b differentiated 
M6 acute erythroleukemia 4% 
M7 acute megakaryoblastic < 1% 
leukemia 
1)de novo AML = no exposure to cytotoxic agent in the past. 
Ref. Schiffer et al., 1989; Second MIC Cooperative Study Group, 1988; Arthur et al., 1989. 
The diagnosis of AML. 
As in ALL, the examination of blood and bone marrow of an AML-patient is performed 
using various diagnostic methods. Each contributes in varying degrees to the eventual 
diagnosis. Nowadays the three main techniques are: morphologic examination 
(Romanows1:y- or Wright's stain) using the FAB-classification, immunologic investigation 
and chromosomal studies. 
The F AB-classification of AML. 
The F AS-classification of AML is based on the morphologic phenotype of the blast cells, 
the degree of maturation along one or more cell lines and the degree of maturation of the 
cells which are generated by a myeloid stem cell (Bennett et al, 1985, Figure 1, Table 1). 
This classification is used to separate the myeloid from the lymphoid leukemias. It also 
distinguishes AML from another disorder with characteristics similar to those of AML: 
the myelodysplastic syndrome (MDS). MDS occurs in patients older than those with 
AML. Its onset is insidious and its course is mitigated in the majority of cases. However, 
30% of MDSs evolve to AML. Both MDS and AML are characterized by proliferation of 
blast cells and ineffective maturation of progenitor cells. MDS presents with multiple 
cytopenias in the blood with a normo- or hypercellular marrow showing evidence of 
maturation arrest and dysplasia. The absolute amount of blast cells in the bone marrow 
and periferal blood is lower than in AML which is in fact one of the criteria by which the 
FAR-classification separates MDSs from AMLs (Bennett et al, 1982). The FAB-clas-
sification, using precise quantitative and qualitative criteria of bone marrow smears and 
peripheral blood, established five subtypes of MDS (fable 2). The separation of MDSs 
and leukemias of lymphoid origin from AML is crucial since these disorders require 
different therapeutic approaches. 
Table 2 
RA 
RARS 
RAEB~ 
CMML 
" 
Ref. 
F AB-Classification of MDS1l 
Refractory anemia 
Refractory anemia with ring sideroblasts 
Refractory anemia with excess of blasts 
Chronic myelomonocytic leukemia 
Refractory anemia with excess of blasts 
in transformation. 
MDS = less than 30% blasts in the bone marrow 
(while AML = more than 30% blasts in the bone marrow) 
Highest risk for evolving into AML 
Bennett et al., 1982 
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Immwwphenotyping of AML. 
Certain cell surface markers are characteristic for various stages of stem cell development 
and these are used to study AML-blasts. lmmunophenotyping demonstrates the myeloid 
origin of the blast cell and is especially helpful in cases of F AB-MO or acute 
undifferentiated leukemia (AUL) (Second M!C Cooperative Study Group, 1988, Bennett 
et al, 1991). This FAB-subtype originates from a very early stage of development and 
blasts show almost no differentiation which do cause problems with morphologic 
classification. 
Cytogenetic investigation of AML. 
Chromosomal aberrations are found in the majority of patients with AML (Yunis et al, 
1981). These abnormalities have an impact on prognosis, independently of other factors 
(Golomb et al, 1978, Fourth International Workshop on Chromosomes in Leukemia, 
1984, Arthur et al, 1989, Keating et al, 1987). Various subclassifications of cytogenetic 
abnormalities are used. Sakurai and Sandberg reported on the significance of the presence 
of abnormal metaphases for prediction of prognosis (Sakurai and Sandberg, 1973). 
Patients with only normal metaphases clearly had a better prognosis than those with partly 
or only abnormal metaphases. Another subdivision is based on the complexity of the 
abnormal karyotype and this shows a deterioration of prognosis with increasing 
complexity (Lawler and Swansbury, 1987). However, intensified therapy regimen in the 
past few years showed that a third subdivision or the Chicago-classification retained its 
predictive value for prognosis. This classification is based on specific chromosomal 
abnormalities which are often found in specific FAB-subtypes (First International 
Workshop on Chromosomes in Leukaemia, 1978, Second International Workshop on 
Chromosomes in Leukemia, 1980, Second MIC Cooperative Study Group, 1988, Bitter et 
al, 1987, Keating et al, 1987, table 1). 
Cytogenetic-morphologic classification of AML (Chicago-classification) subdivides this 
disease in distinct prognostic groups. 
T(8.·2I)(q22;q22) in AML-M2: this translocation is found in 40% of AMLs with FAR-
classification M2 and represents 7 to 12% of all AMLs. In 80% an additional karyotypic 
abnormality is found, mostly loss of a sex chromosome or an interstitial deletion of 9q21-
3l. The median age of the patients is 30 years and the disease is rare in patients over 50 
years of age. This translocation is associated with a good prognosis since most patients 
obtain a complete remission (CR) using standard AML therapy. However, a recent study 
reported a survival rate similar to that found in AML in general (Groupe Fran<;ais de 
Cytogenetique Hematologique, 1990). 
T(I5;17)(q22;ql2) in AML-M3: in 70 to 90% of acute promyelocytic leukemia (APL) or 
AML-M3 a t(l5;17) is found. This chromosomal translocation is also found in younger 
patients with a median age of 30 years and is associated with an intermediate to good 
prognosis (Keating et a!, 1987). A remarkable finding in these patients is the frequent 
occurrence of a disturbance of normal blood coagulation in the form of a disseminated 
intravascular coagulation (DIC). Contrary to the usual therapy in AML, patients with 
APL respond very wen to therapy with all-trans retinoic acid which may effect a 
complete remission in the majority of these patients (Castaigne eta!, 1990). 
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Recently, several groups isolated the gene on chromosome 17 which is involved in the 
translocation (Borrow et al, 1990, Chomienne et al, 1990a, de The et al, 1990, Alcalay et 
al, 1991). This gene encodes the retinoic acid receptor "' (RARa). The translocation 
cleavage of this gene in its first intron is followed by juxtaposition to the 11!!!! gene on 
chromosome 15, which has an as yet unknown function. 
Retinoic acid is a derivative of Vitamin A and induces differentiation of leukemic cells of 
a patient with APL into mature granulocytes in vitro (Chomienne et al, 1990b). Although 
the general assumption exists that the translocated RARa plays a crucial role in APL with 
t(l5; 17), the exact mode in which it participates in the proces of leukemogenesis is still 
an enigma. 
T(16;16)(pl3;q22), inv(16)(p13;q22) or del(16)(q22) in AML-M4 with eosinophilia: 
abnormalities involving chromosome 16 are found in 20% of AML-M4. Patients are 
young and morphologic examination of the bone marrow reveals an increase in abnormal 
eosinophilic cells. This specific cytogenetic-morphologic subgroup carries a favourable 
prognosis since CR-rate and survival are reportedly better than in AML-M4 without 
involvement of chromosome 16 (Le Beau et al, 1983). However, tltis is disputed by 
others who stress the fact that involvement of the central nervous system at diagnosis and 
relapse is responsible for a deteriorated prognosis (Bernard et al, 1989). 
Translocations or deletions with involvemem of llq23: these are found in 35% of AML-
M5 and most of these patients are infants (Kaneko et al, 1982, Koller et al, 1989, 
Raimondi et al, 1989). A frequent translocation in this subtype of AML with a monocytic 
component is t(9; ll)(p22;q23). The prognosis for a patient with AML and llq23-
abnorrnality is poor and the disease is characterized by a short duration of remission after 
conventional chemotherapy. 
Nonrandom cytogenetic abnormalities which are not restricted to a specific FAB-subrype: 
the frequency of most of these aberrations is low and their prognosis is poor (Table 3). 
They include aberrations such as: 
-inversions and translocations involving band 3q21 and 3q26 which are found in AML-
Ml, 2, 4 and 7. Many patients show an increase in abnormal megakaryocytes in the bone 
marrow and thrombocytosis in the periferal blood. 
-trisomy 8. This is the most common cytogenetic abnormality in AML. As a sole 
phenomenon it is found in 8% of AMLs, mostly Ml, M4 and M5. In combination with 
other karyotypic changes it is found in 11% of AMLs, mostly M3. 
-the t(9;22). As in ALL, this translocation heralds an unfavourable disease course in 
AML characterized by therapy-resistance. The genetic organization of the t(9;22) is 
extensively described in this thesis in Chapters !!.2 and !!.3. 
-the t(6;9). The clinical and molecular aspects of this translocation are reported in 
Chapters Il1.2 and III.3 of this thesis. 
Monosomy or abnormality of the long ann of chromosome 5 or 7 (Mire/man et a!, 1978 
and 1981): these karyotypic abnormalities are mainly found in the so-called secondary 
AMLs and are not associated with a specific FAB-subtype (Table 3). Breakpoints on the 
q-arm of chromosome 5 mostly involve bands 5ql3-15 and 5q33 while on 7q this is 7q21-
22 and 7q32-33 or q34-35 (Bitter et al, 1987, Second MIC Cooperative Study Group, 
1988). 
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Table 3 
Cytogenetic Abnonnalities Not Restricted to a Specific FAB-subtype 
Frequency in 
AML Mostly found in Prognosis 
inv(3) 1% FAB-M1 Poor 
t(9;22) 1-3% FAB-M! Poor 
t(6;9) 0.5-4% FAB-M2,M4 Poor 
tris8 4-8% FAB-M!, M4, M5 
(as a sole abo.) 
.y 1% 
+21 1% 
-515q-, -717q- 12% Secondary AML Poor 
(upto47% of the cases) 
Ref. Schiffer et al .. 1989. 
Second MIC Cooperative Study Group, 1988. 
Arthur et al., 1989. 
Contrary to de novo AML, in secondary AMLs an exposure to a toxic factor in the past 
is found which might contribute to the origin of the leukemia. Usually, these patients 
suffered from cancer in the past for which they were treated with radio- or chemotherapy. 
This type of AML is mainly found in patients over 50 and carries a poor prognosis, since 
it responds poorly to therapy and patients show short survival in general (Fourth Internati-
onal Workshop on Chromosomes in Leukemia, 1984, Hoyle eta!, 1989). 
Without therapy a patient with AML usually dies within two months. Using chemotherapy 
consisting of daunorubicin, cytosine arabinoside and thioguanin an overall first complete 
remission (CR) is achieved in 70% of adult patients with AML (Gale, 1990). However, 
the major complication in curing this disease is the frequent relapse after first CR which 
occurs also in prognostically favourable subgroups such as those with a t(8;21) or inv(16) 
(Fenaux et a!, 1989, Preisler et a!, 1989, Schiffer et a!, 1989). An indication of poor 
survival is the fact that only I in 6 patients will be alive 5 to 8 years after AML was 
diagnosed (Bandini et a!, 1991). Therefore, postremission therapy is necessary and new 
approaches such as high dose chemotherapy or bone marrow transplantation after first CR 
are currently investigated on their value to increase the number of long term survivors 
(Reiffers eta!, 1989, Geller eta!, 1990, McMillan eta!, 1990). 
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SUMMARY 
Translocation (6;9)(p23;q34) is a cytogenetic aberration which can be found in specific 
subtypes of both acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). 
This translocation is associated with an unfavorable prognosis. Recently, the genes 
involved in the !(6;9) were isolated and characterized. Breakpoints in both the ~-gene 
on chromosome 6 and the gm-gene on chromosome 9 appear to occur in defined regions 
which allows us to diagnose this type of leukemia at the molecular level. Moreover, due 
to the translocation a chimeric dek-can mRNA is formed which, as we show here, is an 
additional target for diagnosis via eDNA-preparation and the polymerase chain reaction 
(PCR). We studied 17 patients whose blood- and/or bone marrow cells showed a t(6;9) 
with karyotypic analysis (Table 1). Fourteen patients suffered from AML, one patient had 
a refractory anemia with excess of blasts in transformation (RAEBt), one patient had an 
acute myelofibrosis (AMF) and one patient a chronic myeloid leukemia (CML). In 9 
cases studies at the DNA- and RNA-level were possible while in 7 cases only the DNA 
could be analyzed. In one case only RNA was available. Conventional Southern blot 
analysis showed the presence of rearrangements of both the ~-gene and the gm-gene. In 
both genes, breakpoints cluster in one intron in the patients investigated. The presence of 
a consistent chimeric dek-can product after eDNA-preparation followed by the PCR was 
demonstrated. We conclude from our data that the t(6;9) is found in myeloproliferative 
disorders with typical clinical characteristics. This translocation results in highly consis-
tent abnormalities at the molecular level. 
INTRODUCTION 
Since the discovery in 1960 of the Philadelphia chromosome in cases of chronic myeloid 
leukemia (CML) by Nowell and Hungerford, a large number of leukemias has been 
associated with specific chromosomal translocations (I ,2). The development of new 
techniques enabled molecular biologists to isolate and characterize a number of genes 
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Table 1 CLINICAL AND HEMATOLOGIC DATA OF 17 PATIENTS WITH A TRANSLOCATION (6;9)(p23;q34) 
Patient Age/ FAB Clinical Karyotypic %Abo. Baso- WBC % Dlasts Southern PCRO Response Survival 
Sex'' phased) abnorm. metaph. philia'' 109/1 BM PB blot0 to after 
therapy"> diagnosis 
1'' 13/F RAEB diagn. t(6;9) 100 no 1,66 PR ± 18 months 
M4 relapse t(6;9) + RNA n.a. 
+ add.abn. 
2'' 63/F M4 diagn. t(6;9) 93 87 47 30 + no ampl. PR 
3'' 38/M AMF diagn. NM no 5,2 9 5 PR 29 months 
AMF relapse t(6;9) 30 + no ampl. 
4'' 17/F M4 diagn. t(6;9) 97 no 21,2 59 18 + + no therapy 3/4 months 
5'' 13/F M4 diagn. t(6;9) 87 no 29,4 73 58 DNA n.a. + CR 30 months 
relapse 6p- +add.abn. 91 
6 35/M M2 diagn. t(6;9) 80 yes 12,6 58 35 PR 18 months 
t(6;9), +8 20 
relapse 6p- 100 92 95 + no amp!. 
7 'lJl/F M4 relapse t(6;9) 91 no 5,1 92 20 + + CR 17 months 
8 18/M M2 diagn. t(6i9), inv.l 35 no 10 25 < 1 + RNA n.a, CR > 24 months 
after ND 10 DNA n.a. BM: + 
ther. PB:-
9 19/F M2 relapse t(6;9) 100 yes 100 87 94 + + CR 14 months 
10 14/F M4 diagn. t(6;9) 30 + + CR > 36 months 
11 6/F M4 diagn. t(6;9) no 262 80 45 + + NR 2 months 
..., 
.... 
12 28/M M1 diagn. t(6;9) 100 
13 24/F M1 diagn. t(6;9), del.7q 40 
t(6;9) 60 
14 10/M M2 diagn. t(6;9) 100 no 
15 53/M M4 relapse t(6;9) 91 yes 
16 54/F CML diagn. t(6;9) 100 no 
Ph·, her· 
17 53/F RAEBt diagn. t(6;9) 100 no 
after ND 
ther. 
a) Published previously by Von Lindern et al., ref. 19 
b) Published previously by Adriaansen et al., ref. 21 
c) Age in years at diagnosis Sex: M = male, F = female 
d) diagn. = at diagnosis 
after ther. = after therapy; patient 8 -chemotherapy, patient 17- IL2 therapy 
e) > 0.25% basopbils in the bone marrow 
f) + = Southern blot analysis shows rearrangement of the dek- and the £illl:. gene 
DNA n.a = DNA was not available. 
g) + = PCR analysis shows amplification of a chimeric dek-can fragment 
- = no amplification of dek-can while gm. is amplified. 
RNA n.a. = RNA was not available 
no am pl. = despite intact RNA no amplification by PCR 
h) CR = complete remission, PR = partial remission, NR = no remission 
NM = no mitosis 
NO = not done 
WBC = white blood ceU count 
BM = bone marrow 
PB = peripheral blood 
65,9 79 + + 
54,8 95 + RNA n.a. 
47,5 52 37 + no ampl PR 20 months 
100 41 31 + + PR > 4 months 
92 9 + RNA n.a. 11 months 
22 no chemoth. 15 months 
2,5 3 + + 
involved in reciprocal chromosome translocations. Well-lmown examples are the t(8; 14) 
in Burkitt's lymphoma (BL) in which the myc-gene on chromosome 8 is linked to the 
IgH-chain locus on chromosome 14 and t(9;22) in CML in which breakpoints occur in the 
l!hl-gene on chromosome 9 and the llcr-gene on chromosome 22 (3,4,5). 
In a specific subgroup of AML a t(6;9)(p23;q34) can be found (6-10). Patients with this 
type of leukemia are usually quite young and their prognosis is poor. Blast-cells are 
mostly classified as FAB-M2 or M4 (90%) and in a minority as Ml(10%). At the time of 
diagnosis the t(6;9) is usually the sole cytogenetic aberration. Additional karyotypic 
abnormalities are rare but may occur during progression of the disease (9-18). Recently, 
the genes located at the chromosomal breakpoints of this translocation were isolated and 
characterized (19). The gene on chromosome 6 which participates in the reciprocal 
exchange is called dek and encompasses 40 kb (von Lindern et a!, manuscript in prepara-
tion). Southern blot analysis of 4 patients with t(6;9) indicated that breakpoints are located 
in one intron of 9 kb which is called 'intron containing breakpoints on chromosome 6' or 
icb-6. The oo-gene on chromosome 9 is more than 130 kb in length. Here, breakpoints 
occur in one intron of 7.5 kb (icb-9) which is located in the middle of the gene. The oo-
gene is transcribed into a 6.6 kb mRNA. Due to the translocation the 3' part of the oo-
gene is fused to the 5' part of ~' resulting in a chimeric ~-oo gene on the 6p-
derivative (von Lindem et al, manuscript in preparation). This chimeric gene is transcri-
bed into an aberrant 5.5 kb mRNA. The functions of the normal lkl;; and can gene 
products are as yet unlmown and it is equally unclear in which way the hybrid product 
may be involved in leukemogenesis. 
In this study we analyzed 14 patients with AML, one patient with RAEBt, one patient 
with AMF and one patient with CML whose blood or bone marrow cells carried a t(6;9). 
Investigation of the leukemic cells at the DNA- and RNA-level confirms the highly 
consistent involvement of both the Qrl;- and oo-genes in this translocation. The myelop-
roliferative disorder marked by a t(6;9) appears as a distinct clinical entity which, as we 
show here, can now be diagnosed and monitored at the molecular level. 
Patients. 
Clinical and hematologic data of the patients are given in table I. In the case of patients 1 
to 5 various data were published previously (13,19,20,21). Patients 6 to 17 were newly 
admitted cases and fresh or frozen samples were sent to us for molecular investigations by 
the following centers: Regional Cancer Center Marseille, France (patients 6 and 17), 
Universitatsklinik Ulm, Germany (patients 7 and 16), University Hospital Groningen, The 
Netherlands (patient 8), Centre Regional de Transfusion Sanguine et de Genetique 
Humaine Bois-Guillaume, France (patient 9), Free University Hospital Amsterdam, The 
Netherlands and Stichting Nederlandse Werkgroep Leukemie bij Kinderen The Hague, 
The Netherlands (patient 10), Medical Center of the University of Amsterdam, The 
Netherlands (patients II and 15), Imperial Cancer Research Fund, Saint Bartholomew's 
Hospital, London, United Kingdom (patients 12 and 13), Children's Cancer Research 
Institute Vienna, Austria (patient 14). 
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MATERIALS AND METII:ODS 
Samples. 
Bone marrow aspirates and blood samples were collected in heparinized tubes. After 
isolation of the white fraction by Dextran or a Ficoll-Hypaque gradient, cells were frozen 
and stored in liquid Nitrogen until used. 
Conventional Southern Blot Analysis. 
DNA was isolated from blood or bone marrow cells according to standard procedures 
(22) or high molecular weight DNA was prepared in agarose plugs as described previous-
ly (23). The following restriction enzymes were used for digestion of DNA: EcoRV, 
BamHl, Hindlll and/or Bglll. DNA-fragments were separated on a 0.7% agarose gel and 
blotted onto nylon filters (Zeta-probe, Biorad Lab., Richmond, CA) according to the 
manufacturers instructions. Probes used for hybridization, hybridization- and washing-
conditions were described previously (19). In short, rearrangement of the dek-gene is 
detectable using radio-labeled probes MFIE.5 (a 500 bp EcoRI-EcoRI fragment) and 
MF2BH (an 800 bp Bg!II-Hindlll fragment). Probes ALIF4EP (a 200 bp EcoRI-Psti 
fragment) and ALIF6E.3 (a 300 bp EcoRI-EcoRI fragment) are used for the detection of 
breakpoints in the can-gene. In figures lA and IB a schema-tic representation is given of 
a simplified restriction-map of both icb-6 and icb-9 and the localization of the probes used 
is indicated. 
A L ...................... J.S. ......... ...! 
l. ·············'-~'--'~ ................. ! 
1. .... 17 . ....... ..1 
L. ·---~~-~:.§.:.~~-- ...... J L ............... !.~.~~ ..................... J 
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.... ..I 1.. ............ 2. ........ ...1 ...............•...... 
9,11 4 
v v v 
RV RV H RV 
In 
H lr HHH B 11 I In I I I I icb-6 
: ' 1 ~ 
d [] 
rTk5l MF1E.S 
"""" 
Figure lA. Restriction map of the icb-6. Exons are depicted as open boxes. The localization of probes 
MFlE.S and MF2BH are indicated as open boxes beneath the map. Stippled lines or arrowheads indicate 
localization of the breakpoint in the dek-gene of the patients. The patients are numbered according to table 
L The breakpoint-containing fragments of patients 1 and 4 were cloned and the precise breakpoints were 
localized (Ref. 19). The breakpoints of patients 9 and 11 fall into probe MF1E.5. RV =EcoRV, H=Hindill, 
B~BamHL 
73 
B L .................................. ---~·-,_~--- ................................. ...! 
L .... 
L.J.Q .. .J 
1. ______ ..... . 
12 ···········-···.JL ....•......... ~?. ................ I 
L ............... n ................ .J 
16 
1.. ............................ !?....... . ................... J 
1.. .... ? •. .! •. 1.± ........ J L-------~'--~---···----·..1 
4 3 1 
v v v 
] B 11 II RV J I 
[] d <-············-25kb 
AL1F4EP AL1RlE.3 
1 icb-9 
Figure lB. Restriction map of icb-9. Exons are indicated as open boxes. Probes AL1F4EP and AL1F6E.3 
are indicated beneath the map as open boxes. Stippled lines or arrowheads indicate localization of the 
breakpoint in the EID.-gene of the patients which are numbered according to table L The breakpoint-con-
taining fragments of patients 1 and 4 were cloned and the precise breakpoints were localized (Ref. 19). The 
breakpoint of patient 3 falls into probe AL1F6E.3. RV=EcoRV, H=Hindiii, B=BamHI. Bg=Bglll. 
Polymerase Clwin Reaction (PCR). 
RNA-isolation, eDNA-preparation and PCR-conditions were described previously (24,25). 
As a control for the eDNA-synthesis and PCR-reaction not only the chimeric l!l;k-can 
eDNA was amplified from the patient RNA but also the normal £ll!l eDNA. 1 unit Taq 
polymerase was added per reaction (Cetus Corp., Emeryville, CA, USA or BRL, Gibco 
Lab., Life Techno!. Inc., NY, USA). Primers used for eDNA-synthesis and PCR-ampli-
fication consisted of either of the two following sets of sequences: 
Primer-set I 
3'primer in can = 5' ACCAGGTGATTCAGCCT 3' 
5'primer in can = 5' CTGAAAACAACTTTACTTGA 3' 
5'primer in dek = 5' CCTACAGATGAAGAGTTAA 3' 
or: 
Primer-set II 
3'primer in can = 5' GTGTCTCTCGCTCTGG 3' 
5'primer in can = 5' AAGAGACCACAGAGTCG 3' 
5'primer in dek = 5' GGCCAGTGCTAACTTGG 3' 
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5.5 kb dek-can mRNA 
" < primer set 1 290 bp > 
< primer set II 222 bp > 
6.6 kb can mRNA 
" < primer set I 335 bp > 
< primer .at II 305 bp > 
Figure 2. Schematic representation of the reversed PCR of dek-gm and £m! mRNA. Dek is represented as a 
stippled bar while can is shown as an open bar. A 3' primer in £m1 (1) is used to make eDNA while the 
PCR is performed with this primer in combination with a s· primer either in dek (2) or in can (3). This 
results in amplification of a ~-gm or£!!!! fragment which can be detected by the specific oligo-probes 4 
and 5. The size of the fragments generated by the various primer-sets are indicated beneath each drawing. 
The anneal-temperature for these primers was chosen at 45°C. The PCR was performed 
using 24 cycles of denaturation (1 ntin. 30 sec. at 92°C), annealing (1 ntin. at 45°C) and 
extension (5 ntin. at 72°C). Analysis of residual disease was performed by serial 10-fo1d 
dilutions of 1 l'g of total patient RNA into 10 l'g of yeast RNA. Procedures for eDNA-
synthesis and PCR were as described above. Althougb we do not know yet the exact copy 
number of the can- and lk!£-can mRNA per leukemic cell, we assume that both show 
comparable levels of expression based on data obtained by Northern blot analysis (2 to 3 
fold more dek-gm mRNA than gm mRNA, ref.19). Amplification by PCR of the gm-
and lk!£-gm fragment occurs with the same efficiency. We compare PCR-results for gm 
with dek-gm. If 100% of cells with can mRNA also express lk!£-gm mRNA all dilution 
samples will be positive for both gm and dek-gm. If 10% of cells carry a t(6;9) no lkk-
can signal is present in the highest dilution while this still contains gm signal. 
For the sequence-specific detection of amplified fragments two oligomers were designed: 
detection of normal can-eDNA : 5' GITATCTGCATITGCT 3' 
detection of dek-can fusion-eDNA: 5' GCAAAAAGGAAAITCG 3' 
Both 32P end-labeled probes were hybridized at 39"C for 3 hours and filters were washed 
in lxSSPE for 1 hour at the same temperature. A schematic representation of the PCR-
procedure is given in figure 2. 
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RESULTS 
Karyotyping of blood or bone marrow cells of patients was performed in the centers that 
sent samples for molecular analysis. In metaphases of all patients a t(6;9)(p23;q34) had 
been found. Patients I to 4 were analyzed previously with Southern blot (table 1, ref. 19). 
Additionally, we obtained DNA from 12 newly admitted cases (patients 6-17, table !). 
DNA of each patient was digested using a minimum of three different restriction 
enzymes. In figures 3 and 4 some results are shown of conventional Southern blot 
analysis in various patients. A combination of three different restriction enzymes and four 
probes enabled us to localize breakpoints in the !kk- and the &il!l-gene in all !6 patients. 
Moreover, digestion with an additional restriction enzyme (Bglll or EcoRI) (or results of 
PCR-experiments, see further) narrowed down the breakpoint localization in most patients 
to the icb-6 and icb-9. 
An example is patient 10: exact localization of the breakpoint in the =-gene was 
impossible using Southern blot alone since only the EcoRV-digest generated an aberrant 
fragment with probes AL!F4EP and ALIF6E.3 (figure 4), while the Hindiii- and 
BamHI-digests showed germline bands (data not shown). However, a PCR-experiment 
generated a chimeric lkk-= fragment (see below), indicating that in frame joining of 
9M and = had occurred. 
EcoRV Hind !II 
h b 
N 6 9 11 12 13 14 10 15 N 8 8 N 
• 
- - 6.6kb 
5.5 kb -
MF1E.5 MF2BH 
Figure 3. Detection of breakpoints in the dek~ene using EcoRV (patients 6,9,11,12,13,14,10,15) or Hindiii 
(patient 8) as restriction enzymes in combination with probes MFlE.S and MF2BH. The patients are 
numbered according to table 1. The size of the germline bands is indicated in kilobases (kb's). Aberrant 
fragments have the following sizes: patient 6: 4.4kb, patient 9: 7.5kb and >23kb, patient 11: 8kb and 
>23kb, patient 12: 16kb, patient 13: >23kb, patient 14: 16kb, patient 10: 7.Skb. patient 15: >23kb. 
patient 8: 9.5kb. 8h=DNA of periferal blood cells from patient 8, 8b=DNA of bone marrow cells from 
patient 8. N =DNA of thymus or white blood cells from a non·leukemic individual. 
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BamHI Hlndll! EcoRV 
N12 6 13 15 N 14 N $ N11 N 10 N 
... -25Kb 
~· 
:. - --S.Skb 
- 6.1 kb 4kb-·- 3.1 
L-J 
AL1F4EP ALFFGE.S AL1F6E.:Z 
Figure 4. Detection of breakpoints in the ~-gene of 8 patients using restriction-enzymes BamHI, Hind.III 
or EcoRV in combination with probes AL1F4EP and AL1F6E.3. The patients are numbered according to 
table 1. The size of the germline fragments is indicated in kilobases (kb's). Aberrant fragments have the 
following sizes: patient 12: >23kb, patient 6: 9.5kb, patient 13: lOkb, patient 15: 2.4kb, patient 14: Skb, 
patient 9: 6.5kb, patient 11: Skb, patient 10: llkb. N=DNA of thymus or white blood cells from a non-
leukemic individual. 
In the EcoRV-digest of this patient, 3' dek probe MF2BH detects an aberrant band of 7.5 
kb (figure 3). However, a much larger fragment should be expected since the first EcoRV 
site 5' of icb-9 in can is located 16 kb upstream of this intron (Figure lB). Therefore, we 
assume that patient 10 has a large deletion of the 5' s;l!J!-gene which has not been mapped 
more precisely. The most accurate prediction for the position of the icb-9 breakpoint in 
this patient is between the 5' end of icb-9 and probe AL1F4EP (results not shown). 
Patient 8 was diagnosed in a preleukemic phase preceding oven AML. His bone marrow 
contained 25% blasts while in the periferal blood only l% blasts was observed (table 1). 
He suffered from paraneoplastic neutrophilic dermatosis also called variant Sweet's 
syndrome (26). Blood differential counts indicated that more than 95% of his leucocytes 
were granulocytes. The marrow also contained variably high numbers of granulocytes 
which diluted the blasts and therefore it was difficult to diagnose AML on purely 
morphological grounds. We determined whether the periferal blood granulocytes carried 
the t(6;9). Indeed, Southern blot analysis of both blood and bone marrow generated germ 
line and aberrant fragments of equal intensity indicating the presence of the t(6;9) in the 
vast majority of the marrow and blood cells and implying that the granulocytes carried the 
t(6;9) as well (figure 3). 
In 14 cases (patients 2-12, 14, 15, 17, table l) sufficient material was available for RNA-
isolation and subsequent PeR-amplification of chimeric dek-s;l!J! eDNA. As shown in 
figure 2, primer-set I generates a fragment of 290 bp when a chimeric dek-s;l!J! mRNA is 
present and a 335 bp fragment from the can mRNA-template. However, these primers 
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were not optimal and gave rise to aspecific pnmmg on the can-mRNA (see fig.6). 
Therefore, primer set II was made. The lkl>-l:illl product of primer set II is 222 bp while 
the can-fragment is 305 bp (figure 2). Results of the analysis of 4 patients using primer-
set II are shown in figure 5A. Via PCR a hybrid lkl!;-s;w mRNA was detected in 10 
patients with a t(6;9), while RNA from leukemia patients without a t(6;9) or healthy 
controls yielded only the fragment derived from the !:ill! mRNA. No conclusions can be 
drawn for patients 2,3,6 and 14. Although intact RNA of these patients was available, 
neither a dek-can or a can-fragment was detected after eDNA-preparation followed by 
PCR. 
Since PCR is a sensitive diagnostic method we used this technique for analysis of material 
containing a minority of cells carrying the t(6;9). Comparison of amplification of can with 
amplification of dek-can in a dilution series gives an estimation of the fraction of cells 
with t(6;9) in a sample from a patient. Both blood and bone marrow cells from patient 8 
were investigated after chemotherapy. Hematomorphologic studies indicated that still 10% 
blasts were present in the bone marrow (table 1). With PCR the presence of residual 
disease in bone marrow cells was seen in dilutions 10'1 and 10°. 
A B 
7 9 12 15 c 17 y 
- dek-can 222 bp 
• 
' - dek-can 290 bp 
-can 305 bp 
• ~ -can 335bp 
Figure 5. PCR detection of £ill! and dek--Em. transcripts. 
A. Results of .a PCR-experiroent of four patients using primer set II. C=conttol material from an ALL 
patient with a normal karyotype. Primers in can generate a 305 basepair 9!!1 fragment in all five individuals 
while a primer in Em in combination with a primer in dek generates a 222 basepair dek-£a!l fragment ooly 
in the four patients with a t(6;9). 
B. Results of the PCR-experiment of patient 17 using primer set I. Y=yeast RNA, used as a negative 
control. Primers in E!!! generate a 335 bp fragment while a primer in .£§!!. in combination with a primer in 
dek generate a 290 bp dek-gn fragment in the patient. Y =Yeast stays negative for both £W. and dek-£!!1. 
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Blood 
-3 -2 ·1 0 
y 10 10 10 10 
• 
Bone Marrow 
-3 -2 ·1 0 
y 10 10 10 10 
PATiENTS 
- dek-can 290 bp 
-can 335bp 
Figure 6. Results of the PCR in patient 8. RNA was isolated from blood and bone marrow after a second 
chemotherapy cou.rse. 1 p.g total RNA of patient 8 was serially 10-fold diluted in 10 J.L8 yeast RNA. 10'= 1 
p.g patient RNA in 10 ~-tg yeast RNA, 10·1 =0.1 p.g patient RNA in 10 p.g yeast RNA, etc. eDNA-
preparation and PCR were performed according to the protocol using primer set I. The 335 basepair 9!!1 
fragment which is generated by the PCR is detectable both in the blood and the bone marrow of this patient. 
A 290 bp chimeric fragment is visible in the first two dilution steps of the bone marrow sample indicating 
that 1/lOxl/10= 1/100 cells contain the t(6;9). Y = 10 JLg of yeast RNA which is used as a negative control. 
The signal of dek-can in the 10" dilution is comparable with the = signal in the w-' 
dilution, indicating that roughly l/100 cells carry the t(6;9) (see Materials and Methods). 
In the blood no t(6;9) carrying cells could be detected (figure 6). 
Patient 17 had been diagnosed as an RAEBt and in diagnostic pbase all metaphases 
showed a t(6;9). Blood cells were analyzed by us from a period after 4 days of IL-2 
therapy which was given for activation of the T -cells. The karyotype of this sample was 
unknown but 3% blasts had been observed in the periferal blood. Since this low amount 
of blasts may be difficult to detect by Southern blotting we decided to use PCR. Clearly, 
a chimeric dek-can fragment was generated, indicating persistence of the translocation 
(figure 5B). Despite the low number of blast cells, Southern blot analysis confirmed this 
result (data not shown). 
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DISCUSSION 
The entity of acute myeloid leukemia (AML) consists of a heterogeneous group of 
diseases. Subclassification according to the French-American-British Cooperative Group 
(FAB) facilitates diagnosis and enables physicians from different hematologic centers to 
exchange and compare data (27). Moreover, the prognosis for a patient depends on the 
FAB-subtype which is found. Additional independent prognostic factors are the various 
chromosomal abnormalities which are linked to specific FAB-subtypes (28,29). A 
t(6;9)(p23;q34) can be found in 0.5 to 4% of patients with AML (6-8,11,14,30-32). To 
date, 34 patients have been reported in the literature whose karyotype showed a t(6;9) (6-
12,14-18,30-36). When the 17 patients are added who were analyzed by us at the 
molecular level, some general features emerge for this group of 51 patients. Diagnosis of 
this disease is usual! y made in the second or third decade of life in contrast to AML as a 
whole group in which the median age is above 60 years. No striking male or female 
preponderance is found. F AB-classification of the AML was frequently reported as M2 or 
M4 with a minority of Ml. However, the translocation is not restricted to these subtypes 
of AML. Cuneo et a! (20) pointed out that a number of patients with t(6;9) was reported 
who were diagnosed as a refractory anentia with excess of blasts (RAEB) which is a 
subtype of myelodysplastic syndrome (MDS). Close scrutiny of the literature confirmed 
this observation and we estimated RAEB with t(6;9) to be third in rank after AML-M2 
and M4 with this translocation (11,13,14,16,30,35). Patient 3 presented with acute 
myelofibrosis (AMF) which eventually evolved into AML-M4. One of our 17 patients 
was diagnosed as a Ph-, BCR- CML. CML with t(6;9) was reported once before by 
Fleischman (31). However, in some ca= differentiation between CML and MDS/AML 
may be difficult. Whether t(6;9) truly may occur in CML or whether the hematologic 
subclassification is incorrect, is not clear (37). The molecular data are strongly in favour 
of the second possibility. 
Pearson et a! proposed that a correlation might exist between the t(6;9) and basophilia, 
though this has been contradicted by others (10,11,15). In our patient-group this pheno-
menon was reported in two patients with AML-M2 and in one with AML-M4. However, 
to establish the real incidence of basophilia in this specific patient-group, standardized 
prospective studies are needed since detection of this feature involves careful examination 
of marrow morphology. 
To date, the immunophenotype of blast cells has only been studied in two patients and 
this showed HLA-DR/TdT/CD13-positivity in both cases (21). It would be interesting to 
investigate a larger group of patients with t(6;9) for TdT -positivity since its presence in 
leukemias of myeloid origin indicates an unfavorable prognosis. 
One of our patients (patient 8) presented with a variant of Sweet's syndrome, a paranee-
plastic syndrome characterized by high fever, cutaneous lesions and granulocytosis (26). 
At diagnosis, his blood contained mainly mature granulocytes. Southern blot analysis of 
the blood and bone marrow cells of this patient showed germ line and aberrant fragments 
of similar intensity (Figure 3, patient 8). This indicated that the li!;k-can rearrangement 
was present in the majority of cells investigated. Therefore, we assume that ce11s which 
appear as "mature" granulocytes in the blood of this patient at diagnosis carry the dek-can 
rearrangement. This observation gives support to the finding of others that leukemic cells 
can differentiate into polymorphonuclear leucocytes (38,39). 
Karyotyping usually shows a simple t(6;9)(p23;q34) at the time of diagnosis. It is 
noteworthy that in patients 5 and 6 a 6p- derivative was seen in relapse while the 9q+ 
was lost. This is a cytogenetic indication that the 6p- derivative carrying the dek-can 
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fusion gene is important in this type of leukemia. Additional aberrations are rare but may 
occur, especially during progression of the leukemia (9-18). The most frequently observed 
extra cytogenetic abnormalities are trisomy 8 and trisomy 13. Trisomy 8 is often seen 
during progression of myeloid leukemias and is found in many cases of AML and CML 
in accelerated or blastic phase (40). Trisomy 13 is a rare event in leukentias but has been 
reported to occur as a sole aberration in A UL, AML and RAEB ( 41-44). The finding of a 
trisomy 8 or a trisomy 13 in any leukemia is an ominous sign and heralds an unfavorable 
outcome of the disease. One of the patients studied here (patient 13) showed deletion of 
the long arm of chromosome 7 in addition to a t(6;9). This abnormality is associated with 
the so called secondary AML or MDS and also predicts an unfavorable prognosis (45). 
To what extent all these secondary cytogenetic changes contribute to the overall prognosis 
of patients with a t(6;9) is unknown at present. 
The discovery of a translocation (6;9) in metaphases of a patient with leukemia is 
alarming since such patients respond poorly to therapy: in our group of patients only half 
of the recorded cases achieved a complete remission after therapy which is in concordan-
ce with the data in the literature. This forms a sharp contrast to a comparable age-group 
of patients with AML in whom a 77% complete remission rate can be achieved with 
chemotherapy (46,47). Mostly, survival does not exceed 3 years and in the group we 
analyzed only one case, patient 10, survived 3 years after a bone marrow transplantation 
and is still in remission. Correct diagnosis of t(6;9) is of utmost importance in trying to 
improve the prognosis for these patients in future. Since the reciprocal translocation 
involves small chromosomal fragments of similar morphology, cytogenetic diagnosis of 
this disease can be difficult. Initially, von Lindern et a! (19) showed that four out of four 
t(6;9) patients contained breakpoints in both icb-6 and icb-9. Since icb-6 and icb-9 
represent introns in the dek- and can-genes respectively, the translocation apparently fuses 
the same dek 'donor'·exon to the same can 'acceptor'-exon, resulting in the formation of 
uniform lk!$:-can fusion genes on the 6p- chromosome of these patients. The data 
presented in this paper corroborate and furtber extend the initial observation: the trans-
location is amazingly precise and highly consistent in 17 t(6;9) patients analyzed at the 
molecular leveL Since the total target size for the translocation per haploid genome 
amounts to less than 20 kb of DNA (icb-6 and icb-9), this may well explain the low 
incidence of the translocation in AML (0.5%-4%). Standardized Southern blot analysis, 
using restriction enzymes EcoRV, Hind!II and BamHl in combination with the limited 
number of four probes, is a reliable method for diagnosis of t(6;9) and is therefore 
clinically applicable. 
Due to the limited amount of material, intact RNA could only be analyzed in 14 cases 
(table 1). In 10 out of 14 cases the PCR generated a dek-can chimeric fragment using one 
primer set and confirmed the results obtained by Southern blot analysis. Intact RNA of 4 
patients neither yielded can- nor dek-can fragments after amplification. Probably this is 
due to technical insufficiency, since inhibition of the Taq polymerase by substances in 
blood has been described (48). (Moreover, Nortbern blot analysis of patient 2 showed a 
dek-can mRNA, see ref. 19). We infer from our results that the chimeric gene is 
expressed in the leukemic cells of all the t(6;9)-patients that could be analyzed. Moreover, 
the chimeric fragment is detected in all these patients using the same lk!$:-can oligomer, 
indicating that it originates from the same exon fusion product in these 10 cases. 
The uniform findings at the DNA- and RNA-level in 17 patients with t(6;9) indicate that 
this translocation is highly suitable for molecular detection by Southern blorting and 
reversed PCR. The latter technique allows sensitive detection of residual leukemic cells 
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after chemotherapy and after bone marrow transplantation through monitoring the 
presence of the dek-can mRNA. The consistent finding of the chimeric product in patients 
with a t(6;9) also strongly argues for a distinct causative role of the lk];;-can fusion gene 
in this myeloproliferative disorder. Occurrence of this translocation in various subtypes of 
AML (Ml,2,4,AMF) and the observations in patient 8 indicate that the lk];;-gm gene 
product does not cause maturation block. Whether once taken place the translocation 
invariably leads to leukemia remains to be established. 
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SUMMARY 
The translocation (6;9)(p23;q34) is mainly found in specific subtypes of Acute Myeloid 
Leukemia (AML) and Myelodysplastic Syndrome (MDS). The diagnosis of this transloca-
tion is not easy since the cytogenetic change is quite subtle. However, recently the two 
genes involved in this translocation were isolated and diagnosis at the DNA-level became 
an additional option. Both the dek-gene on chromosome 6 and the =-gene on chromoso-
me 9 contain one specific intron where breakpoints of t(6;9) patients were found to 
cluster. The translocation results in a consistent chimeric ~-= mRNA which is 
generated from the 6p- derivative. 
Five centers participated in a study to estimate the incidence of t(6;9) in leukemic patients 
using conventional Southern blot analysis. Patients (n=320) with either acute undifferenti-
ated leukemia (AUL), AML, MDS or acute lymphoblastic leukemia (ALL) were screened 
for rearrangement of the genes involved in this translocation. Four of these 320 patients 
showed rearrangement of the =-gene on chromosome 9 of which one had also a 
rearranged dek-gene on chromosome 6. Moreover, 20 additional patients were studied 
with karyotypic aberrations in which either the short arm of chromosome 6 or the long 
arm of chromosome 9 were specifically involved. Both conventional Southern blot 
analysis and contour-clamped homogenous electric field (CHEF) analysis failed to show 
dek-can rearrangement in any of these patients. The results of our study indicate that the 
incidence of the t(6;9) is as low as reported based on cytogenetic data and that rearrange-
ment of the dek- and can-genes is mainly restricted to this specific translocation. 
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INTRODUCTION 
Research in the past twenty years has clearly proven the diagnostic value of cytogenetics 
in neoplasms since defined karyotypic abnormalities are found in specific tumors and 
subtypes of leukemia and lymphoma (1-4). Moreover, these aberrations are helpful in 
predicting the outcome of the disease in quite a number of cases (5, 6). The translocation 
(6;9)(p23;q34) is mainly found in acute myeloid leukemia (AML) with FAB-classification 
Ml, M2 or M4 and refractory anemia with excess of blasts (RAEB) (7-13). This 
chromosome change predicts a poor prognosis for a patient-group which is characterized 
by its young age. Recently, the genes were isolated which are disrupted by the translocati-
on (14). The ~-gene in band 6p23 is 40 kb large while the =-gene in band 9q34 is 
more than 130 kb. Analysis of 17 patients with a t(6;9) showed that breakpoints cluster in 
one specific 9 kb intron in the ~-gene ('intron containing breakpoints on chromosome 6' 
or icb-6) and a 7.5 kb intron in the =-gene (icb-9) (13,14). The precise defmition of the 
t(6;9) at the DNA-level enables us to use Southern blot analysis for diagnosis of this 
disease in addition to karyotyping. We report on the molecular analysis of 340 patients 
with various types of leukemia which were studied by Southern blot analysis to detect 
rearrangement of the ~- and the =-gene. 
Patients. 
Patient material originated mainly from five sources: the Cytogenetic Laboratory, Depart-
ment of Cell Biology and Genetics of the Erasmus University Rotterdam, The Nether-
lands, the University Hospital in Modena, Italy, Children's Hospital of the University of 
Ulm, Ulm, Germany, Department of Hematology, Cliniques Universitairs St. Luc, UCL, 
Brussels, Belgium, and the Department of Haematology, University of Wales College of 
Medicine, Cardiff, United Kingdom. A total of 320 patients were screened by conventio-
nal Southern blot analysis and this patient-group is represented in table 1. The following 
diagnoses were made: 50 AULs, 102 AMLs, 60 MDSs, 1 Polycythemia Vera and 107 
ALLs. 
In addition, 20 patients with karyotypic abnormalities involving 6p or 9q were analyzed 
by Southern blot and, if enough material was available, by contour-clamped homogenous 
electric field (CHEF) analysis. Data of these patients are given in table 2. The clinical 
diagnoses in these 20 patients were: 8 AMLs, 4 MDSs, 6 ALLs and 2 CMLs. 
The molecular analysis of the patients was performed at the place of origin except for the 
patients from Modena, Italy and the 20 patients with specific involvement of the short 
arm of chromosome 6 or the long arm of chromosome 9 who were analyzed in Rotter-
dam. 
MATERIALS AND METHODS 
Karyotyping. 
Karyotyping was performed at the place of origin. The results of cytogenetic analysis 
were available in Ill cases: 4 cases of AUL, 54 cases of AML, 44 cases of MDS, 6 
cases of ALL, 2 cases of chronic myeloid leukemia (CML) and 1 case of polycythemia 
vera (tables 1 and 2). Although karyograms showed a variable pattern from normal 
karyotype to very complex abnormalities, no classic t(6;9)(p23;q34) had been observed 
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Table 1. 320 Patients screened by conventional Sou them blot analysis ror dek-CfJJJ rearrangement. 
Source Diagnosis 
Rotterdam 2AUL 
12AML 
Modena 13AML 
10MDS 
1 polycythemia 
vera 
Ulm 46AUL 
48AML 
43 pre-T/T-ALL 
64 c-ALL 
14 MDS 
Brussels 2AUL 
29AML 
5MDS 
Cardilf 31 MDS 
•> - : not rearranged 
+: rearranged 
Kllryotype can-gene•> dek-gene•> 
known: no 1(6;9) 
known in 10 cases: 
no 1(6;9) 
known in 7 cases: 
no 1(6;9) 
known in 6 cases; 
no 1(6;9) 
known: no 1(6;9) 
unknown - (n = 46) - (n = 14) 
unknown -(n=46) - (n = 29) 
+ (n = 2, case A: not tested 
case A and case B) case B: + 
unknown not tested 
unknown - (n = 63) - (n = 24) 
+ (n = 1, case C) 
unknown - (n = 13) not tested 
+ (n = 1, case D) caseD:-
normal karyotype not tested 
normal karyotype. not tested 
normal karyotype not tested 
known in 29 cases: - (n = 26) - (n = 27) 
no 1(6;9) 
"' 
"' 
"' 0 
Table 2. 20 Patients wltb karyotypic abnonnalltJes Involving 6p or 9q. 
Patient Diagnosis Age Sex"> Karyotype 
1') AML 67 F 16% 46,XX,del( 13)( q 13q2100) 
25% 46,XX,-6, + ring(6p) 
59% 47,XX,-6, +8, + ring(6p) 
2') AML-M2 39 M 13% 46,XY 
23% 46,XY,inv(16)(p13q22) 
64% 46,XY,I( 1; 18)( q21;q21 ),inv(2) ,1(2;8) ( q37;q 21 ),1(<\; 11) (p22;p 15),1(3;20) (p26;q 12),1( 6; 17) ( p22 ;q 11 ),inv( 16) 
3') ALL 6 M 45% 46,XX 
relapse 55% 53,Xq-, + Xq+ ,Y, + Y,6p· and multiple numerical and structural abnormalities. 
after BMT 
4') AML 52 F 65% 47-50,XX,t(3;22)(p12;p11),5q-,6pt ,(6qter .... p23::?),1lq + ,13p+, + 13p+ ,15p+ ,-17,-21, t a variable 
number of unidentified markers 
35% 49-51 idem, +8 
5"> Secondary 63 F 61% 44,XX,inv(3),dcr(5) 1(5;12)( q13;q13),-12,dcr(16),1(16;17)( q13;qll),-17, and 21q + 
AML 25% 44,XX,inv(3),der(5) 1(5;12)( q13;q13),-12,der(16),1(16;17)( q13;q11),-17, and 6p+ 
14% 44,XX,inv(3),der(5) 1(5;12)(q13;q13),-12,der(16),1(16;17)(q13;qll),-17, and i(8q) 
6') AML 59 M 54% 42-43,XY,-5,-7-,17-,19,-21,6p-[ der(6)1(6;7) (p22;7) ],der(12),1(12;17)(pll;q11),22p+ ,22q +, + 2 markers 
46% 42,XY ,idem,-3,der( 18),1(3; 18) ( q22;q23) 
r> CML 68 M 46,XY,I(6;9;22)(p24;q34;qll) 
8') Myelofibrosis 59 M 46,XY,6p + ,1(7;13),13q-
9') Myelofibrosis 64 M 44XY,-3,-5,-6,-12,-21, 6p+, +mar 1, +mar 2, +mar 3 
10"> Secondary MDS 4Q M 1(3;6)(p11;p23) 
11t) T·cell ALL 26 M 1(3;6)(q13;p23) 
12" CML relapse 1(9;12;12) ( q34;p 13;q 15) 
after BMT 
13') cALL 24 M 38% 46,XY 
62% 45,XV,4p + ,6q-,9p + ,del(9) ( q21 q33),1(12;21 )(p13;q22), 13q-,t( 13;15) ( q 12;q24),-2() 
14b) cALL 17 M 16% 46,XY 
8% 45,XY, + Y,·7,·20 
15% idem, del(1)(p21p31) 
61% idem, 9q+,llq·,15q-,17q-
JS'l cALL 4 F 40% 46,XX 
60% 46,XX,der(9),1 (9; 1) ( q34 ;?),del( J2)(p12),inv( 14)( q211 q32), 18q + 
16b) cALL 2 M 25% 46,XY 
75% 45,XY,-7,-9,1p+ ,16q-,19q + ,20p-, + mar(7qter--. p11::9qll .... q34::?) 
J?'l AML-M6 80 M 22% 46,XY 
28% 46,XY,t(1;22)(p1J;q12) 
50% 46,XY ,I( I ;22)(p 11 ;q 12) ,I (9;17)( q34 ;q 12) 
18"> AML relapse 26 M 6% 46,XY 
after BMT 94% 48,X,t(Y; 18) (pJI ;q22), + 14, + 21,1 ( l;:W)(p35;q 13),1(9; 12) ( q3400;q34), 13q-, 14 p + 
1<1'> MDS III after 57 F 3% 45,){,-X 
M. Hodgkin 50% 43,X,-X,-3,-5,7q-,12p-,13p+ ,ISq- and der(9),1(9;1)( q31;1) 
17% 86,XX,-X,-X,etc. (tetraploid) 
30% 44-45, idem and variable markers 
']jj>> AML-M5 67 M 33% 46,)(Y 
67% 45,)(Y, + X,-8,-IS,dup(1)( q21q31),dci(S)( q12q34),1(6;2)( q23;q34),der(9)(p+ ),del(14)( q21q31) 
a) M = male, F "" female 
Cytogenetic Diagnosis b) Rotterdam, c) Modena, d) Leuven, e) Torino, f) Glasgow. 
"' 
,_. 
in any of these cases. Twenty of these patients showed specific involvement of either 6p 
or 9q. Their karyotype is described in table 2. 
Conventional Southern blot <malysis. 
High molecular weight DNA was extracted from blood or bone marrow cells by standard 
techniques or trapped in agarose plugs as described (15,16). The following restriction 
enzymes were used for digestion of the DNA: Hindlll, BamHI, Bg!II and/or EcoRV. 
Probes used for hybridization were: a 500 bp EcoRI-EcoRI fragment (MF1E.5) and an 
800 bp Bg!II-Hindill fragment (MF2BH) which both detect breakpoints in the icb-6 and a 
200 bp EcoRI-Psti fragment (AL1F4EP) and a 300 bp EcoRI-EcoRI fragment (AL!F6E-
.3) which do the same for the icb-9. Hybridization- and washing conditions were des-
cribed previously (14). A simplified restriction-map of part of the !kk- and =-genes 
containing icb-6 and icb-9 is given in figure 1 and the location of the probes is indicated. 
Comour-clamped Homogenous Electric Field electrophoresis (CHEF). 
High molecular weight DNA from blood or bone marrow cells was isolated in agarose 
plugs as described (16). The rare cutting enzyme Bsshii was used for digestion of the 
DNA since this generates fragments which contain the whole dek-gene and the whole =-
gene (figure I, Ref. 14). On chromosome 6 the !kk-gene is contained in a 150 kb Bsshii 
fragment and if a t(6;9) occurs, an abnormal 180 kb fragment is generated. For the=-
······················· ···························· ···········150 kb--
BssH RV H RVRV HHH BHHRV BssH 
L-:/ In In II Ill llr:bl --~ 
- >'/ 
DEK-<3ENE 
•'' 
: 2 
c •••••••••••••••••••• •••••••• lc!rS ........................... .! 
............ - ............. 160 kb ............................................................... - ............ . 
BssH~H 1i RVH B J L.- ·D I 0 I I I // CAN-GENE / _....cu . J._----'-'----IJ--'--'----'---. ... /
3 4 
................... lcb-9 ..................... , 
Figure 1. Simplified restriction map of part of the dek-gene on chromosome 6 and the £!Yl-gene on 
chromosome 9. The introns in the genes which contain the breakpoints in patients with a t(6;9) are indicated 
as icb-6 and icb-9. The rare cutting enzyme BssiDI generates a 150 kb fragment containing the whole dek-
gene while this is a 180 kb fragment for the £@-gene. Restriction sites: BssH=BssHII. RV=EcoRV. 
B~BamHI. H~Hind!IL Probes' I~MFIE.S. 2~MF2BH, 3~ALIF4EP, 4~ALIF6E.3 
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gene the normal fragment is 180 kb while the aberrant fragment is 150 kb (14). Separati-
on of fragments on a 1% agarose gel was performed by a contour-clamped homogenous 
electric field apparatus (CHEF) at 140 Volts with 30 sec. pulse-time for 18 hours (17). 
Phage lambda oligomers and yeast chromosomes were used as size markers. The four 
probes described above or eDNA-probes of lkls; or = were used for hybridization. 
Hybridization- and washing conditions were identical to a standard Southern blot 
procedure (14). 
RESULTS AND DISCUSSION 
The translocation (6;9)(p23;q34) is a relatively rare event since reports indicate an inci-
dence of 0.5 to 4% in patients with AML (13). Cytogenetic detection of the translocation 
is difficult due to the exchange of chromosomal parts of almost similar length. To exclude 
misdiagnosis of patients with a t(6;9) due to masked translocations (as has been described 
for Philadelphia-negative-BCR-positive leukemias), it was decided to screen a large group 
of patients with AML using Southern blot analysis (18). Although the first reports of the 
t(6;9) mostly involved patients suffering from AML, we and others discovered that this 
translocation is not only restricted to AML (13). Therefore, we decided to analyse not 
only AMLs but also MDSs, AULs and ALLs. 
A total of 320 patients originating from 5 centers were analyzed with conventional 
Southern blotting for rearrangement of the lkls;- and the =-gene, more precisely; for the 
occurrence of breakpoints in icb-6 or icb-9. In some cases only one of these two genes 
could be analyzed due to restrictive amounts of material (table 1). The screening revealed 
four patients with a rearranged =-gene of which one of the three tested had also a 
rearranged dek-gene. Data of these four patients are given in more detail in table 3. It 
should be stressed that the karyotypes of these four patients were not known. The patient 
with a lkk-= rearrangement (case B in table 3) is 39 years old and has an AML-M4 
which are both features fitting the classic t(6;9) patient (13). In case A analysis of the 
dek-gene was not performed while in cases C and D Southern blotting using restriction 
enzymes EcoRV, Bglii and Hindiii in combination with probe MF1E.5 and restriction 
enzyme EcoRV in combination with probe MF2BH showed germline lkls;-bands. 
Patients C and D may belong to a separate group of patients in which the =-gene 
translocates to another, as yet unknown gene. It is noteworthy that patient C is a cALL, a 
phenotype discordant with the leukemic subgroup associated with t(6;9). In fact, von 
Lindem et a! analyzed a patient with AUL and normal karyotype in whom the =-gene 
was fused to a new and unknown gene (von Lindem et a!, manuscript in preparation). 
Causal relationship of the = rearrangement and the leukemia in patients C and D 
remains to be established. However, the data suggest that domains in the C-terminus of 
can are involved in the leukemic process and can be activated by linkage to different N-
terminal protein sequences. 
Since the remaining 316 patients showed only germline bands in various digests (data not 
shown) we decided to focus on patients with involvement of the sbon arm of chromosome 
6 and the long arm of chromosome 9 in all kinds of cytogenetic abnormalities. Involve-
ment of 6p seems to occur predominantly in Non-Hodgkin Lymphoma (19-21). Involve-
ment of the shon arm of chromosome 6 is only rarely found in leukemias of myeloid 
origin (22-25). Recently, strong association of 6p-aberrations with lipoma was reported 
(26,27). 
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Table 3 Four patients with rearrangement of the can-gene 
Patient Age Sex Diagnusis Karyutype WBC BhL~ts (%) can-gene1 dek-gene•l 
(yrs) l091liler BM PB 
A 59 F RAEB unknown 24 17 + not te.sted 
B 39 M AML-M4 unknown 42.5 52 + + 
c 46 M c-ALL unknown 29 92 64 + 
D 64 F RAEB unknown 1.8 14 3 + 
" · : not arranged I + : rearranged 
Involvement of 6p was 
reported in an endometrial 
polyp and other benign uterine 
tumors (28). Besides these 
main groups no other 
neoplasms have been described 
to be associated with specific 
aberrations involving the short 
arm of chromosome 6. The 
patients we collected mostly 
suffered from leukemias of 
myeloid origin. Their karyo-
type is described in table 2 and 
partial karyotypes of some are 
shown in figure 2. 
Cases with involvement of 
band 9q34 are obviously 
numerous since this region is 
participating in the Philadelp-
hia translocation. However, 
involvement in other cytoge-
netic abnormalities is very 
rare. Only few associations 
between specific malignancies 
and karyotypic aberrations 
involving 9q34 were described 
such as t(2;9)(q33;q34), 
t(7;9)(q34;q34), t(9;14) 
(q34;qll), t(9;17)(q34;q23), 
mostly in Non-Hodgkin Lym-
phoma and t(8;9)(pll;q34) in 
Ph-negative CML (29-36). The 
ten patients with involvement 
of band 9q34 showed leukemi-
as of lymphoid or myeloid ori-
gin (table 2). 
It was investigated whether 
Figure 2. Partial karyotype of patients 1 to 7 whose data are 
given in table 2. Cbr 6=chromosome 6 pair, chr 9=chromoso-
me 9 pair. The left chromosome of each pair is normal, while 
the one on the right represents the abnormal derivative. 
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Bssh 
12345C67 
DEK 
-180 kb 
150kb 
Figure 3. Results of the CHEF-experiments of patients 1 to 7 whose data are represented in table 2 and a 
t(6;9) patient as a positive control (C). The restriction enzyme used is Bsshll and the filter was hybridized 
with a probe which covers almost the entire dek eDNA (DK9). A wild type 150 kb fragment containing the 
whole dek-gene is seen in all 8 cases while an additional 180 kb Bsshll-fragment can be seen in lane C. 
involvement of band 6p23 or 9q34 at the cytogenetic level would be due to participation 
of the dek- and/or oo-gene in the cytogenetic aberrations. Most patients show a complex 
karyogram in which the contribution of a 9q34 or 6p23 aberration to the leukemic process 
is highly questionable. However, in patient 7 with CML a t(6;9;22) was seen as a single 
translocation, suggesting a direct causal relationship with the disease (fable 2). Southern 
blot analysis in this case had alteady shown a J:lg:-ll!ll translocation. 
In all 20 patients with aberrations of 6p or 9q conventional Southern blot analysis using 
various digests in combination with the four probes only showed germ line bands, 
indicating that no breakpoints occurred in icb-6 or icb-9 (data not shown). 
To screen for breakpoints outside icb-6 and icb-9 but still within the ~- and/or oo-
gene, we used CHEF-analysis in cases where enough material was available. As an 
example results of the CHEF-experiments of patients 1 to 7 are represented in figure 3. 
Clinical data and karyograms of these patients are shown in table 2. Also with this 
method, no rearrangement of~ or £l!!2 could be found in any of the patients. 
Clinical findings in this specific group of 20 patients with abnormal 6p or 9q chromoso-
mes indicate that they are dissimilar to t(6;9) AML patients (table 2): 
I) They do not show a consistent diagnosis of AML-Ml,2, 4 or RAEB 
2) Cases with AML or MDS are relatively old (between 50 to 70 years) 
3) Most patients show very complex karyotypes. 
These findings sharply contrast to the 'classic' t(6;9) patient who is young (20 to 30 
years) and shows FAB-classification restricted to AML Ml, M2, M4 or RAEB. Moreo-
ver, leukemic cells in these patients have a simple karyotype with t(6;9) often as the sole 
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aberration. 
Our results confinn the rare occurrence of this translocation and show that despite its 
difficult cytogenetic diagnosis this abnormality is seldomly missed. In fact, in the 
collection of 340 patients studied here, one case of t(6;9) AML was found with Southern 
blot analysis that had not been identified before. However, no cytogenetics bad been 
performed in this case. Molecular analysis of patients with karyotypic abnormalities 
involving the short arm of chromosome 6 or the long arm of chromosome 9 indicate that 
dek-£l!!l rearrangement is mostly restricted to the t(6;9). 
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Chapter IV 
GENERAL CONSIDERATIONS. 
A number of cytogenetic translocations in human tumors give rise 10 chimeric genes 
which code for abnormal proteins. Chimeric genes and their protein products can be used 
as tumor-specific markers. The analysis of the structure and function of oncogene 
products is essential to discover the mode in which a particular tumor is formed. The first 
part of this chapter deals with the basic relay system which transmits signals for growth 
and differentiation from outside the cell via the cytoplasm 10 the nucleus. Current 
knowledge of the signal transducing system for cell growth and differentiation will be 
illustrated by examples. In the second part of this chapter, the results of the experimental 
work on Ph+ ALLs and myeloproliferative disorder with a t(6;9) are discussed. 
1. The derangement of a signal-transducing pathway for growth and differentiation 
may occur at various cellular levels. 
Normal growth and differentiation of a cell are regulated by many different protein 
factors which participate in intricate networks of controL The relay system on which these 
networks are based is schematically shown in Figure I (Bishop, 1991). 
In this system, the binding of a ligand to a specific receptor on the cell surface membrane 
triggers processes in the cytoplasm which eventually result in activation and modification 
of nuclear factors. These nuclear factors regulate the expression of genes which encode 
proteins involved in growth and differentiation processes. Disturoance at any level of the 
signal-transducing pathway results in the deregulation of normal growth and differentia-
tion. 
The model of the regulatory pathway is mainly based on studies of viral oncogenes. 
However, evidence is accumulating that protein products of oncogenes and altered 
tumorsuppressor genes may disturb similar regulatory pathways in human tumors 
(Sawyers eta!, 1991). 
The proteins which participate in transduction of signals for growth and differentiation 
can be divided in three main groups: 
a) Cell surface receptors 
b) Factors in the cytoplasm 
c) Nuclear factors 
a. Cell-surface receptors. 
Many growth- and differentiation factors bind to receptors which are protein tyrosine 
kinases (PTKs). Receptor PTKs contain three domains: an extra-cellular binding region, a 
hydrophobic transmembrane domain and an intracellularly located tyrosine kinase domain 
(Figure I). Functional studies of this group of proteins started with the Platelet Derived 
Growth Factor (PDGF) and the Epidermal Growth Factor (EGF) and their receptors 
(Heldin and Westermark, 1990, UHrich and Schlessinger, 1990, Cantley et a!, 1991). A 
growth factor binds extraceiiularly to a specific receptor. 
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(a) 
(b) •• 
(c) 
Cell membrane ~ 
(1) Growth factors, receptor PTKs 
Non receptor PTKs (src) 
G proteins (ras, GAP) 
(2) 
Protein serine/threonine klnases 
crk (SH213 protein) 
Nuclear receptors (3) 
DNA binding proteins 
(RB, P 53) 
Figure 1. Receptors for growth factors and other regulatory proteins exist of an extracellular ligand-binding 
domain (a), a transmembrane domain (b), and a cytoplasmic domain (c). Ligand-binding induces a 
conformational change in the receptor and activation of the cytoplasmic domain. Thereupon, cytoplasmic 
machineries involving many circuitries and proteins (PTKs, serine/threonine kinases, GTPases) generate 
signals (2). These are transferred to the nucleus via nuclear receptors and DNA-binding proteins will 
regulate gene expression of proteins involved in growth and differentiation (3). 
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Factor-binding causes a conformational change of the receptor and concomittant activation 
of the intracellular kinase domain of the receptor (Ullrich and Schlessinger 1990, Cross 
and Dexter, 1991). Next, various cytoplasmic systems are activated such as those 
involving the G-proteins and GTPase Activating Proteins (GAPs) (see further). 
Another example of a PTK-receptor which binds a growth factor is the human CSF-1 
(colony stimulating factor 1) receptor. CSF-1 is a hemopoietic growth factor which 
stimulates growth and expansion of the monocyte-macrophage compartment in the blood 
and bone marrow. Binding of this growth factor causes auto-phosphorylation of the CSF-1 
receptor. As a result the receptor is internalized rapidly by the cell and is degraded. The 
CSF-1 receptor is encoded for by the c-.flm proto-oncogene. Transfection assays with 
mutants of the CSF-1 receptor showed that a point mutation in the extracellular domain of 
the receptor caused transformation of cells while a point mutation in the intracytoplasmic 
C-terminal part resulted in enhanced transformation (Roussel et al, 1988). Moreover, the 
fms-gene had been assigned to chromosome 5q32, a region that is frequently altered in 
MDS-patients. Based on these observations it was thought that mutations in the CSF-1 
receptor might play a role in certain human leukemias. However, screening of a large 
number of patients with AML and MDS showed that these specific mutations occurred 
only in about 10% of such patients (fobal et a!, 1990, Ridge et a!, 1990). Probably, 
additional abnormalities, either of the receptor or of regulatory cellular factors play a role 
in the origin of AML and MDS. 
b. Factors in the cytoplasm. 
So far, most experimental work was performed on two types of proteins which act in the 
cytoplasm: l) Proteins of the m;-family. Contrary to the receptor PTKs such as the CSF-
1 receptor, these are non-receptor PTKs. 2) The GTPases including them-family. 
I) The src family. 
The SRC protein can phosphorylate proteins on tyrosine residues. Its structure has been 
discussed in Chapter IT.3. The protein contains several functional domains (Figure 2). An 
amino-terminal myristylation site is necessary for membrane association of the protein 
(Cross et al, 1985, Buss and Sefton, 1985, Kamps eta!, 1985). Association of SRC with 
the cell membrane is probably required to function properly. Three important domains 
can be discerned in SRC: the src-homology 3 (SH3) region, the SH2-region and the SRI-
region. The SHl-region codes for the kinase function of the protein. The SH3-region has 
a negative regulatory influence on the kinase function of the protein while the SH2-region 
plays a crucial role in the positive regulation of the SRC-protein. The following model 
has been proposed for control of the function of SRC. A tyrosine residue at the C-
terminal part of the protein is phosphorylated by a distinct cytoplasmic PTK (Figure 2(1), 
Okada and Nakagawa, 1989). Probably the phosphorylated tyrosine interacts with a niche 
in the SH2-region of SRC (Cooper et al, 1986, Schuh and Brugge, 1988). This causes 
folding of the protein and thereby inactivation of the kinase domain (Matsuda et a!, 
1990). Deregulation and inappropriate kinase activation may occur if an oncogene product 
such as v-crk interacts with the phosphorylated tyrosine (Figure 2). The protein is 
unfolded and the kinase domain stays in permanent activated condition. Hence, the SRC 
protein is withdrawn from normal control mechanisms (Cantley eta!, 1991). 
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kinase 
domain Tyr 416 
Tyr 527 
COOH 
PP 60 c-src 
active form 
SH3 
SH2 
COOH 
N 
PP 60 c-src v-crk 
SH3 
SH2 
kinase 
domain 
pp 60 c-src 
inactive form 
c 
Figure 2. Control of activation of pp60 c~g£- Normally. control of pp60 c~ occurs via phosphorylation of 
the C-tenninal Tyr-527 residue and folding of the molecule (1). Deregulation occurs when this phosphoryla-
ted residue interacts with the SH2-region of an oncogene product such as v-erk (2). Reference Cantley et al, 
199!. 
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The elucidation of the structure and function of SRC is important to understand how the 
function of the ABL-protein is disturbed by the t(9;22) which is found in patients with 
CML and ALL. The ABL-protein is also a cytoplasmic PTK and shows a striking 
similarity to the SRC-protein. It contains a kinase domain (the SHl region) which is 
regulated by two 5' domains: the SH2-region which has a positive regulatory function on 
the kinase domain and the SH3-region. Experiments, in which ABL-variants with deleted 
or mutated SH3-regions were studied, showed that the SH3-region is required for the 
inhibition of the ABL-kinase function (Franz et al, 1989, Jackson and Baltimore, 1989). 
However, in most cases of Ph+ leukemia the SH3 region remains intact in the BCR-ABL 
fusion protein while this protein also shows an increased kinase activity (Konopka et al, 
1984). Moreover, two patients with Ph+ leukemia were described whose BCR-ABL 
fusion proteins had a partly deleted SH3-region while the kinase activity of these BCR-
ABL variants did not show difference with the kinase activity of BCR-ABL proteins with 
intact SH3-region (Chapter II.3, this thesis). These findings support the hypothesis that in 
the Ph-translocation, deregulation of the kinase function of the abnormal ABL protein is 
exerted via the 5' BCR-sequences (Franz et al, 1989). BCR-ABL constructs with varying 
deletions in the BCR part showed, that the aminoterminal BCR-sequences are important 
for increased tyrosine kinase activity of the BCR-ABL protein (McWhirter and Wang, 
1991). Specifically the BCR first exon sequences seem to play a major part in the 
transformation capacity and tyrosine kinase activation of BCR-ABL proteins with intact 
SH3-region (Muller et al, 1991). Pendergast et al (1991) found that the BCR first exon 
sequences contain at least two SH2-binding sites which specifically interact with the SH2-
domain of ABL and which are essential for BCR-ABL mediated transformation. These 
findings support a model for deregulation of the ABL protein by the t(9;22) which is 
similar to deregulation of SRC (Figure 2). Normal regulation of the ABL protein by 
intramolecular folding and shielding of the kinase domain is impossible because of the 
presence of 5' BCR sequences. Binding of the 5'BCR-sequences to the SH2-region of 
ABL results in an 'open' structure of the protein thereby allowing continuous exertion of 
the kinase function (McLaughlin et al, 1987 and 1989, Lugo et al, 1990, Cantley et al, 
1991). 
Another oncogene product and its family which has been studied intensively is the RAS-
protein. This protein binds GTP and GDP and has intrinsic GTPase activity (Lowy and 
Wi!Jumsen, 1986). Abnormalities of this protein and its family members are often found 
in a broad range of human tumors and are mainly point mutations (Bos, 1989). The 
hypothesis is that point mutations in RAS prevent the hydrolysis of a GTP thereby 
causing the RAS protein to remain in a permanently activated form (Barbacid, 1987, 
Bourne, l990a&b). The activated RAS proteins provide continuous signals to depending 
circuitries which might eventually result in activation of nuclear factors (Figure 1). The 
GTPase activating protein (GAP) is probably of major importance in the control of the 
function of RAS (McCormick, 1989, Wigler, 1990, Hall, 1990, Bourne et al, 1990a&b). 
RAS itself has only weak intrinsic GTPase activity. GAP stimulates the intrinsic GTPase 
activity of RAS, which keeps the protein in GDP-bound (inactive) state. Of interest is that 
GAP contains two domains homologous to the src-homology 2 (SH2) region. The SH2-
region forms a link between the proteins of the tyrosine kinase group (receptors and non-
receptors) and proteins of the RAS family (Ellis et al, 1990, Kaplan et al, 1990, Ander-
son et al, 1990, Muller et al, 1991). 
Proteins of the SRC and RAS families play prominent roles in cytoplasmic transduction of 
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signals for growth and differentiation. Moreover, the pathways they use are not separated. 
Interaction between proteins of both families do occur. 
c. Nuclear factors. 
Translocations in human tumors may generate chimeric gene products which disturb the 
signal-transducing pathway for growth and differentiation at the nuclear level. 
An example is the t(l;l9) which is found in part of childhood acute pre-B leukemias. 
Study of cell lines with the translocation showed that part of the E2A gene, containing the 
transcriptional activating domain, is joined to a homeobox gene on chromosome I, 11!! 
(ru:e-B cellleukemia)(Kamps et a!, 1990, Nourse et a!, 1990). The fusion protein has the 
features of a chimeric transcription factor. The hypothesis is that this chimeric product 
activates transcription of 11!! target genes that normally are not transcribed in pre-B cells. 
Another protein product that exerts its function at the nuclear level and that is disrupted 
by a translocation is the RARa receptcr (see Chapter Ill. I). The t(15;17) in APL joins 
part of a new gene, nm\, to part of the RARa gene. Normally, ligand-binding by the 
RARa receptor induces expression of particular target genes in the cell nucleus. The 
receptor-ligand complex binds to specific response elements in promoter/enhancer 
sequences of the nuclear target genes. The 1(15;17) might render the RARa receptor 
nonresponsive to normal levels of RA. In that case expression of RAR target genes is 
obstructed and normal cell differentiation is prevented (Lewin, 1991). 
Both chimeric gene products illustrate that expression of certain genes at appropriate 
times of cell development is important for normal growth and differentiation. 
Many tumor suppressor genes of which altered forms are found in human tumors contain 
regions homologous to DNA-binding regions of nuclear proteins (Marshall, 1991). 
For example, the retinoblastoma gene product (RB) is located in the nucleus and shows 
DNA-binding properties (Lee et a!, 1987). Phosphorylation of this protein, probably via a 
cytoplasmic kinase, attenuates the binding to DNA. This event is associated with the 
beginning of the S phase and cell proliferation (Shenoy et a!, 1989, Ludlow et a!, 1990). 
Hypophosphorylation of the protein is thought to play a role in the tumor suppressive 
function of the RB protein (Mihara eta!, 1989, Stein eta!, 1990). 
Many products of oncogenes or tumorsuppressor genes contain domains characteristic for 
proteins which play a role at the nuclear level of the signal-transducing pathway for 
growth and differentiation. In many cases more study of structure and function of these 
proteins is needed before their exact role in growth and differentiation can be established. 
So far, the supposition seems true that mutated genes generate abnormal proteins involved 
in tumorigenesis. 
2. Cancer is the result of a multistep proces. 
Slowly, parts of regulatory relays controlling growth and differentiation come into focus. 
Results of in vitro and in vivo studies confirm that most types of tumors have a multifac-
torial origin and transgress several phases prior to a full blown neoplasm (Nowell, 1986, 
Hunter, 1991). Although in the case of tumors such as retinoblastoma and Ph-positive 
leukemia one step was studied extensively, research on other tumors such as colon 
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carcinoma indicate complex multistep processes in tumor fonnation (Fearon and Vogel-
stein, 1990). To study these processes an in vitro model is required. Cooperation of 
oncogenes can be studied in cell culture systems and many synergisms have been revealed 
so far using these systems (Land et a!, 1983a&b, Ruley, 1983, Graf, 1988, reviewed in 
Weinberg, 1989, Ruley, 1990). 
More sophisticated are transgenic mice {Hanahan, 1989). Introduction of a gene into the 
germ line of a mouse and the generation of inbred offspring enables one to study the 
function of the gene in a whole organism. The first experimental models already show 
that oncogenes or abnormal tumor suppressor genes can cause diseases in transgenic 
mice. For example, the retinoblastoma gene, the p53-gene and the ll£!-2 gene were 
studied using this system (Windle et a!, 1990, Lavigeur et a!, 1989, McDonnell and 
Korsmeyer, 1991). 
The bci-2-Ig transgene of the t(14;18) causes a disease in mice similar to human follicular 
lymphoma (McDonnell et a!, 1989). Autopsy of the transgenic mice shows indolent 
follicular hyperplasia in lymph nodes and spleen. At the cellular level polyclonal 
expansion of mature B-cells is found. Ten percent of the ll£!-2-Ig transgenic mice develop 
aggressive monoclonal large cell lymphomas. Analysis of the tumors shows 
rearrangement of the C-J:!ljl£ gene in 50% (McDonnell and Korsmeyer, 1991). Double 
transgenic mice, that are the result of crossing Igh enhancer Ewll£!-2 (Ewll£!-2) 
transgenics with Ewmyc transgenics, die of disseminated malignant lymphomas (Strasser, 
1990). The Ew!2£!-2-myc gene causing aggressive malignant lymphomas in transgenic 
mice illustrates a type of tumor formation in which multiple factors play a role. 
Attempts to generate transgenic mice with llf!-Elll genes driven by the ll£!-promoter have 
not succeeded so far. Bone marrow cells infected with llf!-Elll expressing retrovirus can 
repopulate the bone marrow of aplastic mice and cause myeloid, macrophage or lymphoid 
leukemias (Daley et a!, 1990, Elefanty et a!, 1990, Kelliher et a!, 1990). A llf!-Elll 
transgene under the control of the metallothionein promoter results in lymphoid and 
myeloid leukemias in transgenic mice (Heisterkamp et a!, 1990). A llf!-v-Elll transgene 
related to the p210 causes pre-B and T lymphomas if an Immunoglobulin Heavy chain 
enhancer and promoter are used (Hariharan et a!, !989). However, the llf!-Elll gene 
driven by the ll£!-promoter might be too toxic to generate offspring (Dr. G. Grosveld, 
personal communication). 
3. The 1!£!:-abl and dek-Q!.!!. chimeric genes in human acute leukemias: significance 
for diagnosis 
The aim of the work described in this thesis was to compare the value and practical use 
of molecular techniques to those of karyotyping in the diagnosis of acute leukemias with 
specific translocations. Characterization of specific subtypes of leukemia at the cytogene-
tic and molecular level is essential since defined groups carry their own prognosis and 
require appropriate therapy strategies (reviewed in Chapters ILl and ill.!). 
The experimental work in this thesis concerns Ph+ ALLs and AML with t(6;9). 
a) Ph+ ALL 
The observation of a Ph chromosome indicates a poor prognosis for both adults and 
children with ALL (Fletcher et a!, 1991, Seeker-Walker et a!, 1991). Studies of the 
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leukemic cells at the morphologic, immunologic, cytogenetic or genetic level point to a 
multipotent stem cell or an early myeloid or lymphoid progenitor as the site of origin of 
the leukemia (fachibana et al, 1987, Kalousek et al, 1988, Seeker-Walker et al, 1988, 
Turhan et al, 1988, Craig et al, 1990). Analysis of the t(9;22) at the DNA-level shows 
that breakpoints in the l!!ll-gene on chromosome 9 occur 5' of its tyrosine kinase domain, 
in a 200 kb intron. Two breakpoint regions are found in the Jl.cr-gene on chromosome 22: 
one is the bcr-region. This region in the ll.cr-gene contains most breakpoints of Ph-
positive CML cases and half of the breakpoints of adult cases with Ph+ ALL The other 
half of adults with Ph+ ALL show a breakpoint in the first intron of the Jl.cr-gene, 5' of 
the her-region (Hermans et al, 1987). The chimeric ll.cr-l!!ll gene is transcribed into a 
mRNA with exon joinings b2a2, b3a2 or e1a2. While the b2-b3/a2 junction is found in 
Ph-positive CML and in 50% of adults with Ph-positive ALL, the ela2 joining is almost 
exclusively found in Ph-positive ALL (50% of adults with Ph-positive ALL, almost all 
children with Ph-positive ALL) (Heisterkamp et a!, 1989). 
In murine bone marrow cells infected by retroviruses containing either ela2 or b2-b3/a2 
ll.cr-l!!ll gene constructs the e1a2 protein had a higher tyrosine kinase activity and greater 
transforming capacity than the b2-b3/a2 protein (McLaughlin et al, 1989). According to 
some authors this difference might indicate that in humans two diseases exist: Ph+, 
e1a2+ 'true' de novo ALL and Ph+, b2-b3/a2 ALL In fact, the latter would be a blast 
crisis of CML of which the chronic phase was not recognized in the past (Gale and 
Butturini, 1990). The distinction between CML and ALL is of clinical importance since 
Ph+ ALL has a variable course after treattnent, while lymphoid blast crisis of CML may 
revert to a second chronic phase with appropriate therapy. However, reports of patients 
with Ph+ ALL give no clear evidence for differences in clinical course and prognosis 
between those with ela2 or those with b2-b3/a2 breakpoint joinings (Seeker-Walker et al, 
1991). Moreover, the ela2 junction has been found in clinically 'classic' CML (Selleri et 
a!, 1990). More research is needed to prove that indeed two distinct diseases exist. 
Since in 50% of adults and in almost all children with Ph-positive ALL breakpoints occur 
in the first intron of Jlg:, analysis at the DNA-level is cumbersome because the intron 
measures at least 68 kb (Heisterkamp et al, 1988). A solution might be reversed PCR: 
with this method the mRNA is analyzed. At RNA-level Jl.cr-sequences are linked to l!!ll 
sequences in a small defined region. We started studying a group of patients with ALL 
Karyotyping of blood and bone marrow of the patients was performed and showed 
normal, abnormal but no Ph or abnormal with Ph configuration. In all patients studied so 
far, a Qg:-abl chimeric fragment was consistently found with reversed PCR if a Ph was 
present. Absence of a Ph chromosome correlated with reversed PCR which generated l!!ll 
control fragments, but no Qg:-l!!ll chimeric fragments. Surprisingly, in two patients with a 
Ph chromosome we could not detect a bcr-abl chimeric fragment with the standard bcr-l!!ll 
oligoprobes we use after reversed PCR. Further investigation with Southern blot, 
sequence studies and protein analysis revealed that these two patients had Jl.cr-l!!ll variants 
in which l!!ll exon a2 was deleted (Chapter ll.3). This variant is not restricted to acute 
leukemias, since it is also found in a case of CML (van der Plas et al, 1991). 
Theoretically, the expected frequency of this unusual variant is 0.3% in all patients with 
ll£r-l!!ll rearrangement (0.6 kb(=intron between exon a2 and a3) divided by 200 
kb( =intron where breakpoints are usually found in l!!ll) is 0.003), assuming that 
breakpoints in l!!ll occur at random. So far, 3 patients were found with the ]lg:-l!!ll variant 
lacking l!!ll exon a2, confirming its rare occurrence (Chapter ll.3 and Appendix of this 
thesis). However, reports of Ph+ leukemia patients with breakpoints in Jlg:, but no Qg:-
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abl fragment amplifiable by PCR, indicate that in such cases a variant junction might be 
found (Hooberman et al, 1989). For such cases the use of a 3' primer in l!l1l exon a3 is 
recommended for the PCR. 
In conclusion, most Ph+ ALL patients show either one of three Jlg:-l!lll transitions at the 
mRNA level (i.e. ela2, b2a2 or b3a2). In very few cases deletion of l!l1l exon a2 is found 
at the RNA-level. These variants may be missed if only reversed PCR is used for 
diagnosing bcr-l!lll positive leukemia. To detect such variants, different techniques such as 
karyotyping, Southern blot or sequence analysis are required. In the case of deletion of 
abl exon a2, detection by reversed PCR is possible if a 3' primer in l!l1l exon a3 is used. 
Deletion of abl exon a2 has no functional implications for the BCR-ABL protein. Studies 
at the protein level show no significant difference between Jlg:-l!lll proteins with and 
without abl exon a2 sequences (Chapter II.3 of this thesis). 
Nowadays, clinicians favour high dose chemotherapy in combination with bone marrow 
transplantation (BMT) as therapy of choice for patients with Ph+ ALL (Fletcher et al, 
1991). Monitoring of the disease course under therapy requires a specific and sensitive 
method which is provided by the above mentioned PCR-technique. In our hands this 
method reaches a sensitivity of 1:10', which means that 1 Jlg:-l!lll positive cell in a 
population of 10' cells can be detected (Chapter II.2). Therefore, it is the ideal method to 
diagnose minimal residual disease after therapy. However, the high sensitivity of the PCR 
is at the same time its drawback. Contamination with Jlg:-l!lll cDNAs might give false-
positive results and utmost precautions should be taken to prevent such contaminations. 
Not much is known about the mechanisms which are involved in leukemic relapse after 
BMT. Since PCR-techniques became widely available, the course after BMT could be 
studied with a more sensitive technique than karyotyping or Southern blot analysis 
(Lawler et al, 1989). Cytogenetic studies of Ph+ CML had alneady shown that the 
presence of Ph- donor cells and Ph+ acceptor cells in the post-transplantation bone 
marrow ('mixed chimerism') occurred relatively frequently (Arthur et a!, 1988). Analysis 
by PCR of bone marrow (BM) status after transplantation confirmed that patients may 
still be bcr-abl positive after marrow-ablative treatment and BMT. Despite this 
observation some patients stay in clinical remission (Roth et al, 1989, Lange et al, 1989, 
Delfau et al, 1990, Pignon et a!, 1990). One explanation for this phenomenon might be 
that acceptor cells with the chimeric gene are still present in the bone marrow after 
marrow-ablative therapy. The cells are in a non-proliferative or "silent" state, but they 
still posses the capacity to multiply. So far, it is clear that persistent finding of the Jlg:-l!lll 
product with PCR after BMT precedes cytogenetic and clinical relapse (Sawyers et a!, 
1990). For Ph+CML two main periods can be discerned in the post transplantation 
period. In the first 6 months after BMT transient expression of Jlg:-l!lll may be found in 
patients who might still stay in long-tenn remission. However, recurrence of the leukemia 
can be expected if the bcr-abl product is persistently found beyond the first 6 months after 
BMT (Hughes eta!, 1991). 
b) T(6;9) in AML 
While research on bcr-abl has relatively progressed, the study of the ~-= chimeric 
gene which is the product of the t(6;9) started recently (von Lindern et a!, 1990). The 
~-can chimeric gene is found in various subtypes of AML and MDS. Patients with the 
translocation are young and respond poorly to therapy. In many, an MDS-phase was 
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reported to precede overt AML (Horsman and Kalousek, 1987). These characteristics 
pomt to a multi potent stemcell as the origin of the leukemia. 
The lkk-= chimeric gene is specifically found in all patients studied with a t(6;9) (see 
Chapter lll.2). Diagnosis of this subtype of leukemia is possible now using conventional 
Southern blot ar1alysis, since breakpoints both in the lkls-gene on chromosome 6 and the 
=-gene on chromosome 9 consistently occur in one relatively small intron in each of the 
genes (less than 10 kb). Moreover, the Qtl-£ll!l chimeric gene is transcribed into one 
unique chimeric lkls-can mRNA which forms an ideal target for reversed PCR. This 
sensitive technique enables us to monitor minimal residual disease in patients after 
chemotherapy or BMT (Chapter lli.2). Analysis of a large group of patients with acute 
myeloid leukemia, acute lymphoblastic leukemia, or myelodysplastic syndrome confirmed 
that the lkls-can chimeric gene is restricted to the myeloproliferative discrder with a t(6;9) 
(Chapter 1!!.3). Despite the subtle change at the cytogenetic level, the molecular studies 
indicate that the translocation is seldom missed with karyotyping. 
In conclusion, a new subtype of leukemia is characterized at the molecular level. In 
addition to karyotyping, Southern blot analysis and reversed PCR are appropriate methods 
for the diagnosis and follow up of the myeloproliferative disorder with a t(6;9). 
4. Gene therapy. 
An increasing number of genes involved in tumorigenesis is identified and their concomit-
tant abnormality at the molecular level is elucidated. Molecular techniques enable 
manipulation and modification of such genes in vitro and make introduction of genetic 
material into cells possible. These developments raise hope for the application of somatic-
cell gene therapy in treatment of human malignancies in the future. In cancer of the 
hematopoietic system the target cell for such therapy is the pluripotent hematopoietic stem 
cell. This is an ideal vehicle for the introduction of correcting genes since it produces 
offspring which can repopulate the blood and bone marrow of an individual for a 
prolonged period. Many technical problems still have to be solved before gene therapy 
may be an alternative in the treatment of human malignancies. However, results of 
ongoing research are encouraging (Apperley and Williams, 1990, Cournoyer and Caskey, 
1990, Weatherall, 1991). 
5. Concluding remarks. 
It is clear that in the beginning of cancer research, many scientists hoped to find one 
universal cause of this dire disease. Soon it became evident that a simple explanation of 
the cancer problem did not exist. Although in the past few years many genes and their 
tumor-associated defects became known, their actual function and position in the cascades 
regulating growth and differentiation were a mystery. Recent progress in this field is 
hopeful! and indicates that all along using relatively simple theoretical models we are on 
the right track. 
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SUMMARY. 
Many subtypes of leukemia are characterized by specific cytogenetic translocations. The 
karyotyping of blood or bone marrow is one of the methods which is used nowadays to 
establish a diagnosis of leukemia and to predict the outcome of the disease in an 
individual patient. In an increasing number of translocations which are found in human 
leukemias, the genes at the translocation breakpoints are isolated. The possibility to study 
translocations at the genetic level provides additional methods of diagnosis such as 
Southern blot analysis or the Polymerase Chain Reaction (PCR) (Chapter II.2). The latter 
technique is a major breakthrough. Its high sensitivity allows the monitoring of residual 
leukemia after bone marrow transplantation or chemotherapy more accurately than with 
any other method so far. 
The t(9;22) or Philadelphia translocation is found in 20% of adult ALL and in 5% of 
childhood ALL. This karyotypic abnormality is associated with a poor prognosis within 
the group of ALLs. Diagnosis at the genetic level is possible since breakpoints occur in 
the abl-gene on chromosome 9 and the !2£!:-gene on chromosome 22. Due to the 
translocation a BCR-ABL protein is formed with an increased kinase activity as compared 
to the normal ABL protein. Using various diagnostic methods we detected a variant !2£!:-
l!hl product in two ALL-patients with a classic t(9;22) (Chapter II.3). In most Ph+-
patients a bcr-abl chimeric gene is found in which the region, regulating the l!Jll-kinase 
domain, stays intact. The two patients we analyzed showed !2£!:-l!hl variants in which this 
regulatory domain was partly deleted. However, protein studies showed no difference in 
kinase activity between the BCR-ABL variants and the BCR-ABL proteins which are 
usually found in Ph +-leukemias. These findings give additional support to a hypothesis 
which proposes that in the Qg:-l!Jll translocation the 5' !2£!:-sequences are important for 
deregulation of the ABL kinase. 
The t(6;9) was reported to occur in AML Ml, M2 and M4. The translocation is 
associated with a poor prognosis. Most patients with this translocation are young. A 
survey of the literature showed that the t(6;9) can also be found in a subtype of MDS. 
Recent cloning of the genes involved in the translocation provided additional means to 
diagnosis this subtype of malignancy. We observe that rearrangement of the lk)s-gene on 
chromosome 6 and the can-gene on chromosome 9 consistently occur in patients with a 
t(6;9) (Chapter IIL2). Breakpoints in both genes are located in an intron of less than 10 
kb. A combination of three different restriction enzymes with four different probes suffice 
to diagnose the translocation at the genetic level. Moreover, an additional method of 
diagnosis is the reversed PCR since a lk)s-can mRNA is formed with a unique breakpoint 
junction. The screening of a large group of patients with various types of leukemia and 
MDS indicates that the lk)s-gm chimeric product is restricted to the translocation (Chapter 
III.3). 
Characterization of subtypes of leukemia at the genetic level provides additional methods 
of diagnosis besides karyotyping, hematomorphology or immunophenotyping. Subdivision 
of leukemia in prognostic groups is important for further therapeutic approach in an 
individual case. The finding of molecular variants in patients with specific translocations 
may shed light on the basic proces which underlies a specific subtype of leukemia. 
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SAMENV ATTING. 
In vee! subtypen van leukemie worden specifieke cytogenetische translocaties gevonden. 
Karyotypering van bloed of beenmerg is dan ook een van de methoden die tegenwoordig 
gebruikt wordt om tot een diagnose te komen. Het vinden van bepaalde cytogenetische 
afwijkingen kan van belang zijn om de prognose voor een individuele patient te bepalen. 
In toenemende mate worden de genen geisoleerd, die gelegen zijn op de translocatie-
breekpunten van diverse leukemieen. Hierdoor is het mogelijk deze ziekten te bestuderen 
op genetisch niveau. Diagnose van specifieke subtypen van leukemie wordt nu gedaan met 
behulp van de Southern blot techniek of de Polymerase ketting reactie (PCR) naast 
karyotypering (Hoofdstuk IL2). Vooral de Polymerase ketting reactie is een aanwinst voor 
de diagnostiek, omdat de zeer hoge sensitiviteit gebruikt kan worden om kleine aantallen 
leukemische cellen te detecteren na beenmerg transplantatie of chemotherapie. 
De t(9;22) of Philadelphia translocatie word! gevonden in 20% van de volwassenen met 
acute lymfatische leukemie (ALL) en in 5% van de kinderen met ALL. Deze translocatie 
is geassocieerd met een slechte prognose binnen de groep van ALLs. De diagnose op 
genetisch niveau is mogelijk omdat breuken optreden in het ~-gen op chromosoom 9 en 
het Qg:-gen op chromosoom 22. Door de translocatie ontstaat er een BCR-ABL eiwit dat 
een verhoogde kinase activiteit vertoond in vergelijking met het normale ABL eiwit. Met 
behulp van verschillende diagnostische technieken vonden we een variant van het Q.g:-@1 
product bij twee patienten met Ph' positieve ALL (Hoofdstuk II.3). Bijna aile patienten 
met een Ph' chromosoom hebben een !1£!-;,Ql chimeer gen waarbij bet domein dat de 
kinase activiteit van ABL reguleert intact blijft. De twee patienten die wij bestudeerden 
hadden variante bcr-abl genen waarbij dit regulerende domein gedeeltelijk gedeleteerd 
was. Onderzoek van het eiwit toonde echter aan dat er geen quantitatief verschil was 
tussen de kinase activiteit van de variante BCR-ABL eiwitten en de BCR-ABL eiwitten 
die in het merendeel der gevallen bij Ph' positieve patienten gevonden worden. Deze 
bevindingen ondersteunen de hypothese dat binnen het abnormale BCR-ABL product de 
5' BCR sequenties van belang zijn voor de deregulatie van ABL. 
De t(6;9) wordt gevonden in acute myeloide leukemie (AML) Ml, M2 en M4. De 
translocatie is geassocieerd met een slechte prognose. Dit subtype van leukemie wordt 
gevonden bij jong volwassenen. Literatuuronderzoek wees uit dat deze translocatie ook 
gevonden wordt bij een subtype van MDS. Door de recente klonering van de genen die 
betrokken zijn bij deze translocatie kan dit subtype van leukemie nu ook op genetisch 
niveau gediagnosticeerd worden. Ons onderzoek toonde aan dat zowel het dek-gen op 
chromosoom 6 als het =-gen op chromosoom 9 betrokken zijn bij de t(6;9) (Hoofdstuk 
ID.2). De breukpunten in beide genen worden gevonden in een intron van minder dan 10 
kb. Voor de diagnose van de translocatie op genetisch niveau is het voldoende drie 
verschillende restrictie enzymen te gebruiken in combinatie met vier verschillende probes. 
Omdat op mRNA-niveau een unieke dek-£l!!l overgang optreedt kan men de Polymerase 
ketting reactie ook gebruiken als diagnosticum. We bekeken een grote groep patienten met 
uiteenlopende typen leukemie en MDS. Dit onderzoek gaf aan dat het lk!s;-can chimere 
product aileen gevonden word! bij de t(6;9) (Hoofdstuk ID.3). 
Onderzoek van subtypen van !eukemie op genetisch niveau kan gebruikt worden naast 
karyotypering, ce!morfologisch onderzoek of immunologisch onderzoek om tot een 
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diagnose te komen. Onderverdeling van leukemieen in groepen met een eigen prognose is 
belangrijk voor het therapeutisch beleid in een individueel geval. Het vinden van variante 
producten bij patienten met specifieke translocaties kan helpen bij het vinden van het 
basale mechanisme wat ten grondslag ligt aan een specifiek subtype van leukemie. 
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ALL 
AMF 
AML 
ANLL 
APL 
AUL 
BCR 
lli;r-gene 
BL 
BM 
BMT 
bp 
c-ab1 gene 
CALLA 
eDNA 
CHEF 
CLL 
CMML 
CML 
CNS 
CR 
DIC 
DCC-gene 
DM 
FAB 
GAP 
GDP,GTP 
HSR 
kb 
kD 
MIC 
M-BCR-1 
m-BCR 
MDS 
MPD 
mRNA 
NF-1 gene 
PCR 
Ph 
PR 
PTK 
RAEB(-t) 
RARa 
RB gene 
SH region 
Abbreviations. 
acute lymphoblastic leukemia 
acute myelofibrosis 
acute myeloid leukemia 
acute non-lymphoblastic leukemia 
acute promyelocytic leukemia 
acute undifferentiated leukemia 
5.8 kb breakpoint cluster region=M-BCR-1 
breakpoint cluster region gene 
Burkitt's lymphoma 
bone marrow 
bone marrow transplantation 
basepair 
cellular l!!2J. gene 
common ALL antigen 
complementary deoxyribonucleic acid 
contour-clamped homogenous electric field 
chronic lymphocytic leukemia 
chronic myelomonocytic leukemia 
chronic myeloid leukemia 
central nervous system 
complete remission 
disseminated intravascular coagulation 
deleted in colorectal carcinoma gene 
double minutes 
French-American-British (classification) 
GTPase activating protein 
guanosine diphosphate, guanosine triphosphate 
homogeneously staining regions 
kilo base 
kilodalton 
morphologic-immunologic-cytogenetic (classification) 
major breakpoint cluster region =CML breakpoint cluster 
region=BCR 
minor breakpoint cluster region= ALL breakpoint cluster region 
myelodysplastic syndrome 
myeloproliferative disorder 
messenger ribonucleic acid 
neurofibromatosis-! gene 
polymerase chain reaction 
Philadelphia chromosome 
partial remission 
protein tyrosine kinase 
refractory anemia with excess of blasts (in transformation) 
retinoic acid receptor a 
retinoblastoma gene 
src-homology region 
125 
WBC 
WT-1 gene 
126 
white blood cell count 
Wilms' tumor-1 gene 
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Cytogenetic and Molecular Analysis in Philadelphia Negative CML 
By D.C. van der Plas. A. B.C. Hermans, D. Soekarman, E.M.E. Smit, A. de Klein, N. Smadja, G. Alimena, R. Goudsmit, 
G. Grosveld, and A. Hagemeijer 
We studied the clinical, hematologic, cytogenetic and 
moleeu!ar biologic features in four patients with Philadel-
phia (Ph) neg~nive chronic myeloid leukemia (CML). In alt 
four cases the clinical and hematologic characteristics 
were indistinguishable from Ph positive CML. Cytogenetic 
analysis showed a normal karyotype in two pa'tients and 
chromosomal translocations apparently not affecting chro-
mosome 22 in the other two cases. Southern blot analysis 
using probes of the bcr region. demonstrated a bcr break-
point in all four patients. In situ hybridization with bcr. 
c-abf, and e-sis probes showed unusual hybridizmion sites 
for 5'-bcr and c-ab/ indicating complex chromosomal rear-
rangements affecting three different chromosomes in the 
THE PHILADELPHIA CHROMOSOME (Ph) is found in 94% of chronic myeloid leukemia (CML) patients. 
In the majority of cases it originates from the standard Ph 
translocation t(9:22)(q34;qll).1 As a result of this transloca-
tion the c-ab! oncogene is translocated to a specific site in a 
gene on chromosome 22 band qll called breakpoint cluster 
region (her region)? The part of chromosome 22 distal to the 
breakpoint is translocated to chromosome 9 band q34. 
The 5'hcr-ah/ DNA on the Ph chromosome is transcribed 
into an 8.5 kilo base (kb) chimeric her-ahl mRNA. Depend-
ing on the position of the breakpoint in her either her exon b2 
or b3 are spliced to ahl exon a2. resulting in either b2a2 or 
b3a2 chimeric mRNA.J-10 This 8.5 kb hcr-abl mRNA 
encodes an abl protein of 210 kilodalton (kD), which has in 
vitro enhanced tyrosine kinase activity compared with the 
normal ahf protein.9-11 Approximately 5% of the Ph-positive 
CML patients have cytogenetic variants of the Ph transloca-
tion.14n Southern blot and in situ hybridization studies have 
shown that in variant Ph translocation molecular recombina-
tion of 5'-her and c-ab! takes place in exactly the same way as 
in standard Ph-translocation.14-20 The remaining 6% of CML 
patients show no Ph chromosome and are classified as 
Ph-negative. Ph-negative CML patients have different clini-
cal and hematologic features. ie, older median age (>65 
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four patien~ investigated. Using polymerase chain reac-
tion (PCRJ followed by hybridization to oligonucleotide 
probes specific for the bcr-obl fusion region. the expres-
sion of a chimeric bcr-ab/ mRNA was detected. In these 
patients we demonstrated that (a) CML with a breakpoint 
in the bcr region without cytogenetically detectable Ph 
chromosome is characterized by the same genomic recom-
bination of 5'-bcr and c-ab/ as CML with standard Ph 
translocation and (b) unusual localization of 5'-bcr and c-ab/ 
sequences caused by complex Ph translocation does not 
interfere with transcription of the bcr--ablfusion gene. 
~ 1989 by Grune & Stratton. Inc. 
years). monocytosis, thrombopenia, poor response to chemo-
therapy. rapid transformation to acute leukemia, and shorter 
survival than Ph-positive CML.12.15.21.z: Nevertheless a few 
Ph-negative CML patients present with clinical and hemato-
logic features that are indistinguishable from Ph-positive 
CML. ie. mediin age <60 years. higher WBC with baso-
philia but without monocytosis. no dysplastic changes in 
bone m:l.rrow cells and same survival as in Ph-oositive 
CML23 • 
We report in this article detailed cytogenetic and molecu-
lar analysis in four patients with a disease indistinguishable 
from Ph-positive CML. with either a normal karyotype (two 
cases) or chromosomal translocations apparently not affect-
ing chromosome 22 {two cases). Southern blot analysis and 
in situ hybridization studies demonstrated genomic recombi-
nation of 5'wher and c-ab/ sequences caused by complex Ph 
translocations. eDNA analysis using the polymerase chain 
reaction {PCR) showed expression of ber-abl mRNA. These 
findings are identical to the findings in Ph-positive CML. 
CASE REPORTS 
Patients were diagnosed and treated in three different European 
centers: patient no. I in Rotne., patient no. 2 and 3 in Paris. and 
patient no. 4 in Amsterdam. A summary of clinical and hematologic 
data at diagnosis is given in Table 1. 
Patielll no. I. In September 1984 CML was diagnosed tbat 
responded to hydroxyurea (2.5 gjd): splenomegaly regressed and 
hematologic findings retumed to normal values. Hematologic rem is· 
sion was maintained until January 1986 when thrombocytosis 
appeared increasing to 1.000 x 109 fL. but responded well to 
busulfan (2 mg/d). In December 1987. the patient developed a 
nonlymphoid blast crisis and died in June 1988 due to septic 
complications. 
Patient no. 2. CML was diagnosed in February 1983. Clinical 
and hematologic remission were obtained with hydroxyurea and 
lasted 3 years. In April 1986 accelerated phase occurred with 20% 
myeloblasts in bone marrow (BM). 6-Mercaptopurine was added to 
hydroxyurea. and again hematologic stabilization was obtained. In 
October 1986 a splenectomy was performed. The spleen showed 
imponant myeloid metaplasia. In April 1987 engraftment with 
allogeneic BM was realized with success. 
Patient no. 3. In May 1977 CML diagnosis was made and 
successfully treated with busulfan. Chronic phase lasted 8V~years. In 
January 1986 the first signs of accelerated phase appeared. charac· 
terized by bone pains. asthenia. blast ce!ls in BM (10%) and 
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Tabla 1. Clinical and Hematologic Data 
Patien~ No. 1 ?atW.nt No.2 Patient No.3 Patient No.4 
Sex/ age at diagnosis M,40 F, 33 
Organomegaly Spleno- and hepatomegaly Splenomeg,nly 
M,55 
Hematomoga!y 
8.0 
F, 64 
None 
6.8 
, 
Hb (mmoi/L) 9.0 
WBC(109/L) ,28 
Myoloblasw 
"' Promyolocytes 2% 
MyolocytOs 20% 
Metamyalocytes 
"" Neutrophile. 53% 
Eos.inophils 
'" BasoPhils 
'" LymphocyteS 8% 
Monocytes 
Platelets ( 1 09 /L) 470 
s.o 
80.6 
5% 
4% 
6% 
"" 2% 
2% 
9% 
'" "0 
20 
Normal dffferential count 
5% 
W% 
5% 
65% 
1.5% 
2.5% 
8% 
3% 
2'8 
Bone marrow Hypercollular granulo- Hypercellu!ar typical CML 
450 
Hypercellular myeloid hy-
perplasia normal matu-
ration 
Hypercellular myeloid + 
megakaryocytic hyper-
plasia 
cytic + megakaryocytic no myelofibrosis 
hyperplasia 
lAP 4 4 Unknown 
(normal value) (2Q-100) (20-80) 
9 
(25-100) 
Duration of chronic phase 
'"'' 
3.25+ 
Survival (yr) 3.75+ 
peripheral blood (10%) and thrombopenia {72 x 109/L). In Sept em· 
ber 1986. blastic transfonrmtion occurred with 55% of undifferen-
tiated blast cells in bone marrow aspirate. The patient was treated 
with vincristine, d:lunorubicine, novantronc. and aracytidine. No 
remission was obtained and the patient died in October 1986 of 
::tplasia. cardiac and renal failure, and hemorrhage. 
Patient No. 4. CML was diagnosed in the beginning of 1980. 
following incidental discovery of granulocytosis without other symp-
toms. The patient reacted favorably to repe::tted courses of busulfan. 
In Febru.:u-y 1987 a steady increase of mye!oblasts in the peripheral 
blood was seen, followed within a month by a full blown myeloblastic 
crisis. Among other drugs treatment with alpha-2-interferon bad no 
success. The patient died 2 months later. 
MATERIALS AND METHODS 
Samples. Bone marrow aspirates and blood samples were sent to 
Rotterdam for molecular investigations. The samples were sterile 
and heparinized and reached the laboratory within 24 hours after 
aspiration. All s::unpling was part of diagnostic and clinical follow-up 
procedures and obtained only after informed consent of the 
patients. 
Cytogenetics. The karyotype of leukemic cells was investigated 
at diagnosis using stand:lrd cytogenetic procedures. Chromosomes 
were identified using G andfor R handing techniques and cla.ssified 
according to ISCN (1985).24 Because of unusual findings the 
cytogenetic analyses were repeated several times locally and in 
Rotterdam at the time of the molecular investigation. The constitu-
tional karyotype of each patient was determined and found normal 
using PHA stimulated blood cultures. 
DNA probes. The following probes were used in Southern blot 
analysjs and in situ hybridization~: c-abl, 0.6 kb BamHI + Ll kb 
Hin diii-EcoRI fragment; c-sis, 1.7 kb BamHI fragmen~ 5'-bcr, 2 
kb Bglii-Hin diii fragment; 3'-bcr. 1.2 kb Hin diii-BglH fragment. 
In stand:lrd Ph translocations the S' -bcr probe recognizes the 22q-
derivative and the 3'-bcr probe recognizes the 9q+ derivative. 
Southern blotting was performed following standard tech-
niques.= In situ hybridization was performed as reported previous-
ly.26The probes were 3H-labeled. using the method of Feinberg and 
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3 
5+ 
8.5 
9.3 
7 
7.3 
Vogelstein::7 to a specific activity of IO" cptn/JJ.g DNA. After 
hybridization ::tnd autoradiography the labeled sites were scored on 
R or Q banded metaphases ::tnd assigned to a chromosomal band or 
region. Grain distribution in the in situ hybridization experiments 
was tested on its statisti~ significance using the Poisson distribu-
tion followed by the binomial method. 
eDNA prepar::ttion and ::tmplification with the PCR were per-
formed as described by Herrru:ms et al.28 Oiigonudeotides:!>l 2 ::tnd 3 
(Fig 1) were used as primers to amplify a fragment covering the 
bcr-abl region. As internal positive control in the PCR. an abl 
fragment was ::tmplified. using oligonucleotides I and 3. that is 
::tlways present, irrespective of the Ph translocation. Two 40 mer 
oligonucleotides specific for the breakpoint junctions b2a2 and b3a2 
were used as probes. 
RESULTS 
Cytogenetics 
Patient no. I. At diagnosis 75 meta phases were analyzed 
after Giemsa staining and GTG banding technique without 
evidence of a recognizable Ph chromosome. However, one of 
8.5 kb ber-abl mRNA 
Fig 1. Schematic representation of 8.5 k.b bcr-abl mRNA. 
Localaation of primers used in PCR axporimont is given. V 
indicates that oxon b3 may bo absent or present in 8.5 kb bcr-abl 
mANA. Tho $.® aod localization of the 'tWo fragments ampli1iod in 
tho PCR experiments are presented. 
the two chromosomes 22 ~ppcared slightly shorter. one 
chromosome 19 appeared smaller and sub--metacentric and 
one chromosome 9 appeared identical to the 9q + derivative 
in the standard t(9:22). R-banding studies confirmed these 
findings (Fig 2). A complex chromosomal translocation 
t(9:19:22) resulting in a masked Ph was retained as probable 
interpretation of the karyotype, but routine karyotyping 
showed two apparently normal chromosomes 22. which was 
the reason for inclusion of the case in this study. 
Patient no. 2. At diagnosis 26 meta phases were analyzed 
and 80 metaphases in subsequent studies. All metaphases 
examined showed the same karyotype that was equivocal in 
R and G bands. There were two possible interpretations: 
either a simple translocation t(9:14) ora complex Ph translo-
cation t(9;14;22) (Fig 2). 
Patient no. 3. The BM karyotype of patient no. 3 was 
studied twice during the chronic phase of the disease. 
All 50 metaphases showed a 46.XY normal male karyotype 
(Fig 2). Molecular investigations were performed at the time 
of acceleration 8 years and I 0 months after diagnosis. At 
that time the BM karyotypes were 46,XY in 90% and 
46.XY. t(l;21)(p2l:q22) in 10% of the metaphases. Six 
months later. in blast crisis 45 metaphases were analyzed, 
showing additional abnormal clones: 46.XY(I6%)1 
46,XY ,t ( 1:21 )( 13%) I 46.XY .del (6)(p22)( 13%) I 
49XY.+ 10.+21.+22 (58%). 
Patient no. 4. The BM karyotype of patient no. 4 was 
found to be normal: 46.XX in repeated investigations of 
blood and BM cells during the chronic phase of the disease 
VAN DER Pl...AS ET AL 
(Fig 2). In January 1987 hematologic and clinical data 
indicated progression of CML, 20% of the metaphases were 
abnormal: 47.XX.+8,i(l7q). Remarkably, the type of aber-
rations is the same as often described in progression of Ph 
positive CML. 
Southern Blot Analysis 
DNA from bone marrow andlor blood cells of the four 
patients was digested with Bg!II. BamHI. and Hin diii and 
hybridized to 5'- and 3'-bcrprobes. All patients showed extra 
bands with more than one probe and more than one restric-
tion enzyme indicating the existence of a breakpoint in the 
bcr region of chromosome 22 (Fig 3). The breakpoint was 
found in the Hin diii-Bglii fragment of the bcr region in 
patient no. I. 2. and 4 (ie, between bcr region exon 3 and 4) 
and in the Hin diii-BamHI fragment in patient no. 3 (ie. 
between bcr region ex on 2 and 3). These results are similar to 
our observations in more than 50 CML patients with stan-
dard t(9:22). 
In Situ Hybridization Studies 
The absence of a cytogenetically recognizable Ph chromo-
some in the presence of a bcr breakpoint prompted investigaM 
tion of the chromosomal localization of the various genes of 
interest using in situ hybridization. To this aim metaphase 
spreads of the four patients were hybridized to four different 
probes: (I) c-ahl. (2) 5'-bcr mapping proximal to the break-
point. (3) 3'-bcr mapping distal to the breakpoint. and (4) 
Ag 2. Partial karyotype Of pst1enu no. 1. 2. 3. and 4. R-bands with acridine orange. Patient no. 1 shows t(9;19:22). patient no. 2 
t(9;14;22). and patients no. 3 and 4 have normot karyotype. 
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Fig 3. Southern blot showing genomic DNA from Ph~negative 
CML patients no. 1. 2. 3. and 4 digested with Bg/11 and &rmHI. Tho 
filter with Bg/11 digests was probed with 3'~ and 6'~bcr probe. Tho 
filter with BamHI digests was probed with 3'~bcr. SG:o of gennline 
bends is mark.od. Extra bands are found in all lanes oxc::opt in 
SamHI digost of patient no. 3 probed with 3'-bcr. indicating tho 
pr0$Eince of a breakpoint in the bcr region in all four patients. 
Below tho Southern blot a simple restriction map of the bcr region 
is given:" The 6'-bcr and 3'-bcr probes are indicatOO. Bg. Bg/11; H. 
Hin dill; B. BamHI; E. EcoRJ; b1-b4. bcr region oxon 1-4. Arrows 
mark.od 1. 2. 3. and 4 indicate the fragment in which tho 
breakpoint on chromosome22 is mapped in patients no. 1 through 
4. 
c-sis as an indicator of the distal part of chromosome 22. 
Results are detailed in Table 2 and summarized in Fig. 4. 
Patien1 no. 1. In patient no. 1, with presumably a 
complex t(9;19;22) (Fig 2). it appeared that 5'-bcr and c-ab! 
probes hybridized to the shortened q arm of the 19q- while 
3'-bcr and c-sis hybridized to the 9q+ as in classical t(9;22). 
It is obscure whether the centromere of the chromosome 
designated as I9q- belongs to chromosome 19 or 22. 
Patienl no. 2. In patient no. 2 specific hybridization 
indicated a complex t(9;14:22). Indeed, 5'-bcr and c-ab/ 
probes strongly hybridized to the smallest chromosome 
therefore identifying itself as Ph or 22q-. 3'-bcr and c-sis 
only hybridized to chromosome 22 and to the 14q- that are 
cytogenetically indistinguishable in this case. 
Patients M. 3 and 4. c-ab/ and 5'-bcr showed an abnor-
mal localization on the distal part of 1 pin patients no. 3 and 
4. This part of chromosome 1 showed the same staining 
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properties as the distal part of chromosome 22. In both cases 
c-sis only maps to chromosome 22. while 3' -bcr maps on 
chromosome 22 and in patient no. 3 also on 9q34. In patient 
no. 3 in the minority of cells with t(1;21) specific hybridiza-
tion of c-ab/ and 5'-bcr occurred on the normal chromosome 
I. not involved in the translocation t(l;21}. These results 
indicated that in both patients a complex rearrangement has 
occurred between chromosomes lp36. 9q34. and 22qll, 
resulting in the presence of hybridization sites for c-ab/ and 
5' -bcr probes on I p36. 
Statistics Used in the In Situ Hybridization Experiments 
Grain distribution in the in situ hybridization experiments 
was tested on its statistical significance using the Poisson 
distribution followed by binomial method in the c::tSe of 
chromosomes 9 and 9q+. In theC:lSe of chromosomes 14q-, 
I9q-. 22. and 22q- only the Poisson distribution was 
applied, since the contribution of these chromosomes to the 
DNA-content of a metaphase is relatively sma1Lz9 Binomial 
distribution was tested in the case of chromosome 1. since 
this chromosome contributes to a relatively large part oft!~ 
genomic DNA. The P value for both Poisson and binomial 
distribution wo.s determined at 10-l. 
All experiments were statistically significant for tht 
probes used with the exception of the 3'-bcr probe. whicl 
showed no statistical significance according to the Poissor 
distribution in patient no. 1 on chromosomes 9q + and 22 
and in patients no. 3 and 4 on chromosome 9. Though, in th! 
case of patients no. 1 and 3. experiments with the 3'-bcl 
probe could be demonstrated to be statistically significant fo1 
the chromosomes 9q + and 9, respectively. when the bino-
mial distribution alone was tested. 
Amplification of eDNA by the PCR 
The results of amplification of eDNA followed by hybrid 
ization to breakpoint specific oligonucleotides are shown i1 
Fig 5. A 319 base pairs fragment (bp) corresponding to b2a: 
joining in thebcr-abl mRNA has been found in patient no. 3 
a control CML patient with standard Ph translocation an( 
cell line BVI73. A 394 bp fragment corresponding to b3a: 
joining has been found in patients no. I and 4 and cell lin• 
K562. As expected neither b2a2 nor b3a2 joining have bee1 
detected in leukocytes of a healthy control. 
DISCUSSION 
In this article we report clinical. cytogenetic and molecu 
Jar data obtained in four patients with CML and absence c 
Ph chromosome in bone marrow metaphases. In thes 
patients clinical features at presentation and long surviv:J 
(3. 75 to 9.3 years) contrasted with the atypical symptomatol 
ogy o.nd rapid transformation to blast crisis usually assc 
ciated with Ph~negative CML. Reclassification of these case 
as myelodysplastic (CMML) or myeloproliferative syr 
drom~1 .l0 does not apply to these four patients who had a 
characteristics of classic CML except for the Ph chrom< 
some. 
Southern blotting demonstrated a bcr breakpoint in tb 
four cases. similar to our findings in Ph-positive CM 
VAN DER PLAS ET AL 
Table2. In Situ Hybridization Studies 
No. of Labolod Sitos on Chromosomes end Spodflc Sands 
No. of 
Podcnt and MotePhaoos 
'""'"""' """" 
Anaty:zed Toml lq33-34) 5o+ lq-dlstal) 22. der (22) ,,_ 
Patient No. 1 e-abl 30 96 , (10) 3 2t 
46, XY. c-sis ,92 346 '0 32 (22) 24 
t (9;19;22) 5'-bcr 30 97 2 3 w 
3'ba 32 86 2 8 (7) 6 
Patient No.2 c-ab/ 50 ,65 20 (18) 8 3§ , 
46,XX c·SIS 50 '58 9 '0 24 2 
t(9;14;22) 5'-bcr 50 '56 5 4 '6 
'" 3'-bcr 50 
"' 
4 6 24 
Patient No. 3 c-ab/ 63 230 27 (19) 4 
46. 'XY c-sis 50 ,.7 9 22 
5'-bcr 65 2W w ,. 
3'-bcr 66 2" 
" 
(14)'1! 27 
Patient No.4 ~bl 
"" 
208 36 (29) 4 
46,XX e-sis 63 '82 9 22 
5'-bcr 50 ,.6 7 
" 3'-bcr 56 174 12 (5)# 
" 
.. The number of labeled srtcs on specific parts of chromosomes or specific bands is written in parentheses. 
tin patient 1 chromosome 22 and der(22) were indistinguishable in mitoses studied after in situ hybridization. 
;!:Number of labeled sites on the deleted arm of 19q-. 
§In patient 2 chromosome 22 and 14q- are indistinguishable by cytogenetics only. 
II Number of labeled sites on chromosome 1 (p34-p36). 
'I!Statistically significant using the binomial distribution alone. 
#Statistically not significant according to the Poisson and binomial distribution. 
-Chromosomes 
'""""" 
19/19q-:1/8 (Slt 
19/19q-:6/5 
19/19q-:1/7 (7)t 
19/19q-;1/1 
no. 14:3 
no. 14:3 
no. 14:3 
no. 14:3 
no. 1:28 (201[1 
no. 1:22 
oo. 1:25 (15lll 
oo. 1:19 
oo. 1:26 (17)[[ 
oo. 1:15 
00. 1:19(12111 
oo . 1:17 
PATIENT 2 
~· ac~ 
C·$1S 
PATIENT 1 
PATIENT J 
t~j.~a ~~ = <·•OC > O<< 
.J 
" " 
PATIENT '-
" 
No. of 
""'""""' "''~ 
46 
'03 
42 
50 
95 
,20 
6' 
94 
'50 
97 
''" '53 
'06 
'03 
75 
118 
Fig 4. Summary of results of in situ hybridization wlth F/ -bcr, 3' -bcr, c-sis. end c--abf probes in Ph-nagstiv& CML pstients no. 1, 2, 3. and 
4. Normel chromosomes on the left. Localization of the different probes by in situ hybridi;tation is present&d. 
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Fig 5. A\rtoradiogram of tho PCR experiment Us~ng bcr and 
lilbl primers {FEg 1) a eDNA fragment containing tho bcr-abl fusion 
region was amplified. After gel electrophoresis and blotting onto 
nylon membranes hybridization was performed to breakpoint 
specific oligonuclootido probos b2a2 and b3a2. A 319 bp fragment 
corresponding to a b2a2 joining has boon found in lane 2 (BV173 
celllino).lano4 [Ph positive CMLJ. and lane 6 [patient no. 3). A 394 
bp fragment corresponding to a b3a2 joining has boon found in 
lane 1 (colllino K562).1ano 5 (patient no. 1). and lane 7 [patlont no. 
4). As oxpoctod no bcr-abl joining has boon found in lano 3 
{loukocytos of a hoatthy control). 
patients with standard t(9:22). Cytogenetically patients no. 1 
and 2 showed chromosomal rearrangements involving 9q34 
and chromosomes 19 and 14 respectively, while involvement 
of chromosome 22 was dubious. In situ hybridization studies 
demonstrated that complex translocations t(9:19:22} and 
t(9:14:22) had occurred. As a result of these transl~tions 
5'-bcr and c-ab/ probes hybridized to the same chromosomal 
region. ie. I9q- in patient no. I and 22q- in patient no. 2. 
Similar results were reported by Bartram et af1 in a Ph-
negative CML with t(9:12). and 1 year later by Kurzrock et 
al32 in a Ph-negative. her-positive CML patient with t(9:11). 
In a CML patient with complex t(9:13:15) and two normal 
chromosomes 22 we also found a bcr breakpoint by Southern 
blot analysis (case referred to us by D. Riviere [Brest. 
France]. unpublished observation, 1985). These data 
strongly suggest that in apparently Ph-negative CML. with 
chromosomal rearrangement of 9q34. molecular evidence for 
a bcr breakpoint and for bcr-abl recombination will usually 
be found and that these cases constitute a rare type of variant 
Ph translocation. 
A normal bone marrow karyotype was found in patients 
no. 3 and 4. In situ hybridization studies unexpectedly 
showed hybridization of c-ab/ and 5-bcr probes to the 
chromosomal region 1p35-36 in addition to 9q34 (c-ab!) and 
22qll (5'-bcr). c-Sis hybridized to chromosome 22 as 
expected. In patient no. 3. 3'-bcr hybridized to chromosome 
22 and also to 9q34, which is an indication that t(9:22) 
almost certainly was the first step in a two-step rearrange-
ment in this patient. In situ hybridization studies have been 
reported in four cases of CML, Ph-negative. her-positive. and 
a normal karyotype.19.33 In all four cases c-ah/ was found to 
hybridize to 22q 11 imd the rearrangement was interpreted as 
an insertion of c-ahl in the bcr gene. In patients no. 3 and 4, 
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the exact mechanism of chromosomal rearrangements is not 
completely elucidated. but they are to the best of our 
knowledge the first cases of Ph-negative CML with an 
apparently normal karyotype and translocations or insertions 
of 5'-bcrand c-ab/ on 1p35-36. 
The PCR experiments described here are of crucial impor-
tance because they demonstrate the presence of bcr-ab/ 
mRNA in the three cases investigated (patients no. I. 3, and 
4). The b3a2joining detected in patients no. 1 and 4 and the 
b2a2 joining in patient no. 3 corresponded to the mapping of 
the breakpoint on chromosome 22 by Southern blot analysis. 
The results of Southern blot analysis and the PCR experi-
ment indicated that in these Ph-negative CML patients 
bcr-abl fusion has taken piace analogous to Ph-positive CML 
patients and that transcription was not influenced by the 
unusual chromosomal localization of 5'-bcr and c-ab/ in these 
patients. The occurrence of bcr-abl rearrangements in Ph-
negative CML and the clinical significance of such findings 
have been studied by others.19Xl.Jl·J7 
From the 50 cases with normal karyotypes that have been 
investigated by Southern blotting, including our own 
patients. 20 showed a breakpoint in the bcr region.19.3~36 In 
ten cases RNA or protein analysis demonstrated tran-
scription or translation19.J<; of the chimeric bcr-abl gene. The 
clinical criteria for CML diagnosis. the frequency of molecu~ 
Jar rearrangements. and the interpretation of data are dif-
ferent in each study. Nevertheless most investigators31 •37 
concluded from their studies that in Ph-negative CML the 
finding of bcr-ab/ molecular rearrangements indicated an 
undetected Ph translocation and therefore classify these 
patients to the group of Ph-positive CML with the prognostic 
and therapeutic consequences attached to this diagnosis. The 
remaining cases (Ph negative, bcr negative) constitute the 
group of Ph-negative CML with atypical (ie. myelodysplas-
tic) hematologic features and a relatively short survival. 
Dreazen et al19 challenged this hypothesis and claimed the 
presence of the bcr rearrangement in the majority of their 
Ph-negative CML patients and the finding of atypical fea-
tures. 
Our data support the former observations and indicate 
that in Ph-negative CML. the finding of molecular evidence 
for the presence of a bcr-ab/ fusion gene is diagnostic for 
classical CML. Larger prospective studies are needed to 
clarify the clinical relevance of molecular investigations in 
CML. 
ACKNOWLEDGMENT 
The authors express their gratitude to Professor D. Bootsma for 
advice and support, they are thankful to Professeur A. Najman. 
Service d'HCmatologie. HOpital St. Antoine (Paris) and Dr M.J. 
Grange. Service d"Hematologie du Professeur J. Cacn. HOpital 
LariboisiCre (Paris) for referring their patients and contributing the 
clinical data.. We thank R. Slater, Institute of Human Genetics, 
Amsterdam University for cytogenetic studies of patient no. 4 and R. 
de Cuia. University .. La Sapienza. .. for technical assistance. The 
secretarial assistance of R. Boucke is gratefully acknowledged. 
REFERENCES 
1. Rowley JD: A new consistent chromosomal abnormality in 
chronic myelogenous leukemia identified by quinacrine fluorescence 
and Giemsa staining. Nature 243:290. 1973 
2. Grotren J. Stephenson JR, Heisterkamp N, de Klein A. 
Bartram CR. Grosveld G: Philadelphia chromosomal breakpoints 
are clustered within a limited region, bcr, on chromosome 22. Cell 
36:93. 1984 
3. Canaani E. Gale RP, Steiner-Salz D. Berrebi A. Aghai E. 
Januszewi= E: Altered transcription of an oncogene in chronic 
myeloid leukemia. Lancet I :593, 1984 
4. Collins SJ: Altered transcription of the c-ab! oncogene in K562 
and other chronic myelogenous leukemia cells. Science 225:72. 
1984 
5. Shtivelman E. Lifshitz B. Gale RP. Canaani E: Fused tran-
script of ab/ and bcr genes in chronic myelogenous leukaemia. 
Nature 315:550. 1985 
6. Starn K. Heisterkamp N. Grosveld G, de Klein A. Verma RS. 
Coleman M, Dosik H, Groff en J: Evidence of a new chimeric bcrj 
c-ab! mRNA in patients with chronic myelocytic leukemia and the 
Philadelphia chromosome. N Eng! J Med 313:1429. 1985 
7. Heisterkamp N. Starn K, Grotren J. de Klein A, Grosveld G: 
Structural organization of the bcr gene and its role in the Ph 
translocation. Nature 315:758. 1985 
8. Grosveld G. Verwoerd T. van Agthoven T. de Klein A, 
Ramachandran KL, Hcisterkamp N, Starn K, Groffen J: The 
chronic myelocytic cell line K562 contains a breakpoint in bcr and 
produces a chimeric bcrfc-abl tr:lnscript. Mol Cell Bio\6:607, 1986 
9. Shtivelman E. Gale RP. Dreazen 0, Berrebi A. Za.izov R. 
Kubonish I. Miyoshi I, Canaani E: Bcr··ahl RNA in patients with 
chronic myelogenous leukemia. Blood 69:971, 1987 
10. Kurzroek R, Kloetzer WS. Talpaz M, Blick M. Walters R, 
Arlinghaus RB. Gutterman JU: Identification of molecular v:.J.riants 
of p210 bcr-abl in chronic myelogenous leukemia. Blood 70:233, 
1987 
11. Konopka JB. Witte ON: Detection of c-ab/ tyrosine kinase 
activity in vitro permits direct comparison of normal and altered abl 
gene products.. Mol Cell Biol5:3116, 1985 
12 &mdberg AA.; The cytogenetics of chronic myelocytic leuke-
mia (CML): Chronic phase and blastic crisis. Cancer Genet Cyto-
genet 1:217.1980 
13. Heim S. Billstrom R, KristotTersson U. Mandahl N, Strom-
beek B. Mitelman F: Variant Ph translocations in chronic myeloid 
leukemia. Cancer Genet Cytogenet 18:215. 1985 
14. Heisterhmp N: Stephenson JR. Groffen J, Hansen PF, de 
Klein A, Bartram CR. Grosveld G: Localization of the c-ab! 
oncogene adjacent to a translocation breakpoint in chronic myelo-
cytic leukaemia. Nature 306:239. 1983 
15. Bartram CR. de Klein A. Hagemeijer A. van Agthoven T. 
Geurts van Kessel A. Bootsma D. Grosveld G. Ferguson-Smith MA. 
Davies T. Stone M, Heisterkamp N, Stephenson JR. Groffen J: 
Translocation of c-ab/ oncogene correlates with the presence of a 
Philadelphia chromosome in chronic myelocytic leukaemia. Nature 
306:277,1983 
16. Hagemeijer A. de Klein A. GOdde-Salz E. Turc-Carel C. 
Smit EME. van Agthoven AJ. Grosveld G: Translocation of c-ab! to 
masked Ph in chronic myeloid leukemia. Cancer Genet Cytogenet 
18:95.1985 
17. Hagemeijer A. Bartram CR. Smit EME. van Agthoven AJ. 
Bootsma D: Is chromosomal region 9q34 always involved in variants 
of the Ph tr:lnslocation'? Cancer Genet Cytogenet 13:1. 1984 
18. Bartram CR. Anger B. Carbonell F. Kleihauer E: Involve-
ment of chromosome 9 in variant Ph translocation. Leuk Res 9:1133, 
1985 
19. Drea:zen 0. Klisak I. Rassool F. Goldman JM, Sparkes RS. 
Gale RP: Do oncogenes determine clinical features in chronic 
myeloid leukaemia'? Lancet 1: 1402. 1987 
VAN DER PLAS ET AL 
20. De Braekeleer M: Variant Philadelphia translocations in 
chronic myeloid leukemia. Cytogenet Cell Genet 44:215. 1987 
2L Pugh WC. Pearson M, Vardiman JW. Rowley JD: Philadel-
phia chromosome-negative chronic myelogenous leukaemia: A mor-
phological reassessment. Br J Haemato\60:457, 1985 
22. Ka.ntarjian HM. Keating MJ, Walters RS. McCredie KB. 
Smith TL. Talpaz M, Beran M. Cork A. Trujlllo JM. Freireich EJ: 
Clinical and prognostic features of Philadelphia chromosome nega-
tive chronic myelogenous leukemia. Cancer 58:2023. 1986 
23. Fitzgerald PH. Beard MEJ. Morris CM. Heaton DC. Reeve 
AE: Ph negative chronic myeloid leukemia. Br J Haematoi66:311. 
1987 
24. ISCN (1985): An international system for human cytoge-
netic nomenclature. In Harnden DG. Klinger HP (cds): Basel. 
Karger, 1985 (Published in collaboration with Cytogenet Cell 
Genet) 
25. Maniatis TE. Fritsch EF. Sambrook J: Molecular Cloning: A 
Laboratory ManuaL Cold Spring Harbor. NY. Cold Spring Harbor 
Laboratory. 1982 
26. Bartram CR. de Klein A, Hagemeijer A. Grosveld G. Heis-
terkamp N. Groff en J: Localiza.tion of the human c-sis oncogene in 
Ph positive and Ph negative chronic myelocytic leukemia by in situ 
hybridization. Blood 63:223, 1984 
27. Feinberg AP, Vogelstein B: A technique for radiolabeling 
DNA restriction endonuclease fragments to high specific activity. 
Anal Bioeh 132:6. 1983 
28. Hermans A, Gow J. Selleri L. Von Lindern M, Hagemeijer 
A, Wiedeman LM. Grosveld G: Bcr-abl oncogene activ:.J.tion in 
Philadelphia chromosome positive acute lymphoblastic leukemia. 
Leukemia 10:628. 1988 
29. Mendelsohn ML, Mayall BH. Bogan E. Moore DH. Perry 
BH: DNA content and DNA based centromeric index of the 24 
human chromosomes. Science 179:1126, 1973 
30. Travis LB. Pierre RV. DeWald GW: Ph negative chronic 
granulocytic leukemia: A nonentity. Am J Clin Patho\85:186. 1986 
31. Bartram CR. Kleihauer E. de Klein A. Grosveld G. Teyssier 
JR. Heisterkamp N. Groff en J: C-ab! and bcr are rearranged in a Ph 
negative CML patient. EMBO J 4:683, 1985 
32. Kurzroek R. Blick MB, Talpaz M. Velasquez WS. Trujillo 
JM, Kouttab NM. Kloetzcr WS. Arlinghaus RB, Gutterman JU: 
Rearrangement in the breakpoint cluster region and the clinical 
course in Philadelphia negative chronic myelogenous leukemia. Ann 
Intern Med l 05:673. 1986 
33. Morris CM. Reeve AE. Fitzgerald PH. Hollings PE, Beard 
MEJ, Heaton DC: Genomic diversity correlates with clinical varia-
tion in Ph negative chrorric myeloid leukemia. Nature 320:281, 
1986 
34. Ganesan TS. Rassooi F. Guo AP, Th'ng KH. Dowding C. 
Hibbin JA. Young BD. White H. Kumaran TO. Galton DAG. 
Goldman JM: Rearrangement of the bcr gene in Philadelphia 
chromosome negative chronic myeloid leukemia. Blood 68:957, 
1986 
35. Bartram CR. Carbonell F: Bcr rearrangement in Ph negative 
CML. Cancer Genet Cytogenet 21:183, 1986 
36. Wiedeman LM. Karhi KK. Shivji MKK. Rayter SI. Pegram 
SM. Dowden G. Bevan D. Will A. Galton DAG. Chan LC: The 
correlation of breakpoint cluster region rearrangement and p210 
phljab/ expression with morphological analysis of Ph negative 
chronic myeloid leukemia and other myeloprolifer::ttive clisorders. 
Blood 71:349,1988 
37. Bartram CR: Rearrangement of the c-ab/ and bcr genes in 
Ph-negative CML and Ph-positive acute leukemias. Leukemia 2:63, 
1988 
135 

bcr~abl mRNA Lacking abl Exon A2 Detected by Polymerase Chain Reaction in a Chronic 
Myelogeneous Leukemia Patient 
D.C. van der Plas, D. Soekarman, A.M. van Gent', G. Grosve!d, and A. Hagemeijer 
Department of Cell Biology and Genetics. Emsmus University, Rotterdam, and 'lnterconfcssioneel Ziekenhuis de Baronie. Breda, 
The- Netherlands 
Using the polymerase chain reaction and Southern blot 
analysis the expression was detected of a bcr-abl mRNA 
lacking abl exon a2. This was due to a corresponding 
unusual localization of the breakpoint In the c-ab/ gene and 
was seen in a patient with Philadelphia (Ph) chromosome 
positive chronic myelogeneous leukemia in chronic phase. 
This type of mRNA has been desa-lbed only once before in 
two Ph-positive acute lymphoblastic leukemia patients, by 
Soekarman el a/. {1). The ab/exon a2 sequences, which are 
missing In the three repOrted patients, code for a part of the 
SH3 region of the abl protein. which Is supposed to be 
involvec! In negative regulation of the kinase domain. The 
clinical significance of this finding is discussed. 
INTRODUCTION 
Chronic myelogenous leukemia (CML) is cytogenetically 
characterized by the presence of the Philadelphia (Ph) 
chromosome, which originates from the Ph translocation 
t(9;22) (q34;qll)(2). 
On chromosome 22 the breakpoint is located in band 
q 11 in the bcr gene. In CML the breakpoints in the bcr 
gene are clustered in a region of 5.8 kb, the breakpoint 
cluster region (BCR) (3). The BCR region is part of a 
gene, the bcr gene, and contains four exons (bl-b4) (4). 
In nearly all CML patients the chromosome 22 break· 
point is located between exons b2 and b3, or between b3 
and b4. 
On chromosome 9 the breakpoints are scattered over a 
region of more than 200 kb in the c-ab! gene, either 
between exons IB and IA, or between lA and the second 
exon of C·ahl. which is referred to as abl exon a2 in this 
paper (Figure I) (5). However, the breakpoint is always 
located 5' of c~abl ex on a2. The bcr~abl fusion gene on the 
Ph chromosome is transcribed into a bcr·ahl mRNA. in 
which either BCR exon b2 or b3 is fused to ahl exon 
a2 (6,7). These chimeric mRNAs encode bcr·abl fusion 
proteins of 210 kD (p210), which have enhanced in vitro 
tyrosine kinase activity as compared to the normal abl 
protein (8) and have transforming activity. In Abelson 
murine leukemia virus (AML V) the transforming paten~ 
tial of v-abl is dependent on the tyrosine kinase ac· 
tivity (9). Therefore regulation of the tyrosine kinase 
activity ofp210 bcr·abl is thought to play an important 
role in the leukemogenesis of CML. 
The Ph translocation is also observed in acute lym-
phoblastic leukemia (ALL) and acute myeloblastic leuk· 
emia (AML). although less frequently than in CML. The 
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Rgure 1. Sehematle representation of the normal qbf gene. The 
exons are deplete<! as black boxes an<! numbered aeeordlng to 
Groffen et sf. (3). 
breakpoint in the ahl gene always occurs at the same 
position as in CML. i.e. 5' of abl ex on a2. In 50% of the 
Ph-positive acute leukemias the breakpoint in bcr is also 
identical to that observed in CML, resulting in the same 
bcr-abl products as are observed in CML. In the remain· 
ing 50% the breakpoint in the bcr gene is located more 5', 
i.e. in the first intron. In the latter cases an mRNA is 
transcribed, in which the first exon of the bcr gene (el) is 
spliced to ahl ex on a2, resulting in an ela2 junction (10). 
This mRNA is translated into a bcr-abl fusion protein of 
190 kD (p 190), that also shows enhanced tyrosine kinase 
activity and transforming potential (8). 
Recently Soekarman et a!. (l) reported an aberrant 
localization of the chromosome 9 breakpoint in the abl 
gene in two Ph·positive ALL patients. This new break-
point was located in the intron between abl exons a2 and 
a3, resulting in a bcr·abl mRNA lacking abl exon a2. In 
their first patient, bcr-abl fusion in the mRNA occurred 
between exons b2 and a3, resulting in a 210 kD fusion 
protein, whereas in the second patient bcr exon el 
appeared to be fused to abl exon a3. resulting in a fusion 
protcin of 190 kD. Both proteins showed enhanced tyro· 
sine kinase activity in autophosphorylation assays as 
compared to the normal abl protein. but in the same 
range as observed in other ALL patients. 
In the novel bcr-abl fusion protein 58 amino acids are 
missing, which are encoded by abl exon a2. Interestingly, 
the last 17 amino acids encoded by a2 are part of a 
stretch of 50 amino acids that form the src--homology 3 
region (SH3) of the abl protein (11). This is one of the 
regions that is highly homologous in abl and scr. The 
SH3 region is thought to have a negative regulatory 
effect on the kinase domain, termed SHl (12,13). There-
fore the finding of partial deletion of the SH3 region in 
the two ALL patients indicates that this regulatory 
region is inactive in the bcr·abl fusion proteins. 
In this paper Southern blot and polymerase chain 
reaction (PCR) analysis are reported of bone marrow 
cells of a Ph-positive CML patient in chronic phase, with 
a b2a3 chimeric mRNA and a chromosome 9 breakpoint 
between ahl exons a2 and a3, much the same as in the 
two ALL patients reported by Soekarman eta/. (1). The 
significance of this finding is discussed. A PCR and 
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Southern blot strategy is proposed, which can be used for 
screening patients for the presence of this new bcr-ah! 
rearrangement. 
MATERIALS AND METHODS 
Patient 
A 59-year-old man was first seen in December 1988 with 
complaints of tiredness. Physical examination showed spleno-
megaly. Laboratory investigations revealed Hb 6.0 mmol/L 
leucocyte count 254 x J0"/1 and thrombocyte count 180 x I0"/1. 
The peripheral blood smear contained 42% myclocytcs, I 0% 
promyclocytes, 5% mctamyclocytes, 3% normobi:lsts. 14% 
bands, 24% segmented ncutrophils. and 2% cosinophiis. Blood 
urea. creatinine, and electrolytes were within the normal range. 
Plasma lactate dehydrogenase was elevated (II 53 U(l). The 
bone marrow smear showed increased myelopoiesis. Based on 
these findings. a diagnosis of CML was made. 
The patient was treated with hydroxyurea. During the next 2 
years be remained in chronic phase CML. In December 1990 
acceleration of the disease occurred. The bone marrow biopsy 
showed myelofibrosis. To control the serious anemia the 
patient frequently received blood transfusions. 
Samples 
Sterile bone marrow aspirates and blood samples were taken 
and heparinized. Sampling was part of diagnostic and clinical 
follow-up procedures and was obtained only after informed 
consent of the patient. After Dextran separation. lcucocytes 
were frozen and stored in liquid nitrogen until DNA and RNA 
analysis was performed. 
Cytogenetics 
The karyotype of blood and bone marrow cells was investi-
gated at diagnosis and during the next 2 year:; at 6 month 
intervals using standard cytogenetic procedures (14). Chromo-
somes were identified using the R-banding technique. and 
classified according to ISCN (I 985) (15). The constitutional 
karyotype was determined and found to be normal ~ing PHA 
stimul:lted blood cultures. 
DNA Probes 
The following DNA probes were used: 5'-BCR. 2kb Bglii-
Hindiii fragment; 3'-BCR, 1.2kb Hindiii-Bglii fragment; 
abl, 0.9kb Saul-Kpnl fragment, spanning the 0.6kb intron 
between exons a2 and a3. 
Southern Blotting 
This was performed using standard tcchniques(l6). 
Reversed PCR Analysis 
eDNA synthesis and amplification using the PCR technique 
were performed as described by Hermans et a!. (17). The 
localization of the primers used in the PCR reaction is shown 
t~ehematically in Figure 2. In brief: oligonucleotides I, 2 and 3 
were used as primers to amplify the fragment covering the bcr-
abl region. As an internal positive control in the PCR reaction. 
an abl fragment was amplified, using oligonucleotides I and 4. 
This abl fragment is always present, irrespective of the Ph 
translocation. Four oligonucleotides specific for the breakpoint 
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8.5 Kb bcr·abl mRNA-o-2101<0 protein 
v 
3941319 bp 
7.0 Kb bcr-abl mRNA-190 kD protein 
Figure 2 Schematic representation ol the 8.5 and 7.0 kb bcr-abl 
mRNA. The localization of bcr and abf primers Is shown. Using 
primer 1 and 2, a fragment or 394 or 319 bp ls amplified, depending 
on 1he exon b3 In the mRNA. These lragments have a b3a2 and a 
b2a2 junction, respectlvety. Using primer 1 and 3 a fragment of 
298 bp is amplified with an e1a2 junction. Primers 1 ond 4 are used 
as an internal control to amplify an ob/lragment ol198 bp, which 
should alwsys be present Irrespective of the presence of 1he Ph 
tfansiOC8tJOn. 
junctions cla2. b2a2, b3a2, b2a3. and two oligonucleotides 
specific for b2 and a2 sequences were used as probes. The first 
three oligonucleotides mentioned are the same as described by 
Hermans eta!. (17). The sequences of the remaining oligonuc-
leotides are: b2a3, 5' GCTGACCATCAATAAGGAAGGT-
G.AAAAGCTCCGGGTCTTA 3'; b2. 5' GTGAAACTCCA-
GACTGTCCACAGCA 3'; and a2. 5' TCCACT-
GGCCACAAAATCATACAGT 3'. 
RESULTS AND DISCUSSION 
At diagnosis the karyotype of all 32 metaphases analysed 
from blood and bone marrow was 46,XY.t(9:22) 
(q34:qll), showing a standard Ph translocation. Treat-
ment was started with hydroxyurea. For the next 2 years, 
cytogenetic analysis was performed every 6 months and 
showed persistence of the Ph translocation in a11 meta-
phases examined, without additional cytogenetic aberra-
tions. Both clinically and cytogenetically the patient was 
in chronic phase of CML for these 2 years. 
Molecular analysis was performed on the bone mar· 
row sample obtained at diagnosis. Using Southern blot 
analysis the breakpoint in the BCR region was deter-
mined (Figure 3). A rearranged band was detected in the 
Bglii. but not in the BamHI digested DNA after hybri-
di7..ation with the 5'-BCR probe. Hybridization with the 
3'-BCR probe showed no rearranged bands. This can be 
explained by: (I) a breakpoint in the 5' part of BCR in 
combination with a deletion in the 3' part of BCR: (2) a 
breakpoint in the 5' part ofBCR. resulting in the BamHI 
digested DNA in an aberrant BamHI bcr-abl fragment 
of the same size as the germline BamH I bcr fragment; or 
(3) by a Bgl II polymorphism without a BCR breakpoint. 
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Flgure3. Upper panel: Southern blot ~mal)'l)ls of the CML patlent(1) and normal thymus DNA (N). DNA was digested with the restriction 
enzymes Bg1U {Bg) and BamH1 {S). The lollowlng pi'Qbes were use<!: 1..2kb Hlndiii-Bg11! BCR fragment (3'-BCR), 2.0kb Bg111-Hindlll BCR 
fragment (S'·BCR), and a 0.9 kb Saui-Kpnllragment spanning the lntron between ab/ exon a2 and a3. The sizes ol the germllne fragments 
are given In kllobases {kb). Additional restrletlon fragments are Indicated by arrowheads. Lower panel: A simplified restriction map olthe 
normal BCR region and the part of the ab/ gene surrounding abf exons a2 and a3 is deplded. (Bg) Bg111: (B) BamH"1: (K) Kpnl; {S) Saul. Exons 
are represented by black boxes. The locations of the 3'-BCR. 5'·BCR. and ABL fragments used as probes in the Southern blot analysis are 
shown. 
To check which of the explanations was correct. it was 
investigated if bcr-ahl mRNA was expressed in the 
leukemic cells of this patient. PCR analysis was per-
formed on eDNA preparations obtained from total 
RNA of the bone marrow cells of the patient. A scheme 
indicating the localization of the PCR primers and the 
expected size of the amplified fragments is shown in 
Figure 2. No fragment of the expected size. i.e. 298.319. 
or 394 bp. corresponding to mRNA with an e1a2. b2a.2. 
or b3a2 junction. was visible on gel. nor was such a 
fragment detected after hybridization with oligonucleo-
tides which specifically recognize these bcr-abl fusion 
regions in the amplified fragment (data not shown). 
However. a fragment of 145 bp was amplified instead 
(Figure 4), using primers 1 and 2. The fragment failed to 
hybridize under stringent conditions to ela2, b2a2. or 
b3a2 specific oligonucleotide probes. It also failed to 
hybridize to an oligonucleotide containing exon a2 se-
quences. but hybridized readily to an oligonucleotide 
containing exon b2 sequences. The most likely explana-
tion for these hybridization data and the size of 
the amplified fragment (319-174= 145 bp. i.e. 
UNUSUAL BCR·ABL MRNA IN CML 
b2a2-a2=b2a3) is that the leukemic cells of this CML 
patient express a bcr-ab! mRNA with a b2a3 junction. 
This was checked by determining the breakpoint in the 
abl gene by Southern blotting (Figure 3). The Southern 
blot containing the Bgiii and BamHI digested DNA was 
hybridized to a 0.9 kb Saui-Kpnl genomic fragment 
spanning the abl intron between exon a2 and a3. Indeed, 
both in Bgiii and BamHI digested DNA an aberrant 
restriction fragment was detected. indicating a break-
point in this region. 
Final proof for the presence of a b2a3 junction in the 
bcr-abl mRNA was provided by hybridization of the 
:•CR product to an oligonucleotide specific for the b2a3 
fusion region. This oligonucleotide readily hybridized to 
the 145 bp PCR fragment of the CML patient. whereas it 
failed to hybridize to the PCR product of a Ph-negative 
BCR unrcarranged CML patient (Figure 4), or to the 
319 bp PCR product of a CML patient with a b2a2 
junction (data not shown). ·which served as negative 
controls on the PCR reaction and the hybridization, 
rcspccti vely. 
In conclusion. the leukemic cells of this CML patient 
139 
~ ~ ~ 3 
' 
' ' "! 
" ' 
~ 1: ~ 
' ' ' c;; C;' 
-"'- -
Figure 4. The two panels on the left show the UV picture of the 
ethldl....., bromide stained agarose gel containing the PCR products 
ol the blood cells of the CML patient (1). and of a Ph-negative CML 
patient without bcr-sbl rearrangement (N}. serving as control. Bac-
teriophage A DNA (ljgested with the restrietlon en:cyme Pstl Is used 
as molecular weight marker. Abl Indicates a lane In which primers 1 
and 4 (see Flguro 2) are used to ampllly a 198 bp .ab/lragment. which 
$hould always be present Irrespective of the presen~ of !he Ph 
translocation. Sc:r-abl on top of a lane lndleetes that primers 1 and 2 
are used to amplify a bcr-sbl fragment. A 145 bp lragment was 
detected In the patient (1). As expected. no bcr-sbf fragment was 
amplified In the negative control patle'lt (N). The panel on the right 
shows the autoradiogram of the same agarose gel after blotting onto 
nylon membrane and hybridlUitfon to an oligonucleotide which 
speelllcally recognizes the junelfon between BCR exon b2 and obi 
exon a3 (b2a3). The 145 bp PCR product of the patient (1) readlly 
hybrldb:ed to the b2a3 specific ollgonucleotide. whereas no hybrid I· 
U~tlon signal Is <letected In the negative control patient (N). 
expressbcr-ab/mRNA. in which BCR exon b2 is fused to 
abl exon a3. In the BCR region the breakpoint is located 
between exon b2 and b3. in the abl gene the breakpoint 
occurs at an unusual location. i.e. in the intron between 
cxon a2 and a3. 
To the best of our knowledge the CML patient de-
scribed in this paper and the two ALL patients described 
by Soekarman et aL (I) are the only three cases reported 
with a breakpoint in the abl gene 3' of cxon a2. Theoret-
ically the predicted frequency of occurrence of bcr-abl 
mRNA lacking abl exon a2 is 0.3% of the bcr-abl 
rearranged patients (0.6 kb:200 kb= 0.003). assuming 
that the breakpoints in abl are randomly distributed (1). 
However. in the leukemia patients. in whom the break-
point location in theab/ gene has been determined. it was 
always found 5' of abf exon a.2 (5.7,18-20). In this respect 
a paper by Hooberman et al. (21) is very interesting. 
These authors reported that in one out of six Ph-positive 
and in one out of five Ph-negative ALL or blast crises 
CML patients breakpoints in the BCR gene were found. 
but no bcr-abl mRNA expression could be detected by 
PCR analysis. These patients possibly express the bcr-abl 
mRNA lacking abl exon a2. which was not detected in 
the PCR because of the use of a 3' -primer corresponding 
to abl exon a2 sequences. To our opinion it would be 
worth checking a selected group of patients for the 
expression of mRNA with a fusion between one of the 
her exons and abl exon a3. This especially concerns all 
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Ph-positive ALL or AML patients and all CML patients. 
in whom a. breakpoint in the BCR region is detected 
using Southern blotting. but none of the known bcr-abl 
mRNAs has been found using PCR analysis. The addi-
tional analysis. which is required in these cases is either 
PCR analysis using an abl primer containing abl exon a3 
instead ofa2 sequences, or hybridization of the Southern 
blot to the Saui-Kpni ablprobe. It is expected that using 
this strategy more patients will be identified with this 
unusual breakpoint location in the abl gene. 
Concerning the disease caused by this new bcr-abl 
rearrangement. the following data. reported in this paper 
are important. Firstly. the expression of bcr-abl mRNA 
with a b2a.3 junction is not restricted to acute leukemia 
or blast crisis of CML. but also occurs in the chronic 
phase of CML. Secondly. the CML patient reported in 
this paper and the two ALL patients reported by Soekar-
man eta!. (I) were clinically indistinguishable from other 
Ph-positive CML or ALL patients. In the ALL patients 
the tyrosine kinase activity of the p2l0 proteins in the 
autophosphorylation assay did not differ from other Ph-
positive ALL patients. In the CML patient this assay 
could not be performed because the percentage of blasts 
was too low for this assay. In the bcr-a.bl fusion protein 
of the patients. I7 out of 50 amino acids. forming the 
SH3 region. are missing. The SH3 domain is a negative 
regulator of the kinase domain of the a.bl protein (11-13). 
Important for understanding the mechanism of activa-
tion of the abl oncogene is to compare these patient data. 
to the data. reported by Jackson et aL (22) and van Etten 
et al. (23). who investigated the effect of deletions in the 
mouse abl type IV protein. Jackson et a!. (22) and van 
Etten eta!. (23) reported that in mice. the deletion of 53 
amino acids in the SH3 domain of the abl type IV 
protein. which is homologous to the human SH3 do-
main. results in full activation of the transforming poten-
tial. both with respect to fibroblast and B-lymphoid cell 
transformation in vitro and leukemogenic activity in vivo. 
The same is found in v-abl. in which the SH3 domain is 
absent. Activation of the kinase domain of the abl 
protein can be reached either by replacement of 5' -abl by 
bcr sequences or viral gag sequences or by deletion of the 
SH3 domain. As argued by Soekarman eta!. (I) partial 
deletion of the SH3 domain in the three patients has no 
extra effect on kinase activity of the fusion proteins due 
to the fact that the inhibiting function of the SH3 domain 
is most probably already overruled by the presence of 5'-
bcr sequences in the bcr-abl proteins. 
possible clinical and prognostic implications of this find-
ing. It is expected that molecular analysis in patients such 
as these will contribute to a better understanding of the 
mechanisms of regulation of the kinase activity of the a.bl 
protein. and thus of leukemogenesis. 
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